Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 76
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Molecular screening of transitional B cells as a prognostic marker of improved graft outcome and reduced rejection risk in kidney transplant

  • Perezpayá, Inés
  • Garcia, Sergio G.|||0000-0001-7698-3734
  • Clos Sansalvador, Marta|||0000-0001-8522-7818
  • Sanroque-Muñoz, Marta|||0009-0004-5197-7708
  • Font-Morón, Miriam|||0000-0002-4714-252X
  • Rodríguez-Martínez, Paula|||0000-0002-9001-2501
  • Vila-Santandreu, Anna
  • Bover, Jordi|||0000-0003-3577-2273
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
  • Cañas, Laura
  • Franquesa, Marcella|||0000-0002-1287-8908
Understanding immune cell dynamics in kidney transplantation may provide insight into the mechanisms of rejection and improve patient management. B cells have gained interest with a special relevance of the "regulatory" subsets and their graft outcome prognostic value. In this study, we aimed to prove that the direct immunophenotyping and target gene expression analysis of kidney transplant patients' fresh whole blood will help to identify graft rejection risk and assist in the monitoring of kidney transplanted patients. We employed flow cytometry and qPCR techniques to characterize B and T cell subsets within fresh whole blood samples, with particular emphasis on transitional B cells (TrB) identified as CD19 + CD24 hi CD38 hi. TrB are a relevant population in the context of kidney transplantation and are closely associated with regulatory B cells (Bregs) in humans. Patients were monitored, tracking pertinent clinical parameters and kidney-related events, including alterations in graft function and episodes of biopsy proven rejection. Higher percentages of TrB cells at 3 months after transplantation were positively associated with better graft outcomes and lower biopsy-proven acute rejection risk. Furthermore, a novel panel of B cell regulatory associated genes was validated at 3 months post-transplantation by qPCR analysis of peripheral blood mononuclear cell (PBMC) mRNA, showing high predictive power of graft events and prognostic value. These findings suggest that monitoring TrB may provide interesting patient management information, improve transplant outcomes, and allow for personalized drug regimens to minimize clinical complications.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Towards clinical translation of urinary vitronectin for non-invasive detection and monitoring of renal fibrosis in kidney transplant patients

  • Clos Sansalvador, Marta|||0000-0001-8522-7818
  • Taco, Omar|||0000-0001-9081-5665
  • Rodríguez-Martínez, Paula|||0000-0002-9001-2501
  • Garcia, Sergio G.|||0000-0001-7698-3734
  • Font-Morón, Miriam|||0000-0002-4714-252X
  • Bover, Jordi|||0000-0003-3577-2273
  • Vila-Santandreu, Anna
  • Franquesa, Marcella|||0000-0002-1287-8908
  • Juega-Mariño, Javier|||0000-0002-9927-9683
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
Interstitial fibrosis and tubular atrophy (IFTA) is a critical factor in the prognosis of kidney health. Currently, IFTA quantitation in kidney biopsy samples is crucial for diagnosis and assessing disease severity, but the available non-invasive biomarkers are not satisfactory. Proteomic studies identified urinary vitronectin (VTN) as a potential biomarker for kidney fibrosis. As mass spectrometry techniques are not practical for use in clinical settings, we tested whether evaluation of urinary VTN levels through enzyme-linked immunosorbent assay (ELISA) can help monitor fibrotic changes in kidney transplant recipients and prove the clinical viability of the assay. A total of 58 kidney transplant (KTx) patients who underwent renal biopsy were included in the study. Patients were categorized into two groups referred as no fibrosis (0%) or with fibrosis (≥ 5%) based on their histological findings. In a subsequent/follow-up analysis, the time elapsed from transplantation was also considered. The urinary levels of VTN were measured using ELISA. VTN (p = 0.0180) and VTN normalized by urinary creatinine levels (p = 0.0037), were significantly increased in patients with fibrotic grafts. When focusing on patients with long-term grafts (> 3 years from transplantation, n = 36), VTN exhibited superior potential in identifying fibrotic grafts compared to albuminuria (VTN p = 0.0040 vs. albuminuria p = 0.0132). Importantly, in this group, while albuminuria correctly identified 71% of fibrotic patients, the combination of VTN plus albuminuria correctly classified 89% of fibrotic grafts detected by renal biopsy. VTN has emerged as a valid indicator of renal fibrosis. Of interest, urinary levels of VTN in combination with conventional clinical parameters (such as albuminuria) significantly improved the non-invasive detection of renal fibrosis in kidney transplant patients. The online version contains supplementary material available at 10.1186/s12967-024-05777-5.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Unraveling Enterococcus susceptibility to quaternary ammonium compounds, genes, phenotypes, and the impact of environmental conditions

  • Fernandes Pereira, Ana Paula|||0000-0003-3470-253X
  • Antunes, Patrícia|||0000-0002-3553-2678
  • Bierge, Paula|||0000-0003-0917-3445
  • Willems, Rob J. L.
  • Corander, Jukka
  • Coque, Teresa M.
  • Pich, Oscar Q.|||0000-0003-3561-630X
  • Peixe, Luisa
  • Freitas, Ana R.|||0000-0002-7326-4133
  • Novais, Carla|||0000-0002-3826-6731
Quaternary ammonium compounds (QACs) have been extensively used in the community, healthcare facilities, and food chain, in concentrations between 20 and 30,000 mg/L. Enterococcus faecalis and Enterococcus faecium are ubiquitous in these settings and are recognized as nosocomial pathogens worldwide, but QACs' activity against strains from diverse epidemiological and genomic backgrounds remained largely unexplored. We evaluated the role of Enterococcus isolates from different sources, years, and clonal lineages as hosts of QACs tolerance genes and their susceptibility to QACs in optimal, single-stress and cross-stress growth conditions. Only 1% of the Enterococcus isolates included in this study and 0.5% of publicly available Enterococcus genomes carried qacA/B, qacC, qacG, qacJ, qacZ, qrg, bcrABC or oqxAB genes, shared with.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Blastocystis occurrence and subtype diversity in European wild boar (Sus scrofa) from the Iberian Peninsula

  • Köster, Pamela C.|||0000-0001-5963-8824
  • Figuereido, Ana M.
  • Maloney, Jenny G.|||0000-0002-6405-883X
  • Dashti, Alejandro|||0000-0001-8707-5731
  • Bailo, Begoña|||0000-0002-9453-9431
  • Tinoco Torres, Rita|||0000-0003-4570-459X
  • Fonseca, Carlos|||0000-0001-6559-7133
  • Mysterud, Atle|||0000-0001-8993-7382
  • Habela, Miguel Ángel
  • Rivero-Juarez, Antonio|||0000-0002-5813-6889
  • Vicente, Joaquín|||0000-0001-8416-3672
  • Serrano Ferron, Emmanuel|||0000-0002-9799-9804
  • Arnal, Maria C.|||0000-0002-6770-3400
  • Fernández de Luco, Daniel|||0000-0003-3289-4267
  • Armenteros, José A.|||0000-0001-8776-1299
  • Balseiro, Ana|||0000-0002-5121-7264
  • Cardona, Guillermo A.|||0000-0002-4156-4174
  • Carvalho, João|||0000-0002-3166-450X
  • Hipólito, Dário|||0000-0002-2985-1314
  • Fernandes, Joana M.|||0000-0001-5602-1490
  • Palmeira, Josman Dantas
  • Calero-Bernal, Rafael|||0000-0003-2323-0135
  • González-Barrio, David|||0000-0001-5083-8854
  • Santín, Mónica
  • Carmena, David|||0000-0002-4015-8553
The ongoing increase in wild boar populations across Europe has fostered human-wildlife conflicts, including the transmission of emerging pathogens with zoonotic importance. Blastocystis is a ubiquitous, faecal-oral transmitted protist that can cause gastrointestinal illnesses and is observed in humans and animals worldwide. The role of wildlife in the epidemiology of Blastocystis is insufficiently understood. Thus, we investigated the occurrence and subtype diversity of Blastocystis in free-ranging wild boars from the Iberian Peninsula using conventional PCR and next-generation amplicon sequencing of a fragment of the ssu RNA gene. A total of 459 wild boar faecal samples were collected across Spain (n = 360) and Portugal (n = 99) between 2014 and 2021. Blastocystis was present in 15.3% (70/459; 95% CI 12.1-18.9) of the wild boars analysed, and its occurrence was significantly higher in Portugal (34.3%, 34/99; 95% CI 25.1-44.6) than in Spain (10.0%, 36/360; 95% CI 7.1-13.6). Seven Blastocystis subtypes (ST5, ST10b, ST13-ST15, ST24b, and ST43) were detected among the surveyed wild boar populations, with greater variability detected in Portuguese samples. ST5 was identified in all the Blastocystis-positive animals, whereas 14.3% of them harboured ST mixed colonisations. Our results demonstrate that Blastocystis ST5 is particularly adapted to infect wild boars. The additional identification of zoonotic STs reinforces the role of wild boars as spreaders of zoonotic infections with public health significance.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Improving Initial Medication Adherence to cardiovascular disease and diabetes treatments in primary care, Pilot trial of a complex intervention

  • Corral-Partearroyo, Carmen|||0000-0001-9517-4916
  • Sánchez-Viñas, Alba|||0000-0001-5020-7534
  • Gil-Girbau, Montserrat|||0000-0002-4396-6492
  • Peñarrubia-María, Maria Teresa
  • Aznar-Lou, Ignacio|||0000-0002-6780-5968
  • Serrano-Blanco, Antoni|||0000-0001-6123-0633
  • Carbonell-Duacastella, Cristina|||0000-0002-8794-5490
  • Gallardo-González, Carmen|||0000-0003-0688-1366
  • Olmos-Palenzuela, María del Carmen
  • Rubio-Valera, Maria|||0000-0003-2856-1697
Introduction: The Initial Medication Adherence (IMA) intervention is a multidisciplinary and shared decision-making intervention to improve initial medication adherence addressed to patients in need of new treatments for cardiovascular diseases and diabetes in primary care (PC). This pilot study aims to evaluate the feasibility and acceptability of the IMA intervention and the feasibility of a cluster-RCT to assess the effectiveness and cost-effectiveness of the intervention. Methods: A 3-month pilot trial with an embedded process evaluation was conducted in five PC centers in Catalonia (Spain). Electronic health data were descriptively analyzed to test the availability and quality of records of the trial outcomes (initiation, implementation, clinical parameters and use of services). Recruitment and retention rates of professionals were analyzed. Twenty-nine semi-structured interviews with professionals (general practitioners, nurses, and community pharmacists) and patients were conducted to assess the feasibility and acceptability of the intervention. Three discussion groups with a total of fifteen patients were performed to review and redesign the intervention decision aids. Qualitative data were thematically analyzed. Results: A total of 901 new treatments were prescribed to 604 patients. The proportion of missing data in the electronic health records was up to 30% for use of services and around 70% for clinical parameters 5 months before and after a new prescription. Primary and secondary outcomes were within plausible ranges and outliers were barely detected. The IMA intervention and its implementation strategy were considered feasible and acceptable by pilot-study participants. Low recruitment and retention rates, understanding of shared decision-making by professionals, and format and content of decision aids were the main barriers to the feasibility of the IMA intervention. Discussion: Involving patients in the decision-making process is crucial to achieving better clinical outcomes. The IMA intervention is feasible and showed good acceptability among professionals and patients. However, we identified barriers and facilitators to implementing the intervention and adapting it to a context affected by the COVID-19 pandemic that should be considered before launching a cluster-RCT. This pilot study identified opportunities for refining the intervention and improving the design of the definitive cluster-RCT to evaluate its effectiveness and cost-effectiveness. Clinical trial registration: ClinicalTrials.gov, identifier NCT05094986.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Hepatitis B and C Screening and Linkage to Care in Migrants From Endemic Countries in Barcelona Through a Community Action

  • Not, Anna|||0000-0001-8756-1094
  • Ouaarab-Essadek, Hakima|||0000-0002-8245-772X
  • Montoro-Fernandez, Marcos|||0000-0003-2425-4120
  • Treviño Maruri, Begoña|||0000-0003-4633-8288
  • Buti, Maria|||0000-0002-0732-3078
  • Morillas Cunill, Rosa Ma|||0000-0001-9117-5049
  • Bordoy, Antoni E.|||0000-0002-1165-542X
  • Folch, Cinta|||0000-0001-8400-2668
  • Majó, Xavier|||0000-0003-4338-6014
  • Casabona-Barbarà, Jordi|||0000-0003-4816-5536
  • Gómez i Prat, Jordi|||0000-0001-7041-9526
  • Martró, Elisa|||0000-0002-2867-6649
Background and Aims: Migrants from endemic areas are key populations for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection screening in Europe. This study assessed the feasibility and outcomes of a community action that combined education, screening, and simplified access to care for migrants in Barcelona. Methods: Adult migrants from Pakistan, Romania, and Senegal were included from 2021 to 2023, through a community action involving education, an epidemiological questionnaire, and rapid testing for HBV surface antigen (HBsAg) and HCV antibodies. If positive, DBS samples were collected for laboratory confirmation. Viremic cases were referred to an International Health Unit (IHU). Results: Overall, 786 participants were included (346 from Pakistan, 304 from Senegal and 136 from Romania). Previous screening for HBV and HCV was 8.0% and 7.7%, respectively. HBsAg prevalence was 0.9% for migrants from Pakistan, 8.2% for those from Senegal and 1.4% for those from Romania (n = 30/786, 23 new diagnoses). Among these, 69.6% attended the IHU and were HBV-DNA positive, but none met treatment criteria. Anti-HCV prevalence was 3.5%, 0.7% and 1.4% for migrants from Pakistan, Senegal and Romania, respectively (n = 16/768, 12 new diagnoses), and HCV-RNA prevalence was 0.9%, 0.3% and 0.7%, respectively (N = 6, all new diagnoses); 4 (66.6%) cases were linked to treatment and two were cured. Conclusions: This novel community action successfully reached migrants in a situation of vulnerability and provided them access to testing and care. The high prevalence observed and the limited self-knowledge of their HBV and HCV status justify targeted screening in these groups.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Is ampicillin plus cephalosporins a therapeutic option for Ampicillin-Susceptible Enterococcus faecium?

  • Bierge, Paula|||0000-0003-0917-3445
  • Gómez-Sánchez, Inmaculada|||0000-0002-4255-0882
  • García de la Mària, Cristina|||0000-0002-0585-9469
  • Sánchez-Osuna, Miquel|||0000-0001-5267-4814
  • Capilla, Silvia|||0000-0002-7274-2973
  • Casabella Pernas, Antonio|||0000-0002-2534-3689
  • Espasa, Mateu|||0000-0003-4822-1024
  • Novais, Carla|||0000-0002-3826-6731
  • Miró, José M.|||0000-0001-8057-7755
  • Pich, Oscar Q.|||0000-0003-3561-630X
  • Gasch, Oriol|||0000-0001-8518-458X
Objectives: Enterococcus faecium, a significant hospital associated pathogen, poses substantial treatment challenges. While combinations of ampicillin with cephalosporins are first-line therapies to treat Enterococcus faecalis high-mortality-rates infections, their efficacy against ampicillin-susceptible E. faecium (ASEfm) is less clear. This study evaluates the effectiveness of combining ampicillin with ceftriaxone or ceftaroline against ASEfm strains. Methods: Ten ASEfm bloodstream isolates from complicated infections were analyzed. Susceptibility to several antibiotics, including ceftriaxone, ceftaroline, and cefotaxime, was determined using standard methods. Time-kill assays were conducted to assess the synergistic and additive effects of ampicillin in combination with ceftriaxone or ceftaroline. Results: Time-kill studies revealed that ampicillin combined with ceftaroline demonstrated synergistic and/or additive effects in 7 out of 10 strains analyzed. In contrast, ampicillin combined with ceftriaxone showed less pronounced synergy, with only 3 out of 10 strains exhibiting synergistic and/or additive effects. Conclusions: Our findings indicate that ampicillin combined with ceftaroline, or ceftriaxone provides synergistic activity against some but not all ASEfm clinical isolates. The observed synergy suggests that these combinations could offer a potential therapeutic option for challenging ASEfm infections.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

External validation of models to predict hepatocellular carcinoma in Hepatitis C Virus cured F3-F4 patients

  • Carvalho-Gomes, Ângela
  • Valcheva, Tsveta Vladi
  • Sahuco, Ivan
  • Vidal, Enrique
  • Martínez-Arenas, Laura
  • Vinaixa, Carmen
  • Aguilera, Victoria
  • García García, Sonia
  • Berenguer, Marina
[EN] Background & AimsSeveral hepatocellular carcinoma (HCC) risk-models have been developed to individualise patient surveillance following sustained viral response (SVR) in Hepatitis C Virus patients. Validation of these models in different cohorts is an important step to incorporate a more personalised risk assessment in clinical practice. We aimed at applying these models to stratify the risk in our patients and potentially determine cost-saving associated with individualised HCC risk-stratification screening strategy. MethodsPatients with baseline F3-4 fibrosis treated with new oral direct-acting antivirals who had reached a SVR were regularly followed as part of the HCC surveillance strategy. Six models were applied: Pons, aMAP, Ioannou, HCC risk, Alonso and Semmler. Validation of the models was performed based on sensitivity and the proportion of patients labelled as "high risk". ResultsAfter excluding 557 with less than 3 fibrosis, 12 without SVR, 18 with a follow up (FU) <1 year, 17 transplant recipients, 16 lost to FU and 31 with HCC at time of antiviral therapy, our cohort consisted of 349 F3-4 SVR patients. Twenty-three patients (6.6%) developed HCC after a median FU of 5.12 years. The sensitivity of the different models varied between 0.17 (Semmler7noalcohol) and 1 (Alonso A and aMAP). The lowest proportion of high-risk patients corresponded to the Semmler-noalcohol model (5%). Sixty-three and 90% of the Alonso A and aMAP patients, respectively were labelled as high risk. The most reliable HCC risk-model applied to our cohort to predict HCC development is the Alonso model (based on fibrosis stage assessed by liver stiffness measurements or Fibrosis-4 index (FIB-4) at baseline and after 1 year, and albumin levels at 1 year) with a-100% sensitivity in detecting HCC among those at high risk and 63% labelled as high risk. The application of the model would have saved the cost of 1290 ultrasound no longer being performed in the 37% low-risk group. ConclusionIn our cohort, the Alonso A model allows the most reliable reduction in HCC screening resulting in safely stopping life-long monitoring in about a third of F3-F4 patients achieving SVR with DAAs.; image, Instituto de Salud Carlos III, Grant/Award Numbers: FI20/00033, INT20/00061, PI19/01360; Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas; Gilead Research Scholars, Grant/Award Number: GLD18-192
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Association of miR-126-3p, miR-1260b and miR-374a-5p with the incidence of heart failure in a population-based cohort: the Hortega Follow-Up Study

  • Grau-Perez, Maria
  • Martinez-Arroyo, Olga
  • Rubia-Martinez, Marta
  • Flores-Chova, Ana
  • Rodríguez-Hernández, Zulema
  • Fernández-Navarro, Pablo
  • Gonzalez-Neira, Anna
  • Alonso, María Rosario
  • Pita, Guillermo
  • Pineda, Silvia
  • Martin-Escudero, Juan C.
  • Redon, Josep
  • Tellez-Plaza, Maria
  • Cortes, Raquel
  • Guasque Ortega, Ana|||0000-0002-2900-8466
[EN] Background: Circulating microRNAs (miRNAs) are emerging markers for cardiovascular prevention and control. miRNAs associated to vascular damage are candidates to play a causal role in the microvascular dysfunction of heart failure (HF). The aim was to evaluate the observational and causal (Mendelian randomization) association of miRNAs related with vascular alterations (miR-126-3p, miR-1260b and miR-374a-5p) with HF incidence in a sample from the general population. Methods: Plasma miRNAs levels were measured in 985 Hortega Study participants using real time quantitative polymerase chain reaction (RT-qPCR). Single nucleotide polymorphisms (SNPs) were genotyped with the TOPMED imputable Illumina GSA array. We identified genetic instrumental variables for miR-126-3p (33 SNPs), miR-1260b (22 SNPs) and miR-374a-5p (35 SNPs) and run several Mendelian randomization approaches. Results: The hazard ratio (95 % confidence interval) of HF by a 10-fold increase in miR-126-3p, miR-1260b and miR-374a-5p was 1.53 (1.09, 2.14), 1.38 (1.03, 1.86), and1.30 (1.09, 1.57), respectively. The corresponding rate differences were 9.7 (-0.1, 19.5), 12.0 (0.4, 23.6) and 9.1 (1.2, 17.1) per 10000 person-years. In flexible dose-response analysis, increased miRNAs levels were associated with higher HF risk, both in the relative and additive scale. In Mendelian randomization analysis, consistently suggestive positive causal associations were found with HF for increased miR-126-3p and miR-1260b levels, but not for miR-374a-5p. Conclusions: In observational analysis, miR-126-3p, miR-1260b and miR-374a-5p levels were positively associ-ated with HF incidence. Mendelian randomization analysis supported a causal role for miR-126-3p and miR-1260b, thus suggesting a potential use as prognostic and therapeutic targets for HF prevention and control., We thank Nuria Alvarez y Belen Herraez, from the Human Genotyping-CEGEN Unit, at the National Center for Cancer Research from the Carlos III Health Institutes, in Madrid (Spain) , for their contribution in the genotyping procedure. This research was funded by health sciences research grants from the Carlos III Health Institute (grant numbers PI19/01796 to J.R.; PI21/00249 and CP22/00069 to R.C.; PI23/01179 to A.O.; FI20/00096 to O.M.-A; and FI22/00032 to A.F.-C.; PI15/00071 and PI22CIII/00029 to M.T.-P.) . This work was also sup-ported by the State Agency for Research (PID2019-108973RB-C21 to M. T.-P.) . Grant IJC2020-045308-I, Juan de la Cierva Incorporacion funded by MCIN/AEI/10.13039/501100011033 and by ESF-Investing in Your Future (to A.O.) ; CNS2022-136175, Research Consolidation Grants, funded by MCIN/AEI/10.13039/501100011033 and European Union "Next Generation EU"/PRTR" (to R.C) .; FP7-HEALTH 11 (grant number no 278249) . It was co-funded by the European Union (the European Regional Development Fund (ERDF) and the European Social Fund (FSE) ) ; CIBER of Obesity and Nutrition Physiopathology (CIBEROBN) (grant numbers CIBER-02-08-2009, CB06/03 and CB12/03/30016) . CIBER of Cardiovascular diseases (CIBERCV) (grant number CB16/11/00261) . CIBEROBN and CIBERCV are co-funded with European Funds for Regional Development (FEDER) , and IDIFEDER/2021/072, CIAICO/2022/181 and INVEST/2023/180 from the Generalitat Valenciana of Spain. Z.R.-H. received a fellowship associated to a Spain National Investigation Agency project (PRE2020-093926) . The genotyping service was carried out at the Genotyping Unit-CEGEN in the Spanish Na-tional Cancer Research Centre (CNIO) , supported by Instituto de Salud Carlos III (ISCIII) , Ministerio de Ciencia e Innovacion. CEGEN is part of the initiative IMPaCT GEN oMICA (IMP/00009) cofunded by ISCIII and the European Regional Development Fund (ERDF)
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Use of Attention Maps to Enrich Discriminability in Deep Learning Prediction Models Using Longitudinal Data from Electronic Health Records

  • Carrasco-Ribelles, Lucía Amalia
  • Cabrera-Bean, Margarita
  • Llanes-Jurado, José
  • Violán, Concepcion
[EN] Featured Application A better discrimination in a prediction model does not imply a better interpretability. In healthcare, where transparency is crucial, both discriminability and interpretability should be checked before stating that a new model is better.Abstract Background: In predictive modelling, particularly in fields such as healthcare, the importance of understanding the model's behaviour rivals, if not surpasses, that of discriminability. To this end, attention mechanisms have been included in deep learning models for years. However, when comparing different models, the one with the best discriminability is usually chosen without considering the clinical plausibility of their predictions. Objective: In this work several attention-based deep learning architectures with increasing degrees of complexity were designed and compared aiming to study the balance between discriminability and plausibility with architecture complexity when working with longitudinal data from Electronic Health Records (EHRs). Methods: We developed four deep learning-based architectures with attention mechanisms that were progressively more complex to handle longitudinal data from EHRs. We evaluated their discriminability and resulting attention maps and compared them amongst architectures and different input processing approaches. We trained them on 10 years of data from EHRs from Catalonia (Spain) and evaluated them using a 5-fold cross-validation to predict 1-year all-cause mortality in a subsample of 500,000 people over 65 years of age. Results: Generally, the simplest architectures led to the best overall discriminability, slightly decreasing with complexity by up to 8.7%. However, the attention maps resulting from the simpler architectures were less informative and less clinically plausible compared to those from more complex architectures. Moreover, the latter could give attention weights both in the time and feature domains. Conclusions: Our results suggest that discriminability and more informative and clinically plausible attention maps do not always go together. Given the preferences within the healthcare field for enhanced explainability, establishing a balance with discriminability is imperative., This work was supported by a research grant from the Carlos III Institute of Health, Ministry of Economy and Competitiveness (Spain), awarded on the 2019 call under the Health Strategy Action 2013-2016, within the National Research Programme oriented to Societal Challenge and the Technical, Scientific and Innovation Research National Plan 2013-2016, (reference PI19/00535), and the PFIS Grant FI20/00040, co-funded with European Union ERDF (European Regional Development Fund) funds. This work has also been funded through project 6-SENSES (PID2022-138648OB-I00) funded by MCIN/AEI/10.13039/501100011033 and "ERDF A way of making Europe", EU. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Cytomegalovirus Reactivation Is Associated With Lower Rates of Hepatocellular Carcinoma Recurrence After Liver Transplantation

  • Aguilera, Victoria
  • Romero Moreno, Sarai
  • Conde, Isabel
  • Rubín, Angel
  • Carvalho-Gomes, Angela
  • Romero, Mario
  • Zamora-Olaya, Javier
  • Gómez-Bravo, Miguel Angel
  • Fuentes-Valenzuela, Esteban
  • Dopazo, Cristina
  • Bilbao, Nikita
  • Gonzalez, Antonio
  • Sanchez-Martinez, Ana
  • Pascual, Sonia
  • Rivera-Esteban, Jesus
  • Martínez-Arenas, Laura
[EN] In patients with hepatocellular carcinoma (HCC), undergoing liver transplantation (LT), cytomegalovirus reactivation (CMVr) may modulate the immune system to prevent tumor recurrence. In this multicenter retrospective study (2010-2015) involving 15 institutions, we assessed the effect of early CMVr in tumor recurrence rates among 771-LT HCC patients with tacrolimus-based immunosuppression (88% men, mean age 58 years). CMV prophylaxis was implemented for 19.7% of patients, while the rest were managed with preemptive therapy. The Milan criteria were met by 88% of patients. Microvascular invasion was present in 12.7% of explanted livers. The serum AFP level before transplantation was 5.1 (3-15) ng/mL. After a median follow-up of 7.4 years, 101 patients (13%) experienced HCC recurrence. CMVr occurred in 235 patients (30.5%) at a median of 41.5 days post-LT and 42 patients (5.6%) had CMV disease. Cumulative exposure to tacrolimus within the first 3 months after LT was similar among patients with and without CMVr. In a multivariate Cox regression analysis, factors associated with an increased rate of HCC recurrence included microvascular invasion [HR:2.82, CI95%:1.55-5.14; p 0.0001], donation after circulatory determination of death [HR:4.43,CI95%:1.52-12.9; p 0.006) and diameter of the main nodule at explant [HR:1.04, CI95%:1.02-1.06; p < 0.001]. Meanwhile CMVr [HR:0.46, CI95%:0.23-0.93, p 0.031] and MELD [HR:0.93, CI95%:0.87-0.99; p0.017] exhibited protective effects. In conclusion, early CMVr may protect against HCC recurrence. The underlying immune mechanisms warrant further investigation., The author(s) declare that financial support was received for the research and/or publication of this article. This study was supported by competitive grants from the Instituto de Salud Carlos III (grant numbers: PI13/01770 and PI18/01759), and co-financed by the European Regional Development Fund "A way to achieve Europe." AC-G and MB were also supported by the Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd) (https://www.ciberehd.org/), which is funded by the Instituto de Salud Carlos III (co-financed by the European Regional Development Fund). VA has received a grant from the AEEH (Asociacion Espanola para el Estudio del Higado, Spain): Beca de Intensificacion. AC-G received a postdoctoral Fellowship from CiberEHD and MB was supported by competitive grants from the Instituto de Salud Carlos III (grant numbers PI23/00088 and INT24/00021) and by Generalitat Valenciana (grant numbers AICO/2021/035 and CIPROM/2023/16). Victoria Aguilera received a grant from the AEEH "Beca de intensificacion para investigadores" in 2021. LM-A was supported by the Instituto de Salud Carlos III (grant numbers FI20/00033 and MV22/00053).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Tesis doctoral (DoctoralThesis)

The impact of metabolic dysfunction-associated steatotic liver disease in the liver transplant setting

  • Martínez Arenas, Laura
[ES] La enfermedad hepática esteatósica asociada a la disfunción metabólica (MASLD, por sus siglas en inglés) se ha convertido en la enfermedad hepática crónica más prevalente a nivel mundial. La incidencia creciente de obesidad, diabetes mellitus tipo 2 y síndrome metabólico ha impulsado este aumento, posicionando a la MASLD como una causa significativa de enfermedad hepática avanzada, incluyendo la cirrosis y el carcinoma hepatocelular. A medida que estas condiciones progresan, se espera que la MASLD sea la principal indicación de trasplante de hígado (TH) en el mundo, con importantes implicaciones para la carga sanitaria. Dado que el TH sigue siendo el único tratamiento curativo para la cirrosis descompensada y es un recurso limitado, mejorar la concienciación, el diagnóstico precoz y la prevención de la MASLD y promover una vida longeva del injerto es imprescindible. Esta tesis doctoral examinó el impacto de la MASLD en el contexto del TH en España, abordando su relevancia tanto como indicación de TH como de condición recurrente después del TH, al mismo tiempo que exploró el papel potencial de varios biomarcadores periféricos no invasivos para optimizar la monitorización de la fibrosis del injerto a largo plazo. Los resultados obtenidos en esta tesis doctoral demostraron que la carga de TH por MASLD en España está creciendo, con predicciones que sugieren un aumento del 5,4% al 10,8% para 2028. En comparación con los datos de América del Norte, la trayectoria de crecimiento de TH por MASLD en España mostró una velocidad menos pronunciada, aunque las comorbilidades metabólicas asociadas a la MASLD fueron frecuentes en todas las poblaciones. En el contexto post-TH, los datos histológicos mostraron que la recurrencia de la esteatosis fue común (63,6%), con un 25% con diagnóstico de esteatohepatitis asociada a la disfunción metabólica (MASH, por sus siglas en inglés), pero solo un 4,6% y un 2,3% con fibrosis significativa y avanzada, respectivamente, a 2 años post-TH. Aunque la biopsia hepática sigue siendo el estándar de oro para detectar la fibrosis del injerto, los valores de la medición de la rigidez hepática (LSM, por sus siglas en inglés) por elastografía transitoria controlada por vibración <8kPa después del TH por MASH se asociaron estrechamente con la ausencia de fibrosis significativa y avanzada (valor predictivo negativo=100%). Por el contrario, en aquellos pacientes con valores de LSM >=8kPa, el uso de herramientas no invasivas complementarias para mejorar la detección no invasiva de fibrosis significativa y avanzada estaba justificado (valor predictivo positivo=20%). En este contexto, los biomarcadores periféricos, en particular la adiponectina, la citoqueratina (CK)-18 M30 y la CK-18 M65, podrían ser herramientas no invasivas potencialmente prometedoras para evaluar la estratificación de la fibrosis en receptores trasplantados por MASH, por enfermedad hepática asociada al alcohol y a la disfunción metabólica (MetALD, por sus siglas en inglés) y por enfermedad hepática asociada al alcohol (ALD, por sus siglas en inglés) (área bajo la curva [AUC]=0,786). Además, una firma del microbioma intestinal en sangre basada en los géneros Parabacteroides, Kocuria, Curvibacter y Ruminococcus también podría ser útil para detectar la fibrosis del injerto en receptores trasplantados por MASH, MetALD y ALD (AUC = 0,68), lo que reduciría la necesidad de procedimientos invasivos en la vigilancia post-TH., [EN] Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most prevalent chronic liver disease worldwide. The increasing incidence of obesity, type 2 diabetes mellitus, and metabolic syndrome has driven this surge, positioning MASLD as a significant cause of advanced liver disease, including cirrhosis and hepatocellular carcinoma. As these conditions progress, MASLD is projected to be the leading indication for liver transplantation (LT) globally, with major implications for healthcare burden. Given that LT remains the only curative treatment for decompensated cirrhosis and is a limited resource, improving awareness, early diagnosis, and prevention of MASLD and promoting a long-term graft survival is essential. This doctoral thesis examined the impact of MASLD within the LT setting in Spain, addressing its relevance both as a LT indication and as a recurrent condition after LT, while exploring the potential role of several peripheral non-invasive biomarkers in optimizing long-term graft fibrosis monitoring. The results obtained in this doctoral thesis demonstrated that the burden of MASLD-related LT in Spain is growing, with predictions suggesting a rise to 5.4%-10.8% by 2028. Compared to North American data, the growth trajectory of MASLD-related LT in Spain showed a less pronounced speed, although MASLD-associated metabolic comorbidities were frequent in all populations. In the post-LT setting, biopsy data showed that steatosis recurrence was common (63.6%), with 25% having a metabolic dysfunction-associated steatohepatitis (MASH) diagnosis but only 4.6% and 2.3% having significant and advanced fibrosis, respectively, at 2 years post-LT. Although liver biopsy remains the gold standard for detecting graft fibrosis, values of liver stiffness measurement (LSM) by vibration-controlled transient elastography <8kPa after LT for MASH strongly correlated with the absence of significant and advanced fibrosis (negative predictive value=100%). In contrast, in those patients with LSM values >=8kPa, complementary non-invasive tools to improve non-invasive detection of significant and advanced fibrosis were warranted (positive predictive value=20%). In this context, peripheral biomarkers, particularly adiponectin, cytokeratin (CK)-18 M30 and CK-18 M65, may be potentially promising non-invasive tools for assessing fibrosis stratification in LT recipients transplanted for MASH, metabolic dysfunction and alcohol-associated liver disease (MetALD) and alcohol-associated liver disease (ALD) (area under the curve [AUC]= 0.786). Additionally, a gut microbiome signature in blood based on the genera Parabacteroides, Kocuria, Curvibacter and Ruminococcus may be also useful to detect graft fibrosis in recipients transplanted for MASH, MetALD and ALD (AUC=0.68), reducing the need for invasive procedures in post-LT surveillance., [CA] La malaltia hepàtica esteatósica associada a la disfunció metabòlica (MASLD, per les seues sigles en anglés) s'ha convertit en la malaltia hepàtica crònica més prevalent a nivell mundial. La incidència creixent d'obesitat, diabetis mellitus tipus 2 i síndrome metabòlica ha impulsat este augment, posicionant a la MASLD com una causa significativa de malaltia hepàtica avançada, incloent-hi la cirrosi i el carcinoma hepatocel·lular. A mesura que estes condicions progressen, s'espera que la MASLD siga la principal indicació de trasplantament hepàtic (TH) en el món, amb importants implicacions per a la càrrega sanitària. Atés que el TH continua sent l'únic tractament curatiu per a la cirrosi descompensada i és un recurs limitat, millorar la conscienciació, el diagnòstic precoç i la prevenció de la MASLD i promoure una vida longeva de l'empelt és imprescindible. Esta tesi doctoral va examinar l'impacte de la MASLD en el context del TH a Espanya, abordant la seua rellevància tant com indicació de TH com a condició recurrent després del TH, al mateix temps que va explorar el paper potencial de diversos biomarcadores perifèrics no invasius per a optimitzar el monitoratge de la fibrosi de l'empelt a llarg termini. Els resultats obtinguts en esta tesi doctoral van demostrar que la càrrega de TH per MASLD a Espanya està creixent, amb prediccions que suggerixen un augment del 5,4% al 10,8% per a 2028. En comparació amb les dades d'Amèrica del Nord, la trajectòria de creixement de TH per MASLD a Espanya va mostrar una velocitat menys pronunciada, encara que les comorbiditats metabòliques associades a la MASLD van ser freqüents en totes les poblacions. En el context post-TH, les dades histològiques van mostrar que la recurrència de la esteatosis va ser comuna (63,6%), amb un 25% amb diagnòstic de esteatohepatitis associada a la disfunció metabòlica (MASH, per les seues sigles en anglés), però només un 4,6% i un 2,3% amb fibrosi significativa i avançada, respectivamente, a 2 anys post-TH. Encara que la biòpsia hepàtica continua sent l'estàndard d'or per a detectar la fibrosi de l'empelt, els valors de mesurament de la rigidesa hepàtica (LSM, per les seues sigles en anglés) per elastografia transitòria controlada per vibració <8kPa després del TH per MASH es van associar estretament amb l'absència de fibrosi significativa i avançada (valor predictiu negatiu=100%). Per contra, en aquells pacients amb valors de LSM >=8kPa, l'ús de ferramentes no invasives complementàries per a millorar la detecció no invasiva de fibrosi significativa i avançada estava justificat (valor predictiu positiu=20%). En este context, els biomarcadores perifèrics, en particular la adiponectina, la citoqueratina (CK)-18 M30 i la CK-18 M65, podrien ser ferramentes no invasives potencialment prometedores per a avaluar l'estratificació de la fibrosi en receptors trasplantats per MASH, per malaltia hepàtica associada a l'alcohol i a la disfunció metabòlica (MetALD, per les seues sigles en anglés) i per malaltia hepàtica associada a l'alcohol (ALD, per les seues sigles en anglés) (àrea sota la corba [AUC]=0,786). A més, una firma del microbioma intestinal en sang basada en els gèneres Parabacteroides, Kocuria, Curvibacter i Ruminococcus també podria ser útil per a detectar la fibrosi de l'empelt en receptors trasplantats per MASH, MetALD i ALD (AUC = 0,68), la qual cosa reduiria la necessitat de procediments invasius en la vigilància post-TH., This study was funded by the Instituto de Salud Carlos III and co-funded by the European Union (grant PI19/01360), by the Generalitat Valenciana (grant AICO/2021/035), and by the CIBEREHD (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – European Regional Development Fund.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

FibroScan compared to liver biopsy for accurately staging recurrent hepatic steatosis and fibrosis after transplantation for MASH

  • Martínez-Arenas, Laura
  • Vinaixa, Carmen
  • Conde, Isabel
  • Lorente, Sara
  • Díaz-Fontenla, Fernando
  • Marques, Patrice
  • Pérez-Rojas, Judith
  • Montalvá, Eva
  • Carvalho-Gomes, Ângela
  • Berenguer, Marina
[EN] Background and aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) recurrence after liver transplantation (LT) seems unavoidable and gradual. We aimed to evaluate the diagnostic accuracy in the post-LT setting of patients transplanted for metabolic dysfunction-associated steatohepatitis (MASH) of recurrent hepatic steatosis and fibrosis identified with FibroScan, compared to biopsy findings. Methods: This prospective cohort study included adults transplanted for MASH between 2010 and 2022 in three LT centres in Spain who underwent FibroScan and biopsy at least 1-year after LT. Results: In total, 44 patients transplanted for MASH after LT were included. The median time from LT to biopsy and FibroScan was 24.5 (interquartile range [IQR]:16-46) and 26.0 (IQR: 16.8-41.5) months, respectively. The median time between biopsy and FibroScan was 2.0 (IQR: 0-5) months. On FibroScan, significant steatosis was diagnosed in about half of the patients (n = 21, 47.7%), yet advanced fibrosis in only two cases (4.6%). On biopsy, a quarter of biopsied patients (n = 11, 25%) had a MASH diagnosis, two (4.6%) with significant fibrosis and one (2.3%) with cirrhosis. All patients with liver stiffness measurement (LSM) values <8 kPa (n = 35, 79.5%) had a fibrosis stage ¿F1 (negative predictive value = 100%). The combination of post-LT hypertension (odds ratio [OR]: 12.0, 95% confidence interval [CI]: 1.8-80.4, p = .010) and post-LT dyslipidaemia (OR: 7.9, 95% CI: 1.3-47.1, p = .024) with LSM (OR: 1.7, 95% CI: 1.1-2.8, p = .030) was independently associated with MASLD. Conclusions: Although biopsy remains the gold standard for detecting fibrosis, our results suggest that LSM values <8 kPa after LT for MASH are strongly correlated with absence of significant/advanced fibrosis., Generalitat Valenciana; Instituto de Salud Carlos III; Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas; Sociedad Espanola de Trasplante Hepatico This research was funded by the Instituto de Salud Carlos III and co- funded by European Regional Development Fund 'A way to make Europe' (grant PI19/01360 to MB, grant INT20/00061 to MB, grant FI20/00033 to LMA, grant MV22/00053 to LMA, grant CD22/00045 to PM, grant PI23/00088 to MB, and grant INT24/00021 to MB), by the Generalitat Valenciana (grant AICO/2021/035 to MB, grant CIGE/2023/073 to PM, and grant CIPROM/2023/16 to MB), by the CIBER -Consorcio Centro de Investigacion Biomedica en Red- [CB06/04/0065], Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion and Union Europea-European Regional Development Fund, and by the Spanish Society of Liver Transplantation (SETH, grant 2022/295 to MB).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Establishing and Validating a Biomolecular Signature of Ischemia/Reperfusion Injury in a Porcine Pancreas Allotransplantation Model

  • Ray, Samrat
  • Ganesh, Sujani
  • Martínez-Arenas, Laura
  • Parmentier, Catherine
  • Kawamura, Masataka
  • Arulratnam, Bhranavi
  • Hobeika, Christian
  • Nogueira, Emmanuel
  • Calderon Novoa, Francisco
  • Selzner, Markus
  • Reichman, Trevor W.
[EN] Background. Despite considerable advancement in surgical and immunological management in pancreas transplantation, graft pancreatitis remains a feared complication after pancreas transplantation. Identification of molecular mechanisms of underlying ischemia/reperfusion injury (IRI) in pancreas transplantation could, therefore, pave the path for targeted therapy to improve surgical outcomes. The aim of the study was to identify and validate the genes differentially expressed in the early period (24 h) of graft reperfusion in pancreas transplantation. Methods. A porcine pancreas allotransplant model (n = 4) was used to identify and validate the genes aberrantly expressed in 60 min postreperfusion tissue samples (phase 1). Trends of expression of selected genes from phase 1 and corresponding protein product levels in serum were validated at defined time points for >24 h in a technically replicated external cohort (n = 3; phase 2). Results. A total of 104 genes were found to be upregulated at 60 min after pancreas graft reperfusion. The most consistently overexpressed genes were IL6, THBS1, and MIR-21 (micro-RNA) mapped to protein kinase and intracellular signaling molecular pathways. Levels of expression of these genes correlated significantly with serum interleukin-6 (R = 0.60-0.81; P < 0.01) and tumor necrosis factor-alpha levels (R = 0.34-41; P > 0.05) at corresponding time points. Conclusions. The results provide new insights into biomolecular pathways (THBS1-IL6-MIR-21 crosstalk and hydroxymethylglutarate coenzyme A reductase-linked nuclear factor kappa B activation) linked to pancreatic IRI in porcine transplantation model. Identification and validation of some novel molecular pathway interactions in human pancreas transplantation could pave the path for potential targeted therapy in alleviating graft injury in the early phases of pancreatic IRI., S.R. and T.W.R. supported by Ajmera Transplant Centre Felowship award (March 2022-2023), Ajmera Transplant Centre, and Toronto General Hospital, Toronto, Canada. L.M.-A. was funded by the Instituto de Salud Carlos III and co-funded by European Regional Development Fund "A way to make Europe" (grant FI20/00033 and MV22/00053).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Genome-wide methylation analysis of circulating cell-free DNA identifies an episignature in lung cancer: validation of EMP2 as a potential biomarker

  • Alemany-Cosme, Ester
  • Cruz-Chamorro, Dario
  • Garcia, Diana
  • Martinez-Tomas, Raquel
  • Briones-Gomez, Andres
  • Galbis-Caravajal, Jose
  • Calvo, Alfonso
  • Juan, Oscar
  • Lahoz, Agustin
  • Cases, Enrique
  • Palanca-Ballester, Cora
  • Sandoval, Juan
  • Hervás-Marín, David|||0000-0003-0635-4961
[EN] Background: Lung cancer (LC) remains the leading cause of cancer-related mortality worldwide. Its poor prognosis is largely attributed to late-stage diagnosis, highlighting the need for sensitive, minimally invasive biomarkers for early detection. In this study, we aimed to identify circulating cell-free DNA (cfDNA) methylation-based biomarkers for LC through genome-wide profiling of plasma-derived cfDNA from patients with LC (stages I-IV) using the Infinium DNA MethylationEPIC array (> 850,000 CpGs). A relaxed elastic net penalized logistic regression model was applied to identify differentially methylated CpGs between LC patients and non-neoplastic controls, and selected candidates were validated in an independent cohort. Results: A 21-CpG episignature was identified, predominantly hypomethylated in LC, which distinguished cases (n = 25) from controls (n = 8) with a cross-validated area under the curve (AUC) of 0.70. Two CpGs with the largest effect sizes (associated with EMP2 and IKZF2) were selected for validation. Digital droplet PCR (ddPCR) analysis in an independent cohort of 47 individuals (23 LC patients and 24 controls) confirmed significant hypomethylation at the EMP2 locus (median % methylation: 73.60% in tumors vs. 86.83% in controls; p = 0.0034), achieving an AUC of 0.75. Conclusions: Our findings support the utility of methylome-wide cfDNA profiling for LC biomarker discovery. EMP2 promoter methylation represents a promising candidate for the minimally invasive detection of LC across heterogeneous clinical presentations., This work was supported by the ISCIII ("PI19/00572"), co-funded by ERDF/ESF, "A way to make Europe"/"Investing in your future", Proyectos de Generacion de Conocimiento 2022 Proyecto PID2022-137965OB-I00 from MCIN/ AEI /https://doi.org/10.13039/501100011033/ and FEDER "A way to make Europe" and the Conselleria de innovacion, universidades, ciencia y sociedad digital (CIAICO/2022/251). E. Alemany-Cosme was supported by a grant of ISCIII (FI20/00136), D. Cruz-Chamorro and C Palanca-Ballester were supported by Grants from Generalitat Valenciana (CIAPOT/2022/21 and FDEGENT/2019/014), respectively.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

The Role of PemIK (PemK/PemI) Type II TA System from Klebsiella pneumoniae Clinical Strains in Lytic Phage Infection

  • Bleriot Rial, Inés
  • Blasco, Lucía
  • Pacios Santamaría, Olga
  • Fernández-García, Laura
  • Ambroa, Antón
  • López Díaz, María
  • Ortiz-Cartagena, Concha
  • Fernández-Cuenca, Felipe
  • Oteo, Jesús
  • Pascual, Álvaro
  • Martínez-Martínez, Luis
  • Domingo-Calap, Pilar
  • Wood, Thomas K.
  • Tomás, María
[Abstract] Since their discovery, toxin-antitoxin (TA) systems have captivated the attention of many scientists. Recent studies have demonstrated that TA systems play a key role in phage inhibition. The aim of the present study was to investigate the role of the PemIK (PemK/PemI) type II TA system in phage inhibition by its intrinsic expression in clinical strains of Klebsiella pneumoniae carrying the lncL plasmid, which harbours the carbapenemase OXA-48 and the PemK/PemI TA system. Furthermore, induced expression of the system in an IPTG-inducible plasmid in a reference strain of K. pneumoniae ATCC10031 was also studied. The results showed that induced expression of the whole TA system did not inhibit phage infection, whereas overexpression of the pemK toxin prevented early infection. To investigate the molecular mechanism involved in the PemK toxin-mediated inhibition of phage infection, assays measuring metabolic activity and viability were performed, revealing that overexpression of the PemK toxin led to dormancy of the bacteria. Thus, we demonstrate that the PemK/PemI TA system plays a role in phage infection and that the action of the free toxin induces a dormant state in the cells, resulting in inhibition of phage infections., This study was funded by grant PI19/00878 awarded to M. Tomás within the State Plan for R+D+I 2013-2016 (National Plan for Scientific Research, Technological Development and Innovation 2008-2011) and co-financed by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research—European Regional Development Fund "A way of Making Europe" and Instituto de Salud Carlos III FEDER, Spanish Network for the Research in Infectious Diseases (REIPI, RD16/0016/0001, RD16/0016/0006 and RD16/CIII/0004/0002) and by the Study Group on Mechanisms of Action and Resistance to Antimicrobials, GEMARA (SEIMC, http://www.seimc.org/). M. Tomás was financially supported by the Miguel Servet Research Programme (SERGAS and ISCIII). I. Bleriot was financially supported by pFIS program (ISCIII, FI20/00302). O. Pacios and M. López was financially supported by a grant IN606A-2020/035 and IN606B-2018/008, respectively (GAIN, Xunta de Galicia) and M. Gonzalez-Bardanca was financially supported by the Rio Hortega program (ISCIII, CM20/00198), Xunta de Galicia; IN606A-2020/035, Xunta de Galicia; IN606B-2018/008
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Phenotypic and Genomic Comparison of Klebsiella pneumoniae Lytic Phages: vB_KpnM-VAC66 and vB_KpnM-VAC13

  • Pacios Santamaría, Olga
  • Fernández-García, Laura
  • Bleriot Rial, Inés
  • Blasco, Lucía
  • Ambroa, Antón
  • López Díaz, María
  • Ortiz-Cartagena, Concha
  • Fernández-Cuenca, Felipe
  • Oteo, Jesús
  • Pascual, Álvaro
  • Martínez-Martínez, Luis
  • Domingo-Calap, Pilar
  • Tomás, María
[Abstract] Klebsiella pneumoniae is a human pathogen that worsens the prognosis of many immunocompromised patients. Here, we annotated and compared the genomes of two lytic phages that infect clinical strains of K. pneumoniae (vB_KpnM-VAC13 and vB_KpnM-VAC66) and phenotypically characterized vB_KpnM-VAC66 (time of adsorption of 12 min, burst size of 31.49 ± 0.61 PFU/infected cell, and a host range of 20.8% of the tested strains). Transmission electronic microscopy showed that vB_KpnM-VAC66 belongs to the Myoviridae family. The genomic analysis of the phage vB_KpnM-VAC66 revealed that its genome encoded 289 proteins. When compared to the genome of vB_KpnM-VAC13, they showed a nucleotide similarity of 97.56%, with a 93% of query cover, and the phylogenetic study performed with other Tevenvirinae phages showed a close common ancestor. However, there were 21 coding sequences which differed. Interestingly, the main differences were that vB_KpnM-VAC66 encoded 10 more homing endonucleases than vB_KpnM-VAC13, and that the nucleotidic and amino-acid sequences of the L-shaped tail fiber protein were highly dissimilar, leading to different three-dimensional protein predictions. Both phages differed significantly in their host range. These viruses may be useful in the development of alternative therapies to antibiotics or as a co-therapy increasing its antimicrobial potential, especially when addressing multidrug resistant (MDR) pathogens., This study was funded by grants PI19/00878 awarded to M. Tomás within the State Plan for R+D+I 2013-2016 (National Plan for Scientific Research, Technological Development and Innovation 2008–2011) and co-financed by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research—European Regional Development Fund “A way of Making Europe” and Instituto de Salud Carlos III FEDER, Spanish Network for the Research in Infectious Diseases (REIPI, RD16/0016/0001, RD16/0016/0006 and RD16/CIII/0004/0002) and by the Study Group on Mechanisms of Action and Resistance to Antimicrobials, GEMARA (SEIMC, http://www.seimc.org/ accessed on 1 February 2021) and project PID2020-112835RA-I00 funded by MCIN/AEI /10.13039/501100011033, and project SEJIGENT/2021/014 funded by Conselleria d’Innovació, Universitats, Ciència i Societat Digital (Generalitat Valenciana). M. Tomás was financially supported by the Miguel Servet Research Programme (SERGAS and ISCIII). O. Pacios, L. Fernández-García and M. López were financially supported by the grants IN606A-2020/035, IN606B-2021/013 and IN606B-2018/008, respectively (GAIN, Xunta de Galicia). I. Bleriot was financially supported by pFIS program (ISCIII, FI20/00302). P. Domingo-Calap was financially supported by a Ramón y Cajal contract RYC2019-028015-I funded by MCIN/AEI /10.13039/501100011033, ESF Invest in your future, Generalitat Valenciana; SEJIGENT/2021/014, Xunta de Galicia; IN606A-2020/035, Xunta de Galicia; IN606B-2021/013, Xunta de Galicia; IN606B-2018/008
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies

  • González de Aledo, Manuel
  • González-Bardanca, Mónica
  • Blasco, Lucía
  • Pacios Santamaría, Olga
  • Bleriot Rial, Inés
  • Fernández-García, Laura
  • Fernández-Quejo, Melisa
  • López Díaz, María
  • Bou, Germán
  • Tomás, María
This article belongs to the Special Issue Non-antimicrobial Agents as Adjuvants against Bacterial Infections, [Abstract] One of the biggest threats we face globally is the emergence of antimicrobial-resistant (AMR) bacteria, which runs in parallel with the lack in the development of new antimicrobials. Among these AMR bacteria pathogens belonging to the ESKAPE group can be highlighted (Enterococcus spp., Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) due to their profile of drug resistance and virulence. Therefore, innovative lines of treatment must be developed for these bacteria. In this review, we summarize the different strategies for the treatment and study of molecular mechanisms of AMR in the ESKAPE pathogens based on the clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins’ technologies: loss of plasmid or cellular viability, random mutation or gene deletion as well directed mutations that lead to a gene’s loss of function., This study was funded by grants PI16/01163 and PI19/00878 awarded to M. Tomás within the State Plan for R+D+I 2013–2016 (National Plan for Scientific Research, Technological Development and Innovation 2008–2011) and cofinanced by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research-European Regional Development Fund “A way of Making Europe” and Instituto de Salud Carlos III FEDER, Spanish Network for the Research in Infectious Diseases (REIPI, RD16/0016/0006) and by the Study Group on Mechanisms of Action and Resistance to Antimicrobials, GEMARA (SEIMC, http://www.seimc.org/, Accessed on 21 June 2021). I. Bleriot was financially supported by pFIS program (ISCIII, FI20/00302). O. Pacios and M. López was financially supported by a grant IN606A-2020/035 and IN606B-2018/008, respectively, (GAIN, Xunta de Galicia), and M. Gonzalez-Bardanca was financially supported by the Rio Hortega program (ISCIII, CM20/00198), Xunta de Galicia; IN606A-2020/035, Xunta de Galicia; IN606B-2018/008
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Mediterranean diet, energy restriction, physical activity, and atherogenicity of very-low density lipoproteins: findings from two randomized controlled trials

  • Pérez-Vega, Karla Alejandra
  • Castañer, Olga
  • Sanllorente Melenchon, Albert
  • Lassale, Camille
  • Ros Rahola, Emilio
  • Pintó Sala, Xavier
  • Estruch Riba, Ramon
  • Salas Salvadó, Jordi
  • Corella Piquer, Dolores
  • Alonso Gómez, Ángel M.
  • Serra Majem, Lluís
  • Razquin, Cristina
  • Fiol, Miquel
  • Lapetra, José
  • Gómez-Gracia, Enrique
  • Tinahones Madueño, Francisco J.
  • Hernáez, Álvaro
  • Fitó Colomer, Montserrat
Scope: Some very-low density lipoprotein (VLDL) properties may render themmore pro-atherogenic. We aimed to assess whether a Mediterranean diet(MedDiet) or an energy-reduced MedDiet with increased physical activityimproves them.Methods and results: In a sample of the PREvención con DIeta MEDiterránea(PREDIMED) study, a 1-year intervention with MedDiet with extra-virgin oliveoil (n = 89) or nuts (MedDiet-Nuts; n = 79) is compared with a low-fat diet(n = 90). In the PREDIMED-Plus study, a 1-year intervention withenergy-reduced MedDiet and physical activity (n = 103) is compared with anad libitum MedDiet (n = 101). VLDL levels of apolipoprotein C-I, C-III,triglycerides, and cholesterol; the apolipoprotein E-/C-I ratio; and VLDLex-vivo triglyceride transfer are measured. In PREDIMED participants in bothMedDiet groups combined, VLDL apolipoprotein C-III levels are nominallyreduced (−0.023 SD units, 95% CI −0.44 to −0.014, p = 0.037). VLDLtriglyceride transfer is nominally increased in the MedDiet-Nuts group (+0.39SD units, 95% CI 0.012–0.78, p = 0.045). In PREDIMED-Plus, no inter-groupdifferences are detected.Conclusions: In older adults at high cardiovascular risk, MedDiet isassociated with lower VLDL atherogenicity versus a low-fat diet. Nodifferences are seen after an energy-reduced MedDiet with physical activity., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Nutritional assessment of plant-based meat alternatives: a comparison of nutritional information of plant-based meat alternatives in Spanish supermarkets

  • Rizzolo-Brime, Lucía
  • Puyol Martin, Yael
  • Jakszyn, Paula
  • Orta-Ramirez, Alicia
Since the classification of processed meat as carcinogenic by the International Agency for Research on Cancer (IARC) in 2015, an increase in consumption of plant-based meat alternatives (PBMAs) has been observed worldwide. This occurs in a context characterized by concern for health, animal welfare, and sustainability; however, evidence of their nutritional quality is still limited. Therefore, our objective was to evaluate the nutritional profile and processing degree of PBMAs available in Spain. In 2020, products from seven Spanish supermarkets were analyzed for their nutritional content and ingredients. Of the 148 products, the majority were low in sugars but moderate in carbohydrates, total and saturated fat, and high in salt. The main vegetable protein sources were soy (91/148) and wheat gluten (42/148). Comparatively, 43/148 contained animal protein, the most common being egg. Overall, PBMAs had a long list of ingredients and additives, and they were classified as ultra-processed foods (UPFs) according to the NOVA system. This study shows that the PBMAs available in Spanish supermarkets have a variable nutritional composition within and between categories. Further research is needed to determine if replacing meat with these UPFs could be a good alternative towards healthier and more sustainable dietary patterns., info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Activation of PI3K/Akt Signaling Pathway in Rat Hypothalamus Induced by an Acute Oral Administration of D-Pinitol

  • Medina-Vera, Dina
  • Navarro, Juán Antonio
  • Tovar, Rubén
  • Rosell-Valle, Cristina
  • Gutiérrez-Adán, Alfonso
  • Ledesma, Juán Carlos
  • Sanjuan, Carlos
  • Pavón, Francisco Javier
  • Baixeras, Elena
  • Rodriguez de Fonseca, F.
  • Decara, Juan
D-Pinitol (DPIN) is a natural occurring inositol capable of activating the insulin pathway in peripheral tissues, whereas this has not been thoroughly studied in the central nervous system. The present study assessed the potential regulatory effects of DPIN on the hypothalamic insulin signaling pathway. To this end we investigated the Phosphatidylinositol-3-kinase (PI3K)/Protein Kinase B (Akt) signaling cascade in a rat model following oral administration of DPIN. The PI3K/Akt-associated proteins were quantified by Western blot in terms of phosphorylation and total expression. Results indicate that the acute administration of DPIN induced time-dependent phosphorylation of PI3K/Akt and its related substrates within the hypothalamus, indicating an activation of the insulin signaling pathway. This profile is consistent with DPIN as an insulin sensitizer since we also found a decrease in the circulating concentration of this hormone. Overall, the present study shows the pharmacological action of DPIN in the hypothalamus through the PI3K/Akt pathway when giving in fasted animals. These findings suggest that DPIN might be a candidate to treat brain insulin-resistance associated disorders by activating insulin response beyond the insulin receptor., This work was supported by grants from the following institutions: Ministerio de Economía y Competitividad, Gobierno de España (Grant RTC-2016-4983-1), EU-ERDF-Instituto de Salud Carlos III (Grant PI19/01577), and Consejería de Economía, Conocimiento y Universidad, Junta de Andalucía (Grant P18-TP-5194), Proyecto de Investigación en Salud, Consejería de Salud y Familias (PI-0139-2018). D.M-V. (FI20/00227) holds a “PFIS” predoctoral contract from the National System of Health, EU-ERDF-Instituto de Salud Carlos III, Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Evaluation of a Novel Commercial Real-Time PCR Assay for the Simultaneous Detection of Cryptosporidium spp., Giardia duodenalis, and Entamoeba histolytica

  • Dashti, Alejandro
  • Alonso, Henar
  • Escolar-Miñana, Cristina
  • Köster, Pamela C.
  • Bailo, Begoña
  • Carmena, David
  • González-Barrio, David
Thorough independent assessment of the diagnostic performance of novel diagnostic assays is essential to ascertain their true usefulness and applicability in routine clinical practice. This is particularly true for commercially available kits based on multiplex real-time PCR aimed to detect and differentiate multiple pathogens in a single biological sample. Cryptosporidium spp., Giardia duodenalis, and Entamoeba histolytica are the most common diarrhea-causing protozoan species globally. Misdiagnosis is a concern for asymptomatic and chronic infections. Multiplexing, i.e., the detection of more than one parasite in a single test by real-time PCR, allows high diagnostic performance with favorable cost-effectiveness. We conducted a clinical evaluation of the VIASURE Cryptosporidium, Giardia, & E. histolytica real-time PCR assay (CerTest Biotec, San Mateo de Gallego, Spain) against a large panel (n = 358) of well-characterized DNA samples positive for Cryptosporidium spp. (n = 96), G. duodenalis (n = 115), E. histolytica (n = 25), and other parasitic species of the phyla Amoebozoa (n = 11), Apicomplexa (n = 14), Euglenozoa (n = 8), Heterokonta (n = 42), Metamonada (n = 37), Microsporidia (n = 4), and Nematoda (n = 6). DNA samples were obtained from clinical stool specimens or cultured isolates in a national reference center. Estimated sensitivity and specificity were 0.96 and 0.99 for Cryptosporidium spp., 0.94 and 1 for G. duodenalis, and 0.96 and 1 for E. histolytica, respectively. Positive and negative predictive values were calculated as 1 and 0.98 for Cryptosporidium spp., 0.99 and 0.98 for G. duodenalis, and 1 and 0.99 for E. histolytica, respectively. The assay identified six Cryptosporidium species (Cryptosporidium hominis, Cryptosporidium parvum, Cryptosporidium canis, Cryptosporidium felis, Cryptosporidium scrofarum, and Cryptosporidium ryanae) and four G. duodenalis assemblages (A, B, C, and F). The VIASURE assay provides rapid and accurate simultaneous detection and identification of the most commonly occurring species and genetic variants of diarrhea-causing parasitic protozoa in humans. IMPORTANCE Thorough independent assessment of the diagnostic performance of novel diagnostic assays is essential to ascertain their true usefulness and applicability in routine clinical practice. This is particularly true for commercially available kits based on multiplex real-time PCR aimed to detect and differentiate multiple pathogens in a single biological sample. In this study, we conducted a clinical evaluation of the VIASURE Cryptosporidium, Giardia, & E. histolytica real-time PCR assay (CerTest Biotec) for the detection and identification of the diarrhea-causing enteric protozoan parasites Cryptosporidium spp., G. duodenalis, and E. histolytica. A large panel of well-characterized DNA samples from clinical stool specimens or cultured isolates from a reference center was used for this purpose. The VIASURE assay demonstrated good performance for the routine testing of these pathogens in clinical microbiological laboratories.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Occurrence and limited zoonotic potential of Cryptosporidium spp., Giardia duodenalis, and Balantioides coli infections in free-ranging and farmed wild ungulates in Spain

  • Dashti, A.
  • Köster, P. C.
  • Bailo, B.
  • Sánchez de las Matas, A.
  • Habela, M. Á.
  • Rivero-Juarez, A.
  • Vicente, J.
  • Serrano, E.
  • Arnal, M. C.
  • Fernández de Luco, D.
  • Morrondo, P.
  • Armenteros, J. A.
  • Balseiro, A.
  • Cardona, G. A.
  • Martínez-Carrasco, C.
  • Ortiz, J. A.
  • Carpio, A. J.
  • Calero-Bernal, R.
  • González-Barrio, D.
  • Carmena, D.
Little information is currently available on the occurrence and molecular diversity of the enteric protozoan parasites Cryptosporidium spp., Giardia duodenalis, and Balantioides coli in wild ungulates and the role of these host species as potential sources of environmental contamination and consequent human infections. The presence of these three pathogens was investigated in eight wild ungulate species present in Spain (genera Ammotragus, Capra, Capreolus, Cervus, Dama, Ovis, Rupicapra, and Sus) by molecular methods. Faecal samples were retrospectively collected from free-ranging (n = 1058) and farmed (n = 324) wild ungulates from the five Spanish bioregions. Overall infection rates were 3.0% (42/1382; 95% CI: 2.1–3.9%) for Cryptosporidium spp., 5.4% (74/1382; 95% CI: 4.2–6.5%) for G. duodenalis, and 0.7% (9/1382; 95% CI: 0.3–1.2%) for B. coli. Cryptosporidium infection was detected in roe deer (7.5%), wild boar (7.0%) and red deer (1.5%), and G. duodenalis in southern chamois (12.9%), mouflon (10.0%), Iberian wild goat (9.0%), roe deer (7.5%), wild boar (5.6%), fallow deer (5.2%) and red deer (3.8%). Balantioides coli was only detected in wild boar (2.5%, 9/359). Sequence analyses revealed the presence of six distinct Cryptosporidium species: C. ryanae in red deer, roe deer, and wild boar; C. parvum in red deer and wild boar; C. ubiquitum in roe deer; C. scrofarum in wild boar; C. canis in roe deer; and C. suis in red deer. Zoonotic assemblages A and B were detected in wild boar and red deer, respectively. Ungulate-adapted assemblage E was identified in mouflon, red deer, and southern chamois. Attempts to genotype samples positive for B. coli failed. Sporadic infections by canine- or swine-adapted species may be indicative of potential cross-species transmission, although spurious infections cannot be ruled out. Molecular evidence gathered is consistent with parasite mild infections and limited environmental contamination with (oo)cysts. Free-ranging wild ungulate species would not presumably play a significant role as source of human infections by these pathogens. Wild ruminants do not seem to be susceptible hosts for B. coli.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Heart disease characterization and myocardial strain analysis in patients with PACS1 Neurodevelopmental Disorder

  • Latorre-Pellicer, Ana
  • Trujillano, Laura
  • del Rincón, Julia
  • Peña-Marco, Mónica
  • Gil-Salvador, Marta
  • Lucia-Campos, Cristina
  • Arnedo, María
  • Puisac, Beatriz
  • Ramos, Feliciano J.
  • Ayerza-Casas, Ariadna
  • Pié, Juan
Background: PACS1 neurodevelopmental disorder (PACS1-NDD) (MIM# 615009) is a rare autosomal dominant disease characterized by neurodevelopmental delay, dysmorphic facial features, and congenital malformations. Heart disease (HD) is frequently present in individuals with PACS1-NDD, but a compressive review of these anomalies and an evaluation of cardiac function in a cohort of patients are lacking. Methods: (i) Cardiac evaluation in 11 PACS1-NDD patients was conducted using conventional echocardiography. (ii) Heart function was assessed by tissue Doppler imaging, and two-dimensional speckle tracking was performed in seven patients and matched controls. (iii) This systematic review focused on determining HD prevalence in individuals with PACS1-NDD. Results: In our cohort, 7 of 11 patients presented HD. (Among them, three cases of ascending aortic dilatation (AAD) were detected and one mitral valve prolapse (MVP).) None of the patients showed echocardiographic pathological values, and the left global longitudinal strain was not significantly different between patients and controls (patients −24.26 ± 5.89% vs. controls −20.19 ± 1.75%, p = 0.3176). In the literature review, almost 42% (42/100) of individuals with PACS1-NDD reportedly experienced HD. Septal defects were the most common malformation, followed by patent ductus arteriosus. Conclusions: Our results show a high prevalence of HD in PACS1-NDD patients; in this way, AAD and MVP are reported for the first time in this syndrome. Furthermore, a detailed cardiac function evaluation in our cohort did not reveal evidence of cardiac dysfunction in individuals with PACS1-NDD. Cardiology evaluation should be included for all individuals with Schuurs-Hoeijmakers syndrome.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Psychometric properties of the engaged living scale (ELS) Spanish version in a large sample of Spanish pilgrims

  • Navarrete, J.
  • Colomer-Carbonell, A.
  • Sanabria-Mazo, J. P.
  • Luciano, J. V.
  • Soler, J.
  • García-Campayo, J.
  • Demarzo, M.
  • Montero-Marín, J.
  • Bohlmeijer, E. T.
  • Campos, D.
  • Cebolla, A.
  • Feliu-Soler, A.
Engaged Living (values clarity and committed action) is a main process of psychological flexibility as defined by Acceptance and Commitment Therapy. The Engaged Living Scale (ELS) was designed to measure it. The purpose of this study was to translate the ELS to Spanish and to examine the reliability and validity of its scores in a heterogeneous sample of 752 Spanish pilgrims of the Way of Saint James (pre-post analysis: n = 285). Confirmatory factor analyses were computed to study the structural validity of the ELS scores. In addition, network analyses were computed to examine convergent and discriminant validity. The included variables were engaged living, mindfulness facets, satisfaction with life, subjective happiness, affect, depression, anxiety, and perceived stress. Results showed that the Spanish version of the ELS is two-factorial (valued living [VL] and life fulfillment [LF]). The ELS scores showed good reliability. In addition, it was able to detect VL and LF changes after the Way underscoring its sensitivity to change. The network analyses indicated adequate convergent and discriminant validity of the ELS. Changes in satisfaction with life, life fulfillment, happiness, and valued living scores were most strongly associated with changes in perceived stress, affect, mindfulness facets, depression, and anxiety. In short, the Spanish version of the ELS appeared to be a reliable and valid instrument to assess the engaged response style in the current samples.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Blastocystis occurrence and subtype diversity in European wild boar (Sus scrofa) from the Iberian Peninsula

  • Köster, Pamela C.
  • Figueiredo, Ana M.
  • Maloney, Jenny G.
  • Dashti, Alejandro
  • Bailo, Begoña
  • Torres, Rita T.
  • Fonseca, Carlos
  • Mysterud, Atle
  • Habela, Miguel Á.
  • Rivero-Juarez, Antonio
  • Vicente, Joaquín
  • Serrano, Emmanuel
  • Arnal, Maria C.
  • de Luco, Daniel Fernández
  • Armenteros, José A.
  • Balseiro, Ana
  • Cardona, Guillermo A.
  • Carvalho, João
  • Hipólito, Dário
  • Fernandes, Joana
  • Palmeira, Josman D.
  • Calero-Bernal, Rafael
  • González-Barrio, David
  • Santin, Monica
  • Carmena, David
The ongoing increase in wild boar populations across Europe has fostered human–wildlife conflicts, including the transmission of emerging pathogens with zoonotic importance. Blastocystis is a ubiquitous, faecal-oral transmitted protist that can cause gastrointestinal illnesses and is observed in humans and animals worldwide. The role of wildlife in the epidemiology of Blastocystis is insufficiently understood. Thus, we investigated the occurrence and subtype diversity of Blastocystis in free-ranging wild boars from the Iberian Peninsula using conventional PCR and next-generation amplicon sequencing of a fragment of the ssu RNA gene. A total of 459 wild boar faecal samples were collected across Spain (n = 360) and Portugal (n = 99) between 2014 and 2021. Blastocystis was present in 15.3% (70/459; 95% CI 12.1–18.9) of the wild boars analysed, and its occurrence was significantly higher in Portugal (34.3%, 34/99; 95% CI 25.1–44.6) than in Spain (10.0%, 36/360; 95% CI 7.1–13.6). Seven Blastocystis subtypes (ST5, ST10b, ST13–ST15, ST24b, and ST43) were detected among the surveyed wild boar populations, with greater variability detected in Portuguese samples. ST5 was identified in all the Blastocystis-positive animals, whereas 14.3% of them harboured ST mixed colonisations. Our results demonstrate that Blastocystis ST5 is particularly adapted to infect wild boars. The additional identification of zoonotic STs reinforces the role of wild boars as spreaders of zoonotic infections with public health significance.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

An intragenic duplication in the AFF2 gene associated with Cornelia de Lange syndrome phenotype

  • Lucia-Campos, Cristina
  • Parenti, Ilaria
  • Latorre-Pellicer, Ana
  • Gil-Salvador, Marta
  • Bestetti, Ilaria
  • Finelli, Palma
  • Larizza, Lidia
  • Arnedo, María
  • Ayerza-Casas, Ariadna
  • Del Rincón, Julia
  • Trujillano, Laura
  • Morte, Beatriz
  • Pérez-Jurado, Luis A.
  • Lapunzina, Pablo
  • Leitão, Elsa
  • Beygo, Jasmin
  • Lich, Christina
  • Kilpert, Fabian
  • Kaya, Sabine
  • Depienne, Christel
  • Kaiser, Frank J.
  • Ramos, Feliciano J.
  • Puisac, Beatriz
  • Pié, Juan
Cornelia de Lange syndrome (CdLS, OMIM #122470, #300590, #300882, #610759, and #614701) is a rare congenital disorder that affects the development of multiple organs and is characterized by physical abnormalities and cognitive and behavioral disabilities. Its molecular basis is mainly based on alterations in genes encoding structural and regulatory proteins related to the cohesin complex. Moreover, other transcriptional regulatory factors have been linked to this syndrome. However, additional causative genes are still unknown, since many patients still lack a molecular diagnosis. Herein, we describe a case with multiple affected family members presenting with an intragenic duplication in the AFF2 gene. The direct tandem intragenic duplication of exons 10, 11 and 12 was detected through high-resolution array Comparative Genomic Hybridization and next-generation sequencing technologies. Confirming the X-linked inheritance pattern, the duplication was found in the patient, his mother and his maternal aunt affected (dizygotic twins). Targeted sequencing with Oxford Nanopore Technologies revealed an aberrant transcript which is predominantly expressed in the patient and his aunt. Along with these results, a significant reduction in AFF2 gene expression levels was detected in these two individuals. Clinically both subjects exhibit a classic CdLS phenotype, whereas the mother is mostly unaffected. Consistent with the phenotypical differences observed between the mother and the aunt, there is a marked difference in X-inactivation patterns skewing. Given the crucial role of AFF2 in transcriptional regulation, it is not surprising that AFF2 variants can give rise to CdLS phenotypes. Therefore, the AFF2 gene should be considered for the molecular diagnosis of this syndrome.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Cytomegalovirus reactivation is associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation

  • Aguilera, Victoria
  • Romero Moreno, Sarai
  • Conde, Isabel
  • Rubín, Angel
  • Carvalho-Gomes, Angela
  • Romero, Mario
  • Zamora-Olaya, Javier
  • Gómez-Bravo, Miguel Angel
  • Fuentes-Valenzuela, Esteban
  • Dopazo, Cristina
  • Bilbao, Nikita
  • González, Antonio
  • Sánchez-Martínez, Ana
  • Pascual, Sonia
  • Rivera-Esteban, Jesús
  • Herrero, José Ignacio
  • Lorente, Sara
  • Cuadrado-Lavín, Antonio
  • Nogueras, Flor
  • Martínez-Arenas, Laura
  • González-Grande, Rocío
  • Berenguer, Marina
  • Rodriguez-Perálvarez, Manuel
In patients with hepatocellular carcinoma (HCC), undergoing liver transplantation (LT), cytomegalovirus reactivation (CMVr) may modulate the immune system to prevent tumor recurrence. In this multicenter retrospective study (2010–2015) involving 15 institutions, we assessed the effect of early CMVr in tumor recurrence rates among 771-LT HCC patients with tacrolimus-based immunosuppression (88% men, mean age 58 years). CMV prophylaxis was implemented for 19.7% of patients, while the rest were managed with preemptive therapy. The Milan criteria were met by 88% of patients. Microvascular invasion was present in 12.7% of explanted livers. The serum AFP level before transplantation was 5.1 (3–15) ng/mL. After a median follow-up of 7.4 years, 101 patients (13%) experienced HCC recurrence. CMVr occurred in 235 patients (30.5%) at a median of 41.5 days post-LT and 42 patients (5.6%) had CMV disease. Cumulative exposure to tacrolimus within the first 3 months after LT was similar among patients with and without CMVr. In a multivariate Cox regression analysis, factors associated with an increased rate of HCC recurrence included microvascular invasion [HR:2.82, CI95%:1.55–5.14; p 0.0001], donation after circulatory determination of death [HR:4.43,CI95%:1.52–12.9; p 0.006) and diameter of the main nodule at explant [HR:1.04, CI95%:1.02–1.06; p < 0.001]. Meanwhile CMVr [HR:0.46, CI95%:0.23–0.93, p 0.031] and MELD [HR:0.93, CI95%:0.87–0.99; p0.017] exhibited protective effects. In conclusion, early CMVr may protect against HCC recurrence. The underlying immune mechanisms warrant further investigation.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Brain structural and functional substrates of ADGRL3 (latrophilin 3) haplotype in attention-deficit/hyperactivity disorder

  • Moreno‑Alcázar, Ana
  • Ribases Haro, Marta
  • Sanchez Mora, Cristina P
  • Palomar Martínez, Gloria
  • Bosch Munso, Rosa M
  • Casas Brugué, Miquel
  • Ramos-Quiroga, Josep Antoni
TDAH; Genotipatge; Imatges per ressonància magnètica, TDAH; Genotipado; Imagen de resonancia magnética, ADHD; Genotyping; Magnetic resonance imaging, Previous studies have shown that the gene encoding the adhesion G protein-coupled receptor L3 (ADGRL3; formerly latrophilin 3, LPHN3) is associated with Attention-Deficit/Hyperactivity Disorder (ADHD). Conversely, no studies have investigated the anatomical or functional brain substrates of ADGRL3 risk variants. We examined here whether individuals with different ADGRL3 haplotypes, including both patients with ADHD and healthy controls, showed differences in brain anatomy and function. We recruited and genotyped adult patients with combined type ADHD and healthy controls to achieve a sample balanced for age, sex, premorbid IQ, and three ADGRL3 haplotype groups (risk, protective, and others). The final sample (n = 128) underwent structural and functional brain imaging (voxel-based morphometry and n-back working memory fMRI). We analyzed the brain structural and functional effects of ADHD, haplotypes, and their interaction, covarying for age, sex, and medication. Individuals (patients or controls) with the protective haplotype showed strong, widespread hypo-activation in the frontal cortex extending to inferior temporal and fusiform gyri. Individuals (patients or controls) with the risk haplotype also showed hypo-activation, more focused in the right temporal cortex. Patients showed parietal hyper-activation. Disorder-haplotype interactions, as well as structural findings, were not statistically significant. To sum up, both protective and risk ADGRL3 haplotypes are associated with substantial brain hypo-activation during working memory tasks, stressing this gene’s relevance in cognitive brain function. Conversely, we did not find brain effects of the interactions between adult ADHD and ADGRL3 haplotypes., This work was supported by several grants from the Plan Nacional de I+D+i and co-funded by the Instituto de Salud Carlos III-Subdirección General de Evaluación y Fomento de la Investigación and the European Regional Development Fund (FEDER): Research Project Grant (PI11/01629, PI11/01766, PI16/01505, PI17/00289, PI18/01788, PI19/00394, PI19/00721, and PI19/01224), Miguel Servet Research Contracts (CP09/00119 and CPII15/00023 to MR, CP10/00596 to EP-C and CP14/00041 and CPII19/00009 to JR), Sara Borrell contract (CD15/00199 to CSM), PFIS contract (FI20/00047 to LF), mobility grant (MV16/00039 to CSM), Pla Estratègic de Recerca i Innovació en Salut (PERIS); Generalitat de Catalunya (MENTAL-Cat; SLT006/17/287) and the Agència de Gestió d’Ajuts Universitaris i de Recerca-AGAUR, Catalonian Government (2009SGR211 and 2017SGR1461). The funding organizations played no role in the study design, data collection and analysis, or manuscript approval.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Mediterranean diet, energy restriction, physical activity, and atherogenicity of very-low density lipoproteins: findings from two randomized controlled trials

  • Pérez-Vega, Karla Alejandra
  • Castañer, Olga
  • Sanllorente Melenchon, Albert
  • Lassale, Camille
  • Ros Rahola, Emilio
  • Pintó Sala, Xavier
  • Estruch Riba, Ramon
  • Salas Salvadó, Jordi
  • Corella Piquer, Dolores
  • Alonso Gómez, Ángel M.
  • Serra Majem, Lluís
  • Razquin, Cristina
  • Fiol, Miquel
  • Lapetra, José
  • Gómez-Gracia, Enrique
  • Tinahones Madueño, Francisco J.
  • Hernáez, Álvaro
  • Fitó Colomer, Montserrat
Scope: Some very-low density lipoprotein (VLDL) properties may render themmore pro-atherogenic. We aimed to assess whether a Mediterranean diet(MedDiet) or an energy-reduced MedDiet with increased physical activityimproves them.Methods and results: In a sample of the PREvención con DIeta MEDiterránea(PREDIMED) study, a 1-year intervention with MedDiet with extra-virgin oliveoil (n = 89) or nuts (MedDiet-Nuts; n = 79) is compared with a low-fat diet(n = 90). In the PREDIMED-Plus study, a 1-year intervention withenergy-reduced MedDiet and physical activity (n = 103) is compared with anad libitum MedDiet (n = 101). VLDL levels of apolipoprotein C-I, C-III,triglycerides, and cholesterol; the apolipoprotein E-/C-I ratio; and VLDLex-vivo triglyceride transfer are measured. In PREDIMED participants in bothMedDiet groups combined, VLDL apolipoprotein C-III levels are nominallyreduced (−0.023 SD units, 95% CI −0.44 to −0.014, p = 0.037). VLDLtriglyceride transfer is nominally increased in the MedDiet-Nuts group (+0.39SD units, 95% CI 0.012–0.78, p = 0.045). In PREDIMED-Plus, no inter-groupdifferences are detected.Conclusions: In older adults at high cardiovascular risk, MedDiet isassociated with lower VLDL atherogenicity versus a low-fat diet. Nodifferences are seen after an energy-reduced MedDiet with physical activity., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

  • ADAM-ARTIGUES, ANNA
  • Brasó-Maristany, Fara
  • Cervera Vidal, Raimundo
  • Tormo, Eduardo
  • Arribas López, Joaquin Vicente
  • Arenas Lahuerta, Enrique Javier
  • Martínez-Sabadell, Alex
Breast cancer; Heterodimerization, Cáncer de mama; Heterodimerización, Càncer de mama; Heterodimerització, Anti-HER2 therapies have markedly improved prognosis of HER2-positive breast cancer. However, different mechanisms play a role in treatment resistance. Here, we identified AXL overexpression as an essential mechanism of trastuzumab resistance. AXL orchestrates epithelial-to-mesenchymal transition and heterodimerizes with HER2, leading to activation of PI3K/AKT and MAPK pathways in a ligand-independent manner. Genetic depletion and pharmacological inhibition of AXL restored trastuzumab response in vitro and in vivo. AXL inhibitor plus trastuzumab achieved complete regression in trastuzumab-resistant patient-derived xenograft models. Moreover, AXL expression in HER2-positive primary tumors was able to predict prognosis. Data from the PAMELA trial showed a change in AXL expression during neoadjuvant dual HER2 blockade, supporting its role in resistance. Therefore, our study highlights the importance of targeting AXL in combination with anti-HER2 drugs across HER2-amplified breast cancer patients with high AXL expression. Furthermore, it unveils the potential value of AXL as a druggable prognostic biomarker in HER2-positive breast cancer., A.A.-A., E.J.A., and F.B.-M. were supported by Asociación Española contra el Cáncer AECC (PRDVA18013LLUC to A.A.-A., POSTD211413AREN to E.J.A., and AECC_Postdoctoral17-1062 to F.B.-M.). A.M.-S. was funded by the Spanish Government (PFIS FI20/00188). J.Ar. is supported by Breast Cancer Research Foundation (BCRF-20-08), Instituto de Salud Carlos III Project reference number AC15/00062, and the EC under the framework of the ERA-NET TRANSCAN-2 initiative cofinanced by FEDER, Instituto de Salud Carlos III (CB16/12/00449 and PI19/01181), and Asociación Española Contra el Cáncer (AECC). A.P. was supported by Instituto de Salud Carlos III—PI19/01846, Breast Cancer Now—2018NOVPCC1294. P.E. and A.L. were funded by Instituto de Salud Carlos III and cofinanced by FEDER (PI18/01219 to P.E. and CB16/12/00481 to A.L.). J.M.C. was funded by Sociedad Española de Oncología Médica (Rio Hortega-SEOM) and Compromiso ADAMED.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The Role of Purported Mucoprotectants in Dealing with Irritable Bowel Syndrome, Functional Diarrhea, and Other Chronic Diarrheal Disorders in Adults

  • Abril Gil, Maria del Mar
  • Albert Bayo, Merce
  • Exposito Fernandez, Elba
  • Gonzalez Castro, Ana Maria
  • Lobo Alvarez, Beatriz
  • Santos Vicente, Fco Javier
  • Alonso Cotoner, Carmen
  • Ganda Mall, John-Peter
Chronic diarrhea; Mucoprotectans; Mucus, Diarrea crónica; Mucoprotectores; Moco, Diarrea crònica, Mucoprotectors; Moc, Chronic diarrhea is a frequent presenting symptom, both in primary care medicine and in specialized gastroenterology units. It is estimated that more than 5% of the global population suffers from chronic diarrhea. and that about 40% of these subjects are older than 60 years. The clinician is frequently faced with the need to decide which is the best therapeutic approach for these patients. While the origin of chronic diarrhea is diverse, impairment of intestinal barrier function, dysbiosis. and mucosal micro-inflammation are being increasingly recognized as underlying phenomena characterizing a variety of chronic diarrheal diseases. In addition to current pharmacological therapies, there is growing interest in alternative products such as mucoprotectants, which form a mucoadhesive film over the epithelium to reduce and protect against the development of altered intestinal permeability, dysbiosis, and mucosal micro-inflammation. This manuscript focuses on chronic diarrhea in adults, and we will review recent evidence on the ability of these natural compounds to improve symptoms associated with chronic diarrhea and to exert protective effects for the intestinal barrier., Supported in part by Fondo Europeo de Desarrollo Regional (FEDER), Fondo de Investigación Sanitaria and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Subdirección General de Investigación Sanitaria, Ministerio de Economía y Competitividad, Ajuts per a la contractació de personal investigador FI—Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya, The Swedish Research Council and The European Commision: FIS LOBO 2019? (BL); FI20/00256 (MA-B). PI17/0190 (JS); PI15/00301 (CA-C); CIBERehd CB06/04/0021 (JS & CA-C); dnr 2019–00653 (J-PGM); 2020FI_B1 00127, 2019FI_B 00817 (MA-B); GA No:848228 (JS, CA-C, EE, AMG-C, BL).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The target antigen determines the mechanism of acquired resistance to T cell-based therapies

  • Morancho Armisen, Beatriz
  • Román Alonso, Macarena
  • Ovejero Romero, Pablo
  • Arribas López, Joaquin Vicente
  • Arenas Lahuerta, Enrique Javier
  • Martínez-Sabadell, Alex
  • Rius Ruiz, Irene
  • Escorihuela Baez, Marta
Cancer; Antigen; Resistance, Cáncer; Antígeno; Resistencia, Càncer; Antigen; Resistència, Despite the revolution of immunotherapy in cancer treatment, patients eventually progress due to the emergence of resistance. In this scenario, the selection of the tumor antigen can be decisive in the success of the clinical response. T cell bispecific antibodies (TCBs) are engineered molecules that include binding sites to the T cell receptor and to a tumor antigen. Using gastric CEA+/HER2+ MKN45 cells and TCBs directed against CEA or HER2, we show that the mechanism of resistance to a TCB is dependent on the tumor antigen. Acquired resistant models to a high-affinity-CEA-targeted TCB exhibit a reduction of CEA levels due to transcriptional silencing, which is reversible upon 5-AZA treatment. In contrast, a HER2-TCB resistant model maintains HER2 levels and exhibit a disruption of the interferon-gamma signaling. These results will help in the design of combinatorial strategies to increase the efficacy of cancer immunotherapies and to anticipate and overcome resistances., This work was supported by Asociación Española Contra el Cancer (AECC), Breast Cancer Research Foundation (BCRF-21-008), and Instituto de Salud Carlos III (PI19/01181). A.M.S. was funded by the Spanish Government (PFIS FI20/00188). B.M. was funded by a fellowship from PERIS (Departament de Salut, Generalitat de Catalunya). M.R.A. was funded by Agency for Management of University and Research Grants (AGAUR, 2022 FI_B2 00080). P.O.R. was funded by the BBVA. E.J.A. was funded by the AECC (POSTD211413AREN). VHIO acknowledges the Cellex Foundation for providing research facilities and equipment, the Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) from the Institute of Health Carlos III (ISCIII), and the Department of Health (Generalitat de Catalunya, SLT008/18/00198 SLT008/18/00205) for their support on this research. The authors acknowledge financial support from the State Agency for Research (Agencia Estatal de Investigación) (CEX2020-001024-S/AEI/10.13039/501100011033) and for the Cancer Immunology and Immunotherapy (CAIMI-2) program funded by BBVA Foundation. We would like to remark the funding from B.M PERIS (Spain). The authors thank Dr. Anne Freimoser-Grundschober and Roche for helping provide the TCBs. The graphical abstract was created with BioRender.com.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The leading role of MYC in DNA damage response: exploring opportunities for therapeutic inhibition

  • Giuntini, Fabio
  • Massó-Vallés, Daniel
  • Whitfield, Jonathan
  • Soucek, Laura
DNA damage response; DNA damage response inhibitors; MYC inhibition, Respuesta al daño del ADN; Inhibidores de la respuesta al daño del ADN; Inhibición de MYC, Resposta al dany de l'ADN; Inhibidors de la resposta al dany de l'ADN; Inhibició de MYC, MYC performs a dual role in DNA Damage Response (DDR), promoting genomic instability through replication stress, R-loop formation, and topoisomerase-mediated damage, while simultaneously activating DNA repair pathways to maintain cell survival. This review provides a comprehensive analysis of how MYC inhibition affects DDR pathway dependencies. In fact, when MYC is inhibited, cancer cells lose both their proficient DNA repair capacity and their protective mechanisms against replication stress. This creates a therapeutic window in which combining MYC inhibitors with DDR-targeting agents may achieve synergistic anti-cancer effects. Central to this approach is the exploration of rational combination strategies that pair MYC inhibitors with various DDR modulators including Poly (ADP-ribose) polymerase (PARP) inhibitors, ATR/CHK1 inhibitors, and other DNA repair pathway disruptors. This review summarizes preclinical evidence demonstrating enhanced therapeutic efficacy when MYC inhibition is combined with DDR-targeting agents and discusses early clinical findings that support this promising therapeutic strategy., The author(s) declared that financial support was received for this work and/or its publication. We thank the Spanish Association of Metastatic Breast Cancer for the Chiara Giorgetti Award 2022, Instituto de Salud Carlos III (FI20/00274 – FG PFIS doctoral bursary), Ministerio de Ciencia e Innovación (Retos de Colaboración RTC2019-007067-1, Líneas Estratégicas PLEC2021-007959), Generalitat de Catalunya (AGAUR 2017/SGR 537 and 2021/SGR 01509), EDIReX (H2020 INFRAIA 731105-2), the European Research Council (ERC-2023-ADG 101142260), the Spanish Ministry of Science and Innovation and European Union through the NextGenerationEU program, in the context of the Plan de Recuperacion, Transformacion y Resiliencia (RETOS; CPP2022-009808) and the FERO foundation for funding support.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Acute stress triggers sex-dependent rapid alterations in the human small intestine microbiota composition

  • Rodiño Janeiro, Bruno Kotska
  • Khannous, Olfat
  • Pigrau Pastor, Marc
  • Willis, Jesse R.
  • Pardo Camacho, Cristina
  • Albert Bayo, Mercé
  • Martínez Martínez, Cristina
  • lobo, beatriz
  • Santos, Javier
  • Salvo Romero, Eloisa
  • Nieto Ruiz, Adoración
  • Expósito , Elba
  • Fortea, Marina
  • González Castro, Ana Maria
  • Guagnozzi, Danila
  • Vicario Perez, Maria
  • Alonso Cotoner, Carmen
Irritable bowel syndrome; Small intestine microbiota; Stress, Síndrome del intestino irritable; Microbiota del intestino delgado; Estrés, Síndrome de l'intestí irritable; Microbiota de l'intestí prim; Estrès, Background/aims: Digestive disorders of gut-brain interaction (DGBI) are very common, predominant in females, and usually associated with intestinal barrier dysfunction, dysbiosis, and stress. We previously found that females have increased susceptibility to intestinal barrier dysfunction in response to acute stress. However, whether this is associated with changes in the small bowel microbiota remains unknown. We have evaluated changes in the small intestinal microbiota in response to acute stress to better understand stress-induced intestinal barrier dysfunction. Methods: Jejunal biopsies were obtained at baseline and 90 min after cold pain or sham stress. Autonomic (blood pressure and heart rate), hormonal (plasma cortisol and adrenocorticotropic hormone) and psychological (Subjective Stress Rating Scale) responses to cold pain and sham stress were monitored. Microbial DNA from the biopsies was analyzed using a 16S metabarcoding approach before and after cold pain stress and sham stress. Differences in diversity and relative abundance of microbial taxa were examined. Results: Cold pain stress was associated with a significant decrease in alpha diversity (P = 0.015), which was more pronounced in females, along with significant sex differences in the abundance of specific taxa and the overall microbiota composition. Microbiota alterations significantly correlated with changes in psychological responses, hormones, and gene expression in the intestinal mucosal. Cold pain stress was also associated with activation of autonomic, hormonal and psychological response, with no differences between sexes. Conclusions: Acute stress elicits rapid alterations in bacterial composition in the jejunum of healthy subjects and these changes are more pronounced in females. Our results may contribute to the understanding of female predominance in DGBI., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by Fondo Europeo de Desarrollo Regional (FEDER), Fondo de Investigación Sanitaria and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), y de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Subdirección General de Investigación Sanitaria, Ministerio de Economía y Competitividad y Ministerio de Ciencia e Innovación: EII2011-0035, CD15/00010 and MV17-00043 (BR-J); CM10/00155 (MP); FI12/00254 (ES-R); FI20/00256 (MA-B); CP18/00116 (CM); PI19/01643 (BL); PI16/00583, PI19/01643 and CPII16/00031 (MV); PI17/0190 (JS); INB Grant PT17/0009/0023 (TG); PI15/00301 (CA-C); CIBEREHD CB06/04/0021 (AG-C, DG, BL, MV, JS, CA-C); CIBERINFEC CB21/13/00061 (TG). Vall d'Hebron Institut de Recerca, Programa de becas predoctorales Amics de Vall d'Hebron: PRED-VHIR-2014-018 (MF), PRED-VHIR-2016-53 (CP-C). Ajuts per a la contractació de personal investigador FI, Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya: 2020FI_B1 00127 & 2019FI_B 00817 (MA-B), SGR423 (TG). Formación de profesorado universitario (FPU) program from the Spanish Ministerio de Universidades: FPU2020-02907 (OK-L). European Union's Horizon 2020 research and innovation program: ERC-2016-724173 (TG). Gordon and Betty Moore Foundation: GBMF9742 (TG).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer

  • Giuntini, Fabio
  • Zacarias Fluck, Mariano F
  • Arnal, Magdalena
  • Pedretti, Flaminia
  • Grueso, Judit
  • Guzman Torres, Marta
  • González-Larreategui, Íñigo
  • Herencia Ropero, Andrea
  • Casacuberta-Serra, Sílvia
  • Serrano del Pozo, Erika
  • Rodríguez, Olga
  • Llop-Guevara, Alba
  • Balmaña, Judith
  • Nonell, Lara
  • Whitfield, Jonathan
  • Soucek, Laura
  • Serra, Violeta
Cancer; DNA damage; Omomyc, Càncer; Dany a l'ADN; Omomyc, Cáncer; Daño en el ADN; Omomyc, MYC is dysregulated in most human cancers and is a DNA damage response (DDR) modulator capable of both promoting genomic instability and enhancing DNA repair. Here, we show that Omomyc, the only direct MYC inhibitor that has completed a phase 1 trial, shuts down DDR genes in triple-negative breast cancer (TNBC), causing DDR defects and inducing DNA damage. Since DDR-deficient tumors are currently targeted by poly ADP-ribose polymerase inhibitors (PARPis), we tested combinations with Omomyc. We show that Omomyc-induced DNA damage is enhanced by PARPis and that the inhibitors cooperate even in models with intrinsic or acquired PARPi resistance, both in vitro and in vivo. Moreover, using patient-derived models and clinical samples, we reveal a role for MYC as a predictor of PARPi resistance. Overall, our research highlights the opportunity of combining MYC inhibition by Omomyc with PARPis in PARPi-resistant TNBC, where MYC transcriptional activity represents a predictive biomarker of resistance to therapy., We acknowledge the kind support from the Vall d’Hebron Institute of Oncology and the Cellex Foundation for providing research facilities and equipment. We thank the Spanish Association of Metastatic Breast Cancer for the Chiara Giorgetti Award 2022, Instituto de Salud Carlos III (FI20/00274 – F.G., PFIS doctoral bursary); Ministerio de Ciencia e Innovación (Retos de Colaboración RTC2019-007067-1 and Líneas Estratégicas PLEC2021-007959); Generalitat de Catalunya (AGAUR 2017/SGR 537 and 2021/SGR 01509); EDIReX (H2020 INFRAIA 731105-2); the European Research Council (ERC-2023-ADG 101142260); the Spanish Ministry of Science and Innovation and the European Union through the NextGenerationEU program, in the context of the Plan de Recuperacion, Transformacion y Resiliencia (RETOS; CPP2022-009808); and the Fero Foundation for funding support.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Present and Future Therapeutic Approaches to Barrier Dysfunction

  • Albert Bayo, Merce
  • Abril-Gil, Mar
  • Serra Ruiz, Xavier
  • Henao Paez, Alejandro
  • Exposito Fernandez, Elba
  • Gonzalez Castro, Ana Maria
  • Lobo Alvarez, Beatriz
  • Santos Vicente, Fco Javier
  • Guagnozzi, Danila
  • Fortea, Marina
  • Alonso Cotoner, Carmen
  • Ganda Mall, John-Peter
Permeabilidad intestinal; Nutrientes; Prebióticos, Intestinal permeability; Nutrients; Prebiotics, Permeabilitat intestinal; Nutrients; Prebiòtics, There is converging and increasing evidence, but also uncertainty, for the role of abnormal intestinal epithelial barrier function in the origin and development of a growing number of human gastrointestinal and extraintestinal inflammatory disorders, and their related complaints. Despite a vast literature addressing factors and mechanisms underlying changes in intestinal permeability in humans, and its connection to the appearance and severity of clinical symptoms, the ultimate link remains to be established in many cases. Accordingly, there are no directives or clinical guidelines related to the therapeutic management of intestinal permeability disorders that allow health professionals involved in the management of these patients to carry out a consensus treatment based on clinical evidence. Instead, there are multiple pseudoscientific approaches and commercial propaganda scattered on the internet that confuse those affected and health professionals and that often lack scientific rigor. Therefore, in this review we aim to shed light on the different therapeutic options, which include, among others, dietary management, nutraceuticals and medical devices, microbiota and drugs, and epigenetic and exosomes-manipulation, through an objective evaluation of the scientific publications in this field. Advances in the knowledge and management of intestinal permeability will sure enable better options of dealing with this group of common disorders to enhance quality of life of those affected., This work was supported in part by Fondo Europeo de Desarrollo Regional (FEDER), Fondo de Investigación Sanitaria and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Subdirección General de Investigación Sanitaria, Ministerio de Economía y Competitividad, Ajuts per a la contractació de personal investigador FI–Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya; The Swedish Research Council, and the European Commision. PI19/0164 (BL), FI20/00256 and 2020FI_B1 00127, 2019FI_B 00817 (MA-B); PI17/0190 (JS); CIBERehd CB06/04/0021 (JS and CA-C); dnr 2019-00653 (JP-GM); GA no:848228 (JS, CA-C, EE, AG-C, and BL). MF received support from FWO (Fonds Wetenschappelijk Onderzoek) grant G.093818 to P. Vanden Berghe, KU Leuven.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Nutritional assessment of plant-based meat alternatives: a comparison of nutritional information of plant-based meat alternatives in Spanish supermarkets

  • Rizzolo-Brime, Lucía
  • Puyol Martin, Yael
  • Jakszyn, Paula
  • Orta-Ramirez, Alicia
Since the classification of processed meat as carcinogenic by the International Agency for Research on Cancer (IARC) in 2015, an increase in consumption of plant-based meat alternatives (PBMAs) has been observed worldwide. This occurs in a context characterized by concern for health, animal welfare, and sustainability; however, evidence of their nutritional quality is still limited. Therefore, our objective was to evaluate the nutritional profile and processing degree of PBMAs available in Spain. In 2020, products from seven Spanish supermarkets were analyzed for their nutritional content and ingredients. Of the 148 products, the majority were low in sugars but moderate in carbohydrates, total and saturated fat, and high in salt. The main vegetable protein sources were soy (91/148) and wheat gluten (42/148). Comparatively, 43/148 contained animal protein, the most common being egg. Overall, PBMAs had a long list of ingredients and additives, and they were classified as ultra-processed foods (UPFs) according to the NOVA system. This study shows that the PBMAs available in Spanish supermarkets have a variable nutritional composition within and between categories. Further research is needed to determine if replacing meat with these UPFs could be a good alternative towards healthier and more sustainable dietary patterns., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Eosinophils in the Gastrointestinal Tract: Key Contributors to Neuro-Immune Crosstalk and Potential Implications in Disorders of Brain-Gut Interaction

  • Rodiño Janeiro, Bruno Kotska
  • Albert Bayo, Merce
  • Lobo Alvarez, Beatriz
  • Santos Vicente, Fco Javier
  • Farre, Ricard
  • Martínez, Cristina
  • Vicario Perez, Maria
  • Salvo Romero, Eloisa
Disorders of brain-gut interaction; Intestinal eosinophils; Neuro-immune interaction, Trastorns de la interacció cervell-intestí; Eosinòfils intestinals; Interacció neuroimmune, Trastornos de la interacción cerebro-intestino; Eosinófilos intestinales; Interacción neuroinmune, Eosinophils are innate immune granulocytes actively involved in defensive responses and in local and systemic inflammatory processes. Beyond these effector roles, eosinophils are fundamental to maintaining homeostasis in the tissues they reside. Gastrointestinal eosinophils modulate barrier function and mucosal immunity and promote tissue development through their direct communication with almost every cellular component. This is possible thanks to the variety of receptors they express and the bioactive molecules they store and release, including cytotoxic proteins, cytokines, growth factors, and neuropeptides and neurotrophines. A growing body of evidence points to the eosinophil as a key neuro-immune player in the regulation of gastrointestinal function, with potential implications in pathophysiological processes. Eosinophil–neuron interactions are facilitated by chemotaxis and adhesion molecules, and the mediators released may have excitatory or inhibitory effects on each cell type, with physiological consequences dependent on the type of innervation involved. Of special interest are the disorders of the brain–gut interaction (DBGIs), mainly functional dyspepsia (FD) and irritable bowel syndrome (IBS), in which mucosal eosinophilia and eosinophil activation have been identified. In this review, we summarize the main roles of gastrointestinal eosinophils in supporting gut homeostasis and the evidence available on eosinophil–neuron interactions to bring new insights that support the fundamental role of this neuro-immune crosstalk in maintaining gut health and contributing to the pathophysiology of DBGIs., This study was funded in part by the Fondo Europeo de Desarrollo Regional (FEDER), the Fondo de Investigación Sanitaria, the Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), the Instituto de Salud Carlos III, Subdirección General de Investigación Sanitaria, and the Ministerio de Economía y Competitividad: FI12/00254 (E.S-R.), CD15/00010 (B.K.R.-J.), FI20/00256 (M.A-B.), PI19/01643 (B.L.), PI17/0190 (J.S.), CP18/00116 (C.M), CPII16/00031 and PI19/01643 (M.V.), CIBEREHD CB06/04/0021 (J.S., R.F., M.V.).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma

  • Zacarias Fluck, Mariano F
  • Massó-Vallés, Daniel
  • Giuntini, Fabio
  • González-Larreategui, Íñigo
  • Kaur, Jastrinjan
  • Casacuberta-Serra, Sílvia
  • Jauset González, Antoni
  • Martínez Martín, Sandra
  • Martín Fernández, Génesis
  • Serrano del Pozo, Erika
  • Foradada Felip, Laia
  • Grueso Gragera, Judit
  • Nonell Malezon, Lara
  • Whitfield, Jonathan
  • Beaulieu, Marie-Eve
  • Soucek, Laura
MYC; Omomyc; Melanoma, MYC; Omomyc; Melanoma, MYC; Omomyc; Melanoma, MYC's key role in oncogenesis and tumor progression has long been established for most human cancers. In melanoma, its deregulated activity by amplification of 8q24 chromosome or by upstream signaling coming from activating mutations in the RAS/RAF/MAPK pathway—the most predominantly mutated pathway in this disease—turns MYC into not only a driver but also a facilitator of melanoma progression, with documented effects leading to an aggressive clinical course and resistance to targeted therapy. Here, by making use of Omomyc, the most characterized MYC inhibitor to date that has just successfully completed a phase I clinical trial, we show for the first time that MYC inhibition in melanoma induces remarkable transcriptional modulation, resulting in severely compromised tumor growth and a clear abrogation of metastatic capacity independently of the driver mutation. By reducing MYC's transcriptional footprint in melanoma, Omomyc elicits gene expression profiles remarkably similar to those of patients with good prognosis, underlining the therapeutic potential that such an approach could eventually have in the clinic in this dismal disease., M.F.Z.-F. was supported by the Juan de la Cierva Programme of the Spanish Ministry of Economy and Competitiveness (IJCI-2014-22403) and Fundació La Marató de TV3 (grant 474/C/2019); F.G. was supported by Spanish Ministry of Science and Innovation Contratos Predoctorales de Formación en Investigación en Salud (PFIS; FI20/00274); I.G.-L. was supported by a grant from the University Teacher Training Program (FPU), Ministry of Universities (FPU20/04812); and S.M.-M. was supported by the Generalitat de Catalunya “Contractació de Personal Investigador Novell (FI-DGR)” 2016 fellowship (2016FI_B 00592). This project was funded by grants from the Spanish Ministry of Science and Innovation (Fondo de Inversión en Salud [FIS] PI19/01277, which also supported I.G.-L. and S.M.-M, and Retos-Colaboración 2019 RTC2019-007067-1), La Marató TV3, the Generalitat de Catalunya AGAUR 2017 grant SGR-3193, and the European Research Council (ERC-PoC II/3079/SYST-iMYC [813132]). We thank the rest of the Soucek laboratory for critical reading of the manuscript, and the personnel at Vall d'Hebron Research Institute (VHIR) High Technology Unit. We acknowledge Vall d'Hebron Institute of Oncology and the Cellex Foundation for providing research facilities and equipment.
Docta Complutense
Publication Artículo de revisión (ReviewArticle)

Advances in the Treatment of Gastroenteropancreatic Neuroendocrine Carcinomas: Are we Moving Forward?

  • García Carbonero, Rocío
  • Anton Pascual, Beatriz
  • Modrego, Andrea
  • Riesco Martinez, Maria del Carmen
  • Lens Pardo, Alberto
  • Carretero Puche, Carlos
  • Rubio Cuesta, Beatriz
  • Soldevilla Navarro, Beatriz
Poorly differentiated gastroenteropancreatic neuroendocrine carcinomas are aggressive neoplasms of challenging clinical management. A small proportion of patients with early-stage disease may achieve long-term survival, but the majority of patients present with rapidly lethal metastatic disease. Current standard of care still follows the treatment paradigm of small cell lung cancer, a far more common G3 neuroendocrine neoplasm, although emerging molecular and clinical data increasingly question this approach. In this article, we will briefly summarize epidemiology and prognosis of gastroenteropancreatic neuroendocrine carcinomas to emphasize the very low incidence, aggressive nature, and orphan status of this tumor entity. We will also discuss the current pathological classification and its limitations, as well as recent data on their differential biological background compared with small cell lung cancer, and its potential implications for patients care. Then, we will review the standard of care of systemic therapy, basically focused on platinum-based cytotoxic chemotherapy, including some recent randomized trials providing evidence regarding efficacy of irinotecan vs etoposide platinum doublets. Finally, we will present a comprehensive overview of novel therapeutic strategies in current clinical development, including recently reported data on immunotherapy, tumor-agnostic therapies (microsatellite instability, high tumor mutational burden, NTRK and RET gene fusions, BRAF or KRAS inhibitors), and additional treatment strategies targeting other tumor vulnerabilities (ie, Notch pathway, novel targets for radioligand therapy), and provide some insights regarding unmet needs and future perspectives to improve patient's care and prognosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Mindfulness-Based Program Plus Amygdala and Insula Retraining (MAIR) for the Treatment of Women with Fibromyalgia, a Pilot Randomized Controlled Trial

  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Gasión, Virginia
  • Navarro-Gil, Mayte|||0000-0003-4842-0453
  • Morillo, Héctor|||0000-0002-9852-2776
  • Colomer-Carbonell, Ariadna|||0000-0001-8923-6316
  • Borràs, Xavier|||0000-0003-3972-1385
  • Tops, Mattie
  • Luciano, Juan Vicente|||0000-0003-0750-1599
  • Garcia-Campayo, Javier|||0000-0002-3797-4218
  • Montero-Marín, Jesús|||0000-0001-5677-1662
  • Feliu-Soler, Albert|||0000-0003-2810-7670
The lack of highly effective treatments for fibromyalgia (FM) represents a great challenge for public health. The objective of this parallel, pilot randomized controlled trial (RCT) was two-fold: (1) to analyze the clinical effects of mindfulness plus amygdala and insula retraining (MAIR) compared to a structurally equivalent active control group of relaxation therapy (RT) in the treatment of FM; and (2) to evaluate its impact on immune-inflammatory markers and brain-derived neurotrophic factor (BDNF)in serum. A total of 41 FM patients were randomized into two study arms: MAIR (intervention group)and RT (active control group), both as add-ons of treatment as usual. MAIR demonstrated significantly greater reductions in functional impairment, anxiety, and depression, as well as higher improvements in mindfulness, and self-compassion at post-treatment and follow-up, with moderate to large effectsizes. Significant decreases in pain catastrophizing and psychological inflexibility and improvementsin clinical severity and health-related quality of life were found at follow-up, but not at post-treatment,showing large effect sizes. The number needed to treat was three based on the criteria of ≥50% Fibromyalgia Impact Questionnaire (FIQ) reduction post-treatment. Compared to RT, the MAIRshowed significant decreases in BDNF. No effect of MAIR was observed in immune-inflammatorybiomarkers (i.e., TNF-α, IL-6, IL-10, and hs-CRP). In conclusion, these results suggest that MAIR, as an adjuvant of treatment-as-usual (TAU), appears to be effective for the management of FM symptomsand for reducing BDNF levels in serum.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Improving depressive symptoms through personalised exercise and activation (Idea), Study protocol for a randomised controlled trial

  • García-Estela, Aitana|||0000-0001-8529-544X
  • Angarita-Osorio, Natalia|||0000-0001-8925-2754
  • Alonso Marsol, Sandra
  • Polo, Maria
  • Roldán-Berengué, Maria
  • Messaggi Sartor, Monique|||0000-0002-2807-3266
  • Mur Milà, Estanislao|||0000-0003-4380-030X
  • Vargas-Puertolas, Laura
  • Pérez Solà, Víctor|||0000-0002-5825-2337
  • Duarte Oller, Esther|||0000-0002-4058-1802
  • Colom, Francesc|||0000-0002-9516-9030
Individuals who suffer from depressive symptoms experience a substantial impact on psychosocial functioning, physical health, mortality, and quality of life. In the search for therapeutic strategies, exercise has been found to play a relevant part in its treatment. However, the promotion of exercise entails adherence difficulties that arose out of the tendency towards sedentarism led by symptomatology. Personalised exercise plans on top of usual care have the potential to enhance behavioural changes and mental health. The present study aims at evaluating the changes in functioning deriving from a blended intervention merging a psychological intervention with a personalised exercise programme based on medical assessment. We will conduct a three-arm randomised controlled trial in which 172 participants suffering from mild-moderate depressive symptoms will be allocated to Intervention A (personalised exercise group programme + app with motivational messages), B (personalised exercise group programme + app with no motivational messages) or control group (app with no motivational messages). Data regarding global functioning, well-being, symptoms, physical activity, and exercise capacity will be collected at baseline, 4, 12, and 36 weeks. The results of this trial will provide information about whether this physical activity support programme may be efficient for improving mental and physical health outcomes. Trial registration: ClinicalTrials.gov NCT04857944 (accessed on 15 April 2021). Registered April 2021.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Social inequities in the impact of COVID-19 lockdown measures on the mental health of a large sample of the Colombian population (PSY-COVID study)

  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Useche-Aldana, Bernardo
  • Ochoa, Pedro Pablo|||0000-0003-3035-8647
  • Rojas-Gualdrón, Diego Fernando|||0000-0002-2293-0431
  • Mateo Canedo, Corel|||0000-0002-0620-9257
  • Carmona Cervelló, Meritxell|||0000-0003-0907-9168
  • Crespo-Puig, Neus|||0000-0001-8036-6739
  • Selva Olid, Clara|||0000-0001-7390-9889
  • Muro Rodríguez, Anna|||0000-0002-1331-9921
  • Méndez Ulrich, Jorge Luis|||0000-0001-9718-0607
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Luciano, Juan Vicente|||0000-0003-0750-1599
  • Sanz Ruiz, Antoni|||0000-0002-7952-4477
The identification of general population groups particularly vulnerable to the impact of COVID-19 lockdown measures on mental health and the development of healthcare policies are priority challenges in the current and future pandemics. This study aimed to identify the personal and social determinants of the impact of COVID-19 lockdown measures on mental health in a large sample of the Colombian population. In this cross-sectional study, an anonymous online survey was answered by 18,061 participants from the general population residing in Colombia during the first wave of the COVID-19 outbreak (from 20 May to 20 June 2020). The risk of depression, anxiety, and somatization disorders were measured using the Patient Health Questionnaire (PHQ-2), Generalized Anxiety Disorder Scale (GAD-2), and Somatic Symptom Questionnaire (SSQ-5), respectively. Overall, 35% of participants showed risk of depression, 29% of anxiety, and 31% of somatization. According to the analysis of social determinants of health, the most affected groups were people with low incomes, students, and young adults (18-29 years). Specifically, low-income young females were the most at-risk population group. These findings show how the lockdown measures affected the general population's mental health in Colombia and highlight some social risk factors in health.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)

  • Colomer-Carbonell, Ariadna|||0000-0001-8923-6316
  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Hernández-Negrín, Halbert
  • Borràs, Xavier|||0000-0003-3972-1385
  • Suso-Ribera, Carlos|||0000-0002-2655-1017
  • García Palacios, Azucena|||0000-0001-9250-8714
  • Muchart, Jordi
  • Munuera, Josep|||0000-0001-5154-1796
  • D'Amico, Francesco|||0000-0001-7995-826X
  • Maes, Michael|||0000-0002-2012-871X
  • Younger, Jarred W.
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Rozadilla-Sacanell, Antoni|||0000-0002-7555-189X
  • Luciano, Juan Vicente|||0000-0003-0750-1599
There is evidence that low-dose naltrexone (LDN; <5.0 mg/day) reduces pain and improves the quality of life of people with fibromyalgia syndrome (FMS). However, no randomised controlled trials with long-term follow-ups have been carried out. The INNOVA study will evaluate the add-on efficacy, safety, cost-utility and neurobiological effects of LDN for reducing pain in patients with FMS, with a 1-year follow-up. A single-site, prospective, randomised, double-blinded, placebo-controlled, parallel design phase III trial will be performed. Eligibility criteria include being adult, having a diagnosis of FMS and experiencing pain of 4 or higher on a 10-point numerical rating scale. Participants will be randomised to a LDN intervention group (4.5 mg/day) or to a placebo control group. Clinical assessments will be performed at baseline (T0), 3 months (T1), 6 months (T2) and 12 months (T3). The primary endpoint will be pain intensity. A sample size of 60 patients per study arm (120 in total), as calculated prior to recruitment for sufficient power, will be monitored between January 2022 and August 2024. Assessment will also include daily ecological momentary evaluations of FMS-related symptoms (eg, pain intensity, fatigue and sleep disturbance), and side effects via ecological momentary assessment through the Pain Monitor app during the first 3 months. Costs and quality-adjusted life years will be also calculated. Half of the participants in each arm will be scanned with MRI at T0 and T1 for changes in brain metabolites related to neuroinflammation and central sensitisation. Inflammatory biomarkers in serum will also be measured. This study has been approved by the Ethics Committee of the Fundació Sant Joan de Déu. The results will be actively disseminated through peer-reviewed journals, conference presentations, social media and community engagement activities. .
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Fetuin-A, inter-α-trypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes

  • Reverté Calvet, Laia|||0000-0003-4690-2387
  • Yeregui, Elena|||0000-0003-2994-4219
  • Olona, Montserrat|||0000-0001-5303-9361
  • Gutiérrez-Valencia, Alicia|||0000-0003-3445-1574
  • Buzón, Maria José|||0000-0003-4427-9413
  • Martí, Anna
  • Gómez-Bertomeu, Frederic
  • Auguet, Teresa
  • López Cortés, Luis Fernando|||0000-0002-3804-3458
  • Burgos, Joaquín|||0000-0001-8445-3047
  • Benavent-Bofill, Clara
  • Boqué, Carme
  • García-Pardo, Graciano|||0000-0003-0274-6001
  • Ruiz-Mateos, Ezequiel|||0000-0001-6747-7813
  • Mestre, Maria Teresa
  • Vidal, Francesc|||0000-0002-6692-6186
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Rull, Anna|||0000-0002-8907-7754
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Focusing on Comorbidity-A Novel Meta-Analytic Approach and Protocol to Disentangle the Specific Neuroanatomy of Co-occurring Mental Disorders

  • Fortea, Lydia|||0000-0001-6778-2316
  • Albajes-Eizagirre, Anton
  • Yao, Yuan-Wei
  • Soler, Edu
  • Verdolini, Norma|||0000-0001-9488-2881
  • Hauson, Alexander O.
  • Fortea, Adriana
  • Madero, Santiago|||0000-0002-1123-4211
  • Solanes, Aleix|||0000-0002-2491-200X
  • Wollman, Scott C.
  • Serra Blasco, Maria|||0000-0001-5793-9906
  • Wise, Toby
  • Lukito, Steve
  • Picó-Pérez, Maria|||0000-0002-1573-2445
  • Carlisi, Christina
  • Zhang, JinTao
  • Pan, PingLei
  • Farré-Colomés, Álvar
  • Arnone, Danilo
  • Kempton, Matthew|||0000-0003-3541-9947
  • Soriano-Mas, Carles|||0000-0003-4574-6597
  • Rubia, Katya|||0000-0002-1410-7701
  • Norman, Luke
  • Fusar-Poli, Paolo|||0000-0003-3582-6788
  • Mataix-Cols, David|||0000-0002-4545-0924
  • Valentí, Marc
  • Via, Esther|||0000-0002-2331-3232
  • Cardoner, Narcís|||0000-0001-9633-0888
  • Solmi, Marco|||0000-0003-4877-7233
  • Shin, Jae I.
  • Vieta, Eduard|||0000-0002-0548-0053
  • Radua, Joaquim|||0000-0003-1240-5438
In mental health, comorbidities are the norm rather than the exception. However, current meta-analytic methods for summarizing the neural correlates of mental disorders do not consider comorbidities, reducing them to a source of noise and bias rather than benefitting from their valuable information. We describe and validate a novel neuroimaging meta-analytic approach that focuses on comorbidities. In addition, we present the protocol for a meta-analysis of all major mental disorders and their comorbidities. The novel approach consists of a modification of Seed-based d Mapping-with Permutation of Subject Images (SDM-PSI) in which the linear models have no intercept. As in previous SDM meta-analyses, the dependent variable is the brain anatomical difference between patients and controls in a voxel. However, there is no primary disorder, and the independent variables are the percentages of patients with each disorder and each pair of potentially comorbid disorders. We use simulations to validate and provide an example of this novel approach, which correctly disentangled the abnormalities associated with each disorder and comorbidity. We then describe a protocol for conducting the new meta-analysis of all major mental disorders and their comorbidities. Specifically, we will include all voxel-based morphometry (VBM) studies of mental disorders for which a meta-analysis has already been published, including at least 10 studies. We will use the novel approach to analyze all included studies in two separate single linear models, one for children/adolescents and one for adults. The novel approach is a valid method to focus on comorbidities. The meta-analysis will yield a comprehensive atlas of the neuroanatomy of all major mental disorders and their comorbidities, which we hope might help develop potential diagnostic and therapeutic tools.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Common variants in Alzheimer's disease and risk stratification by polygenic risk scores

  • De Rojas, Itziar|||0000-0002-2148-381X
  • Moreno-Grau, Sonia
  • Tesi, Niccolo|||0000-0002-1413-5091
  • Grenier-Boley, Benjamin
  • Andrade, Victor|||0000-0003-0682-269X
  • Jansen, Iris E.|||0000-0003-1901-8131
  • Pedersen, Nancy L.|||0000-0001-8057-3543
  • Stringa, Najada|||0000-0001-6350-452X
  • Zettergren, Anna|||0000-0002-7182-8417
  • Hernández, Isabel|||0000-0001-8119-393X
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • Antúnez, Carmen
  • Antonell, Anna|||0000-0002-3286-8459
  • Tankard, Rick M.|||0000-0002-8847-9401
  • Bis, Joshua C.|||0000-0002-3409-1110
  • Sims, Rebecca|||0000-0002-3885-1199
  • Bellenguez, Céline|||0000-0002-1240-7874
  • Quintela, Inés|||0000-0002-0239-7975
  • González-Perez, Antonio
  • Calero, Miguel|||0000-0001-5366-3324
  • Franco-Macías, Emilio|||0000-0003-4186-1037
  • Macías, Juan|||0000-0002-4778-790X
  • Blesa, Rafael|||0000-0003-4026-2884
  • Cervera Carles, Laura|||0000-0003-2286-200X
  • Mendez-Gonzalez, Manuel|||0000-0002-5218-0774
  • Frank García, Ana
  • Royo, Jose Luís
  • Moreno, Fermin|||0000-0001-5200-3164
  • Huerto Vilas, Raquel
  • Baquero, Miquel|||0000-0002-6861-1831
  • Diez-Fairen, Monica|||0000-0003-1882-0309
  • Lage, Carmen|||0000-0003-1703-121X
  • García-Madrona, Sebastián
  • García-González, Pablo|||0000-0003-0125-5403
  • Alarcón-Martín, Emilio|||0000-0002-0985-872X
  • Valero, Sergi|||0000-0002-6599-948X
  • Sotolongo Grau, Oscar|||0000-0002-9679-0670
  • Ullgren, Abbe
  • Naj, Adam C.|||0000-0002-9621-2942
  • Lemstra, Afina W.|||0000-0002-8933-3260
  • Benaque, Alba
  • Pérez-Cordón, Alba|||0000-0002-6028-0791
  • Benussi, Alberto|||0000-0002-8703-6940
  • Rábano, Alberto|||0000-0001-9320-6566
  • Padovani, Alessandro|||0000-0002-0119-3639
  • Squassina, Alessio|||0000-0001-7415-7607
  • de Mendonça, Alexandre|||0000-0002-0488-1453
  • Arias Pastor, Alfonso
  • Kok, Almar A. L.
  • Meggy, Alun
  • Pastor, Ana Belén|||0000-0001-9637-4688
  • Espinosa, Ana|||0000-0001-7399-3267
  • Corma Gómez, Anaïs|||0000-0002-1078-0237
  • Martín Montes, Angel|||0000-0002-1694-786X
  • Sanabria, Ángela|||0000-0002-7501-9895
  • DeStefano, Anita L.|||0000-0002-9335-2819
  • Schneider, Anja|||0000-0001-9540-8700
  • Haapasalo, Annakaisa|||0000-0003-0959-2957
  • Kinhult Ståhlbom, Anne
  • Tybjærg-Hansen, Anne
  • Hartmann, Annette M.
  • Spottke, Annika
  • Corbatón-Anchuelo, Arturo
  • Rongve, Arvid|||0000-0002-0476-4134
  • Borroni, Barbara|||0000-0001-9340-9814
  • Arosio, Beatrice|||0000-0002-0615-3580
  • Nacmias, Benedetta|||0000-0001-9338-9040
  • Nordestgaard, Børge G.|||0000-0002-1954-7220
  • Kunkle, Brian W.
  • Charbonnier, Camille|||0000-0003-1172-0196
  • Abdelnour, Carla|||0000-0002-7636-9758
  • Masullo, Carlo|||0000-0001-7798-3410
  • Martínez Rodríguez, Carmen
  • Muñoz-Fernandez, Carmen
  • Dufouil, Carole|||0000-0003-2442-4476
  • Graff, Caroline|||0000-0002-9949-2951
  • Ferreira, Catarina B.
  • Chillotti, Caterina
  • Reynolds, Chandra A.|||0000-0001-6502-7173
  • Fenoglio, Chiara|||0000-0001-6332-4721
  • Van Broeckhoven, Christine|||0000-0003-0183-7665
  • Clark, Christopher|||0000-0001-7210-7702
  • Pisanu, Claudia|||0000-0002-9151-4319
  • Satizabal, Claudia L.|||0000-0002-1115-4430
  • Holmes, Clive
  • Buiza-Rueda, Dolores|||0000-0002-3504-9299
  • Aarsland, Dag|||0000-0001-6314-216X
  • Rujescu, Dan|||0000-0002-1432-313X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Galimberti, Daniela|||0000-0002-9284-5953
  • Wallon, David|||0000-0002-2634-7198
  • Seripa, Davide|||0000-0001-7331-0470
  • Grünblatt, Edna|||0000-0001-8505-7265
  • Dardiotis, Efthimios|||0000-0003-2957-641X
  • Düzel, Emrah
  • Scarpini, Elio|||0000-0002-6395-2119
  • Conti, Elisa
  • Rubino, Elisa|||0000-0002-7553-7553
  • Gelpi, Ellen|||0000-0003-2948-4187
  • Rodríguez-Rodríguez, Eloy|||0000-0001-7742-677X
  • Duron, Emmanuelle
  • Boerwinkle, Eric|||0000-0001-8813-0544
  • Ferri, Evelyn
  • Tagliavini, Fabrizio|||0000-0003-1039-7315
  • Küçükali, Fahri
  • Pasquier, Florence|||0000-0001-9880-9788
  • Sánchez García, Florentino
  • Mangialasche, Francesca
  • Jessen, Frank
  • Nicolas, Gael|||0000-0001-9391-7800
  • Selbæk, Geir|||0000-0001-6511-8219
  • Ortega Linares, Gemma|||0000-0002-7479-4072
  • Chene, Geneviève|||0000-0002-8368-6460
  • Hadjigeorgiou, Georgios
  • Rossi, Giacomina|||0000-0001-6680-2725
  • Spalletta, Gianfranco|||0000-0002-7432-4249
  • Giaccone, Giorgio|||0000-0002-4803-0802
  • Grande, Giulia
  • Binetti, Giuliano|||0000-0003-2759-5844
  • Papenberg, Goran
  • Hampel, Harald
  • Bailly, Henri
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Soininen, Hilkka|||0000-0002-2785-9937
  • Karlsson, Ida K.
  • Alvarez, Ignacio|||0000-0002-8537-3935
  • Appollonio, Ildebrando
  • Giegling, Ina
  • Skoog, Ingmar
  • Saltvedt, Ingvild|||0000-0002-7897-9808
  • Rainero, Innocenzo|||0000-0001-6074-9628
  • Rosas Allende, Irene
  • Hort, Jakub|||0000-0002-1080-3726
  • Diehl-Schmid, Janine|||0000-0002-7745-1382
  • Van Dongen, Jasper|||0000-0001-5599-0046
  • Vidal, Jean-Sébastien|||0000-0001-6770-0720
  • Lehtisalo, Jenni
  • Wiltfang, Jens
  • Thomassen, Jesper Qvist|||0000-0003-3484-9531
  • Kornhuber, Johannes|||0000-0002-8096-3987
  • Haines, Jonathan L.|||0000-0002-4351-4728
  • Vogelgsang, Jonathan|||0000-0001-9326-8193
  • Pineda, Juan A.|||0000-0002-3751-0296
  • Fortea, Juan|||0000-0002-1340-638X
  • Popp, Julius|||0000-0002-0068-0312
  • Deckert, Jürgen|||0000-0003-1008-4650
  • Buerger, Katharina
  • Morgan, Kevin|||0000-0002-8217-2396
  • Fließbach, Klaus
  • Sleegers, Kristel|||0000-0002-0283-2332
  • Molina-Porcel, Laura|||0000-0003-4068-8578
  • Kilander, Lena
  • Weinhold, Leonie
  • Farrer, Lindsay A.|||0000-0001-5533-4225
  • Wang, Li-San
  • Kleineidam, Luca
  • Farotti, Lucia
  • Parnetti, Lucilla|||0000-0001-5722-3967
  • Tremolizzo, Lucio|||0000-0003-0473-6560
  • Hausner, Lucrezia|||0000-0001-9009-2356
  • Benussi, Luisa|||0000-0003-2836-8141
  • Froelich, Lutz|||0000-0003-1494-0813
  • Ikram, M. Arfan|||0000-0003-0372-8585
  • Deniz Naranjo, M. Cándida
  • Tsolaki, Magda|||0000-0002-2072-8010
  • Rosende-Roca, Maitée|||0000-0003-1778-8175
  • Löwenmark, Malin
  • Hulsman, Marc|||0000-0002-9889-3606
  • Spallazzi, Marco|||0000-0002-8091-2063
  • Pericak-Vance, Margaret A.|||0000-0001-7283-8804
  • Esiri, Margaret
  • Bernal Sánchez-Arjona, María
  • Dalmasso, Maria Carolina|||0000-0002-4901-9955
  • Martínez-Larrad, María Teresa
  • Arcaro, Marina|||0000-0002-3821-0682
  • Nöthen, Markus M.|||0000-0002-8770-2464
  • Fernández-Fuertes, Marta
  • Dichgans, Martin|||0000-0002-0654-387X
  • Ingelsson, Martin|||0000-0001-5466-8370
  • Herrmann, Martin J.|||0000-0001-9970-2122
  • Scherer, Martin
  • Vyhnalek, Martin
  • Kosmidis, Mary H.
  • Yannakoulia, Mary
  • Schmid, Matthias
  • Ewers, Michael|||0000-0001-5231-1714
  • Heneka, Michael|||0000-0003-4996-1630
  • Wagner, Michael
  • Scamosci, Michela
  • Kivipelto, Miia
  • Hiltunen, Mikko|||0000-0003-3566-4096
  • Zulaica, Miren
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Fornage, Myriam|||0000-0003-0677-8158
  • Roberto Herrero, Natalia|||0000-0002-5391-2711
  • van Schoor, Natasja M.
  • Seidu, Nazib M.
  • Banaj, Nerisa|||0000-0002-6317-8549
  • Armstrong, Nicola|||0000-0002-4477-293X
  • Scarmeas, Nikolaos|||0000-0001-6453-8908
  • Scherbaum, Norbert|||0000-0003-1759-6990
  • Goldhardt, Oliver
  • Hanon, Olivier|||0000-0002-4697-122X
  • Peters, Oliver|||0000-0003-0568-2998
  • Skrobot, Olivia Anna
  • Quenez, Olivier|||0000-0002-8273-8505
  • Lerch, Ondrej
  • Bossù, Paola|||0000-0002-1432-0078
  • Caffarra, Paolo
  • Dionigi Rossi, Paolo
  • Sakka, Paraskevi
  • Hoffmann, Per|||0000-0002-6573-983X
  • Holmans, Peter|||0000-0003-0870-9412
  • Fischer, Peter
  • Riederer, Peter
  • Yang, Qiong|||0000-0002-3658-1375
  • Marshall, Rachel
  • Kalaria, Rajesh N.
  • Mayeux, Richard|||0000-0001-6519-9696
  • Vandenberghe, Rik|||0000-0001-6237-2502
  • Cecchetti, Roberta
  • Ghidoni, Roberta|||0000-0002-7691-1957
  • Frikke-Schmidt, Ruth|||0000-0003-4084-5027
  • Sorbi, Sandro|||0000-0002-0380-6670
  • Hägg, Sara|||0000-0002-2452-1500
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • Helisalmi, Seppo
  • Botne Sando, Sigrid
  • Kern, Silke
  • Archetti, Silvana
  • Boschi, Silvia|||0000-0003-1610-1917
  • Fostinelli, Silvia
  • Gil-Navarro, Silvia|||0000-0001-9921-9042
  • Mendoza, Silvia
  • Mead, Simon|||0000-0002-4326-1468
  • Ciccone, Simona
  • Djurovic, Srdjan|||0000-0002-8140-8061
  • Heilmann-Heimbach, Stefanie|||0000-0003-1057-465X
  • Riedel-Heller, Steffi|||0000-0003-4321-6090
  • Kuulasmaa, Teemu|||0000-0002-1795-7314
  • del Ser, Teodoro|||0000-0001-9806-7083
  • Lebouvier, Thibaud
  • Polak, Thomas
  • Ngandu, Tiia
  • Grimmer, Timo
  • Bessi, Valentina|||0000-0002-6176-3584
  • Escott-Price, Valentina|||0000-0003-1784-5483
  • Giedraitis, Vilmantas|||0000-0003-3423-2021
  • Deramecourt, Vincent
  • Maier, Wolfgang
  • Jian, Xueqiu
  • Pijnenburg, Yolande|||0000-0003-2464-1905
  • Kehoe, Patrick|||0000-0002-7542-1139
  • García-Ribas, Guillermo
  • Sánchez-Juan, Pascual|||0000-0002-6081-8037
  • Pastor, Pau|||0000-0002-7493-8777
  • Pérez-Tur, Jordi|||0000-0002-9111-1712
  • Piñol-Ripoll, Gerard
  • Lopez de Munain, Adolfo|||0000-0002-9509-4032
  • García-Alberca, Jose María|||0000-0003-2951-6644
  • Bullido, María J.|||0000-0002-6477-1117
  • Alvarez, Victoria|||0000-0002-1916-2523
  • Lleó, Alberto|||0000-0002-2568-5478
  • Real, Luis M.|||0000-0003-4932-7429
  • Mir, Pablo|||0000-0003-1656-302X
  • Medina, Miguel|||0000-0002-7016-5340
  • Scheltens, Philip|||0000-0002-1046-6408
  • Holstege, Henne|||0000-0002-7688-3087
  • Marquié, Marta|||0000-0002-0660-0950
  • Sáez, María Eugenia|||0000-0001-9299-2534
  • Carracedo, Ángel|||0000-0003-1085-8986
  • Amouyel, Philippe|||0000-0001-9088-234X
  • Schellenberg, Gerard D.
  • Williams, Julie|||0000-0002-4069-0259
  • Seshadri, Sudha|||0000-0001-6135-2622
  • van Duijn, Cornelia M.|||0000-0002-2374-9204
  • Mather, Karen A.|||0000-0003-4143-8941
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Serrano-Ríos, Manuel
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Blennow, Kaj|||0000-0002-1890-4193
  • Huisman, Martijn A.
  • Andreassen, Ole A.|||0000-0002-4461-3568
  • Posthuma, Danielle|||0000-0001-7582-2365
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Boada, Mercè|||0000-0003-2617-3009
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • Ramirez, Alfredo|||0000-0003-4991-763X
  • Lambert, Jean-Charles|||0000-0003-0829-7817
  • van der Lee, Sven J.|||0000-0003-1606-8643
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
Genetic discoveries of Alzheimer's disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n = 409,435 and validation size n = 58,190). Here, we add six variants associated with Alzheimer's disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer's disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer's disease. Known genetic loci account for only a fraction of the genetic contribution to Alzheimer's disease. Here, the authors have performed a large genome-wide meta-analysis comprising 409,435 individuals to discover 6 new loci and demonstrate the efficacy of an Alzheimer's disease polygenic risk score.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immunogenicity of Mycobacterial Extracellular Vesicles Isolated From Host-Related Conditions Informs About Tuberculosis Disease Status

  • Schirmer, Sebastian
  • Rauh, Lucas
  • Alebouyeh, Sogol
  • Delgado-Velandia, Mario
  • Salgueiro, Vivian C.
  • Lerma, Laura
  • Serrano-Mestre, José L.
  • Azkargorta, Mikel
  • Elortza, Felix|||0000-0001-8839-5438
  • Lavin, Jose L.|||0000-0003-0914-3211
  • García, Maria Jesus
  • Tórtola Fernández, María Teresa|||0000-0002-9188-298X
  • Gola, Susanne
  • Prados-Rosales, Rafael
Tuberculosis (TB) still represents a major global health problem affecting over 10 million people worldwide. The gold-standard procedures for TB diagnosis are culture and nucleic acid amplification techniques. In this context, both lipoarabinomannan (LAM) urine test and rapid molecular tests have been major game changers. However, the low sensitivity of the former and the cost and the prohibitive infrastructure requirements to scale-up in endemic regions of the latter, make the improvement of the TB diagnostic landscape a priority. Most forms of life produce extracellular vesicles (EVs), including bacteria despite differences in bacterial cell envelope architecture. We demonstrated that Mycobacterium tuberculosis (Mtb), the causative agent of TB, produces EVs in vitro and in vivo as part of a sophisticated mechanism to manipulate host cellular physiology and to evade the host immune system. In a previous serology study, we showed that the recognition of several mycobacterial extracellular vesicles (MEV) associated proteins could have diagnostic properties. In this study, we pursued to expand the capabilities of MEVs in the context of TB diagnostics by analyzing the composition of MEVs isolated from Mtb cultures submitted to iron starvation and, testing their immunogenicity against a new cohort of serum samples derived from TB+ patients, latent TB-infected (LTBI) patients and healthy donors. We found that despite the stringent condition imposed by iron starvation, Mtb reduces the number of MEV associated proteins relative to iron sufficient conditions. In addition, TB serology revealed three new MEV antigens with specific biomarker capacity. These results suggest the feasibility of developing a point-of-care (POC) device based on selected MEV-associated proteins.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

N-Glycans in Immortalized Mesenchymal Stromal Cell-Derived Extracellular Vesicles Are Critical for EV-Cell Interaction and Functional Activation of Endothelial Cells

  • Clos Sansalvador, Marta|||0000-0001-8522-7818
  • Garcia, Sergio G.|||0000-0001-7698-3734
  • Font-Morón, Miriam|||0000-0002-4714-252X
  • Williams, Charles
  • Reichardt, Niels-Christian
  • Falcón-Pérez, Juan M.|||0000-0003-3133-0670
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Roura, Santiago|||0000-0003-4063-9661
  • Franquesa, Marcella|||0000-0002-1287-8908
  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
Mesenchymal stromal cell-derived extracellular vesicles (MSC-EV) are widely considered as a cell-free therapeutic alternative to MSC cell administration, due to their immunomodulatory and regenerative properties. However, the interaction mechanisms between EV and target cells are not fully understood. The surface glycans could be key players in EV-cell communication, being specific molecular recognition patterns that are still little explored. In this study, we focused on the role of N-glycosylation of MSC-EV as mediators of MSC-EV and endothelial cells' interaction for subsequent EV uptake and the induction of cell migration and angiogenesis. For that, EV from immortalized Wharton's Jelly MSC (iWJ-MSC-EV) were isolated by size exclusion chromatography (SEC) and treated with the glycosidase PNGase-F in order to remove wild-type N-glycans. Then, CFSE-labelled iWJ-MSC-EV were tested in the context of in vitro capture, agarose-spot migration and matrigel-based tube formation assays, using HUVEC. As a result, we found that the N-glycosylation in iWJ-MSC-EV is critical for interaction with HUVEC cells. iWJ-MSC-EV were captured by HUVEC, stimulating their tube-like formation ability and promoting their recruitment. Conversely, the removal of N-glycans through PNGase-F treatment reduced all of these functional activities induced by native iWJ-MSC-EV. Finally, comparative lectin arrays of iWJ-MSC-EV and PNGase-F-treated iWJ-MSC-EV found marked differences in the surface glycosylation pattern, particularly in N-acetylglucosamine, mannose, and fucose-binding lectins. Taken together, our results highlight the importance of N-glycans in MSC-EV to permit EV-cell interactions and associated functions.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immune-inflammatory and hypothalamic-pituitary-adrenal axis biomarkers are altered in patients with non-specific low back pain, A systematic review

  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Colomer-Carbonell, Ariadna|||0000-0001-8923-6316
  • Carmona Cervelló, Meritxell|||0000-0003-0907-9168
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Borràs, Xavier|||0000-0003-3972-1385
  • Grasa, Mar
  • Esteve, Montserrat|||0000-0003-2128-7859
  • Maes, Michael|||0000-0002-2012-871X
  • Edo Izquierdo, Sílvia|||0000-0002-6564-3475
  • Sanz Ruiz, Antoni|||0000-0002-7952-4477
  • Luciano, Juan Vicente|||0000-0003-0750-1599
, identifier CRD42020176153.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding

  • Massó Vallés, Daniel|||0000-0003-4231-0456
  • Beaulieu, Marie-Eve|||0000-0001-5224-8436
  • Jauset González, Toni|||0000-0003-2869-5804
  • Giuntini, Fabio
  • Zacarías-Fluck, Mariano F.|||0000-0002-7171-4268
  • Foradada Felip, Laia|||0000-0002-0589-4360
  • Martínez-Martín, Sandra|||0000-0003-4443-0697
  • Serrano, Erika
  • Martín-Fernández, Génesis|||0000-0002-1052-9763
  • Casacuberta-Serra, Sílvia|||0000-0002-2595-1115
  • Castillo Cano, Virginia
  • Kaur, Jastrinjan|||0000-0002-4474-5093
  • López-Estévez, Sergio|||0000-0001-5355-8073
  • Morcillo, Miguel Ángel|||0000-0002-1984-5834
  • Alzrigat, Mohammad|||0000-0001-5514-8625
  • Mahmoud, Loay
  • Luque-García, Antonio|||0000-0001-5785-8436
  • Escorihuela, Marta|||0000-0001-9074-2339
  • Guzmán, Marta|||0000-0002-0924-9887
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Serra, Violeta|||0000-0001-6620-1065
  • Larsson, Lars-Gunnar|||0000-0001-6914-3147
  • Whitfield, Jonathan R.|||0000-0002-4925-7283
  • Soucek, Laura|||0000-0002-4750-7971
While MYC role in metastasis has been long controversial, this manuscript demonstrates that MYC inhibition by either transgenic expression or pharmacologic use of the recombinantly produced Omomyc miniprotein exerts antitumor and antimetastatic activity in breast cancer models in vitro and in vivo, suggesting its clinical applicability.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Plasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment

  • Cano, Amanda|||0000-0001-9567-4283
  • Esteban de Antonio, Ester|||0000-0003-1965-6010
  • Bernuz, Mireia|||0000-0002-2052-6902
  • Puerta, Raquel|||0000-0002-1191-5893
  • García-González, Pablo|||0000-0003-0125-5403
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Olivé Roig, Clàudia|||0000-0002-9438-5639
  • Pérez-Cordón, Alba|||0000-0002-6028-0791
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • Núñez-Llaves, Raúl|||0000-0002-6702-4774
  • Sotolongo Grau, Oscar|||0000-0002-9679-0670
  • Alarcón-Martín, Emilio|||0000-0002-0985-872X
  • Valero, Sergi|||0000-0002-6599-948X
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Martín, Elvira
  • Martino-Adami, Pamela V.
  • Ettcheto, Miren|||0000-0002-4301-7297
  • Camins, Antoni|||0000-0002-1229-5956
  • Vivas, Assumpta
  • Gómez Chiari, Marta|||0000-0001-6726-1721
  • Tejero, Miguel Ángel
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Marquié, Marta|||0000-0002-0660-0950
  • Ramirez, Alfredo|||0000-0003-4991-763X
  • Martí, Mercè|||0000-0002-1846-0043
  • Pividori, María Isabel|||0000-0002-5266-7873
  • Boada, Mercè|||0000-0003-2617-3009
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
In the clinical course of Alzheimer's disease (AD) development, the dementia phase is commonly preceded by a prodromal AD phase, which is mainly characterized by reaching the highest levels of Aβ and p-tau-mediated neuronal injury and a mild cognitive impairment (MCI) clinical status. Because of that, most AD cases are diagnosed when neuronal damage is already established and irreversible. Therefore, a differential diagnosis of MCI causes in these prodromal stages is one of the greatest challenges for clinicians. Blood biomarkers are emerging as desirable tools for pre-screening purposes, but the current results are still being analyzed and much more data is needed to be implemented in clinical practice. Because of that, plasma extracellular vesicles (pEVs) are gaining popularity as a new source of biomarkers for the early stages of AD development. To identify an exosome proteomics signature linked to prodromal AD, we performed a cross-sectional study in a cohort of early-onset MCI (EOMCI) patients in which 184 biomarkers were measured in pEVs, cerebrospinal fluid (CSF), and plasma samples using multiplex PEA technology of Olink© proteomics. The obtained results showed that proteins measured in pEVs from EOMCI patients with established amyloidosis correlated with CSF p-tau181 levels, brain ventricle volume changes, brain hyperintensities, and MMSE scores. In addition, the correlations of pEVs proteins with different parameters distinguished between EOMCI Aβ( +) and Aβ(-) patients, whereas the CSF or plasma proteome did not. In conclusion, our findings suggest that pEVs may be able to provide information regarding the initial amyloidotic changes of AD. Circulating exosomes may acquire a pathological protein signature of AD before raw plasma, becoming potential biomarkers for identifying subjects at the earliest stages of AD development.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Over 40 years (1981-2023) assessing stigma with the Community Attitudes to Mental Illness (CAMI) scale, a systematic review of its psychometric properties

  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Doval Dieguez, Eduardo|||0000-0001-8416-160X
  • Bernadàs, Albert
  • Angarita-Osorio, Natalia|||0000-0001-8925-2754
  • Colomer-Carbonell, Ariadna|||0000-0001-8923-6316
  • Evans-Lacko, Sara
  • Thornicroft, Graham
  • Luciano, Juan Vicente|||0000-0003-0750-1599
  • Rubio-Valera, Maria|||0000-0003-2856-1697
The Community Attitudes to Mental Illness (CAMI) scale measures social stigma towards people with mental illness. Although it has been used worldwide, the psychometric properties of the CAMI have not been systematically reviewed. The main aim of this study was to systematically review the psychometric properties of the different versions of the CAMI more than 40 years after of its publication. A systematic search was conducted in MEDLINE, PsycINFO, Web of Science, and EMBASE from 1981 (year of publication) to 2023 (present). A double review was performed for eligibility, data extraction, and quality assessment. A total of 15 studies enrolling 10,841 participants were included. The most frequently reported factor structure comprises 3 or 4 factors. Overall, the internal consistency seems adequate for the global scale (α ≥ 0.80), except for CAMI-10 (α = 0.69). Internal consistency of the subscales are not supported, with authoritarianism being the weakest factor (α = 0.27 to 0.68). The stability over time of the total scale has been assessed in the CAMI-40, CAMI-BR, and CAMI-10 (r ≥ 0.39). Few studies have assessed the temporal stability of the CAMI subscales. Most of the correlations with potentially related measures are significant and in the expected direction. The 3 and 4 factor structure are the most widely reported in the different versions of the CAMI. Even though reliability and construct validity are acceptable, further item refinement by international consensus seems warranted more than 40 years after the original publication. PROSPERO identification number: CRD42018098956. The online version contains supplementary material available at 10.1186/s13643-023-02230-4.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Can Electronegative LDL Act as a Multienzymatic Complex?

  • Benitez, Sonia|||0000-0003-3565-0743
  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Solé, Arnau|||0009-0007-6517-6188
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
Electronegative LDL (LDL(-)) is a minor form of LDL present in blood for which proportions are increased in pathologies with increased cardiovascular risk. In vitro studies have shown that LDL(-) presents pro-atherogenic properties, including a high susceptibility to aggregation, the ability to induce inflammation and apoptosis, and increased binding to arterial proteoglycans; however, it also shows some anti-atherogenic properties, which suggest a role in controlling the atherosclerotic process. One of the distinctive features of LDL(-) is that it has enzymatic activities with the ability to degrade different lipids. For example, LDL(-) transports platelet-activating factor acetylhydrolase (PAF-AH), which degrades oxidized phospholipids. In addition, two other enzymatic activities are exhibited by LDL(-). The first is type C phospholipase activity, which degrades both lysophosphatidylcholine (LysoPLC-like activity) and sphingomyelin (SMase-like activity). The second is ceramidase activity (CDase-like). Based on the complementarity of the products and substrates of these different activities, this review speculates on the possibility that LDL(-) may act as a sort of multienzymatic complex in which these enzymatic activities exert a concerted action. We hypothesize that LysoPLC/SMase and CDase activities could be generated by conformational changes in apoB-100 and that both activities occur in proximity to PAF-AH, making it feasible to discern a coordinated action among them.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers

  • Jansen, Iris E.|||0000-0003-1901-8131
  • van der Lee, Sven J.|||0000-0003-1606-8643
  • Gomez-Fonseca, Duber
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Dalmasso, Maria Carolina|||0000-0002-4901-9955
  • Grenier-Boley, Benjamin
  • Zettergren, Anna|||0000-0002-7182-8417
  • Mishra, Aniket|||0000-0002-8141-1543
  • Ali, Muhammad|||0000-0002-1399-6631
  • Andrade, Victor|||0000-0003-0682-269X
  • Bellenguez, Céline|||0000-0002-1240-7874
  • Kleineidam, Luca
  • Küçükali, Fahri
  • Sung, Ju Sung
  • Tesí, Niccolo
  • Vromen, Ellen|||0000-0001-7774-5500
  • Wightman, Douglas P.
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Alvarez, Ignacio|||0000-0002-8537-3935
  • Amouyel, Philippe|||0000-0001-9088-234X
  • Athanasiu, Lavinia
  • Bahrami, Shahram
  • Bailly, Henri
  • Belbin, Olivia|||0000-0002-6109-6371
  • Bergh, Sverre|||0000-0001-9593-2967
  • Bertram, Lars|||0000-0002-0108-124X
  • Biessels, Geert Jan|||0000-0001-6862-2496
  • Blennow, Kaj|||0000-0002-1890-4193
  • Blesa, Rafael|||0000-0003-4026-2884
  • Boada, Mercè|||0000-0003-2617-3009
  • Boland, Anne|||0000-0001-8789-5676
  • Buerger, K.
  • Carracedo, Ángel|||0000-0003-1085-8986
  • Cervera Carles, Laura|||0000-0003-2286-200X
  • Chene, Geneviève|||0000-0002-8368-6460
  • Claassen, Jurgen|||0000-0002-1778-8151
  • Debette, Stéphanie|||0000-0001-8675-7968
  • Deleuze, Jean-Francois
  • De Deyn, Peter Paul|||0000-0002-2228-2964
  • Diehl-Schmid, Janine|||0000-0002-7745-1382
  • Djurovic, Srdjan|||0000-0002-8140-8061
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Dufouil, Carole|||0000-0003-2442-4476
  • Duron, Emmanuelle
  • Düzel, Emrah
  • Fladby, Tormod|||0000-0002-9984-9797
  • Fortea, Juan|||0000-0002-1340-638X
  • Froelich, Lutz|||0000-0003-1494-0813
  • García-González, Pablo|||0000-0003-0125-5403
  • Garcia-Martinez, María
  • Giegling, Ina
  • Goldhardt, Oliver
  • Gobom, Johan|||0000-0001-6193-6193
  • Grimmer, Timo
  • Haapasalo, Annakaisa|||0000-0003-0959-2957
  • Hampel, Harald
  • Hanon, Olivier|||0000-0002-4697-122X
  • Hausner, Lucrezia|||0000-0001-9009-2356
  • Heilmann-Heimbach, Stefanie|||0000-0003-1057-465X
  • Helisalmi, Seppo
  • Heneka, Michael|||0000-0003-4996-1630
  • Hernández, Isabel|||0000-0001-8119-393X
  • Herukka, Sanna-Kaisa|||0000-0003-3308-8662
  • Holstege, Henne|||0000-0002-7688-3087
  • Jarholm, Jonas
  • Kern, Silke
  • Knapskog, Anne-Brita
  • Koivisto, A.M.
  • Kornhuber, Johannes|||0000-0002-8096-3987
  • Kuulasmaa, Teemu|||0000-0002-1795-7314
  • Lage, Carmen|||0000-0003-1703-121X
  • Laske, Christoph
  • Leinonen, Ville|||0000-0002-4282-4687
  • Lewczuk, Piotr|||0000-0002-8101-6535
  • Lleó, Alberto|||0000-0002-2568-5478
  • Lopez de Munain, Adolfo|||0000-0002-9509-4032
  • López-Garcia, Sara
  • Maier, Wolfgang
  • Marquié, Marta|||0000-0002-0660-0950
  • Mol, Merel O.|||0000-0003-2533-2530
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • Moreno, Fermin|||0000-0001-5200-3164
  • Moreno-Grau, Sonia
  • Nicolas, Gael|||0000-0001-9391-7800
  • Nöthen, Markus M.|||0000-0002-8770-2464
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Pålhaugen, Lene
  • Papma, Janne M.
  • Pasquier, Florence|||0000-0001-9880-9788
  • Perneczky, Robert|||0000-0003-1981-7435
  • Peters, Oliver|||0000-0003-0568-2998
  • Pijnenburg, Yolande A.L.
  • Popp, Julius|||0000-0002-0068-0312
  • Posthuma, Danielle|||0000-0001-7582-2365
  • Pozueta, Ana
  • Priller, Josef|||0000-0001-7596-0979
  • Puerta, Raquel|||0000-0002-1191-5893
  • Quintela, Inés|||0000-0002-0239-7975
  • Ramakers, Inez
  • Rodríguez-Rodríguez, Eloy|||0000-0001-7742-677X
  • Rujescu, Dan|||0000-0002-1432-313X
  • Saltvedt, Ingvild|||0000-0002-7897-9808
  • Sánchez-Juan, Pascual|||0000-0002-6081-8037
  • Scheltens, Philip|||0000-0002-1046-6408
  • Scherbaum, Norbert|||0000-0003-1759-6990
  • Schmid, Matthias
  • Schneider, Anja|||0000-0001-9540-8700
  • Selbæk, Geir|||0000-0001-6511-8219
  • Selnes, Per
  • Shadrin, Alexey
  • Skoog, Ingmar
  • Soininen, Hilkka|||0000-0002-2785-9937
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Teipel, Stefan
  • Tijms, Betty M.|||0000-0002-2612-1797
  • Tsolaki, Magda|||0000-0002-2072-8010
  • Van Broeckhoven, Christine|||0000-0003-0183-7665
  • Van Dongen, Jasper|||0000-0001-5599-0046
  • van Swieten, John C.
  • Vandenberghe, Rik|||0000-0001-6237-2502
  • Vidal, Jean-Sébastien|||0000-0001-6770-0720
  • Visser, Pieter Jelle|||0000-0001-8008-9727
  • Vogelgsang, Jonathan|||0000-0001-9326-8193
  • Waern, Margda|||0000-0002-8330-6915
  • Wagner, Michael
  • Wiltfang, Jens W.
  • Wittens, Mandy M.J.
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Zulaica, Miren
  • van Duijn, Cornelia M.|||0000-0002-2374-9204
  • Bjerke, Maria
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • Jessen, Frank
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • Pastor, Pau|||0000-0002-7493-8777
  • Hiltunen, Mikko|||0000-0003-3566-4096
  • Ingelsson, Martin|||0000-0001-5466-8370
  • Andreassen, Ole A.|||0000-0002-4461-3568
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Sleegers, Kristel|||0000-0002-0283-2332
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Ramirez, Alfredo|||0000-0003-4991-763X
  • Cruchaga, Carlos|||0000-0002-0276-2899
  • Lambert, Jean-Charles|||0000-0003-0829-7817
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
Amyloid-beta 42 (Aβ42) and phosphorylated tau (pTau) levels in cerebrospinal fluid (CSF) reflect core features of the pathogenesis of Alzheimer's disease (AD) more directly than clinical diagnosis. Initiated by the European Alzheimer & Dementia Biobank (EADB), the largest collaborative effort on genetics underlying CSF biomarkers was established, including 31 cohorts with a total of 13,116 individuals (discovery n = 8074; replication n = 5042 individuals). Besides the APOE locus, novel associations with two other well-established AD risk loci were observed; CR1 was shown a locus for Aβ42 and BIN1 for pTau. GMNC and C16orf95 were further identified as loci for pTau, of which the latter is novel. Clustering methods exploring the influence of all known AD risk loci on the CSF protein levels, revealed 4 biological categories suggesting multiple Aβ42 and pTau related biological pathways involved in the etiology of AD. In functional follow-up analyses, GMNC and C16orf95 both associated with lateral ventricular volume, implying an overlap in genetic etiology for tau levels and brain ventricular volume.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort

  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • García-González, Pablo|||0000-0003-0125-5403
  • Valero, Sergi|||0000-0002-6599-948X
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Hernández, Isabel|||0000-0001-8119-393X
  • Rosende-Roca, Maitée|||0000-0003-1778-8175
  • Vargas, Liliana|||0000-0001-5685-5903
  • Tartari, Juan Pablo
  • Esteban de Antonio, Ester|||0000-0003-1965-6010
  • Bojaryn, Urszula
  • Narvaiza, Leire
  • Alarcón-Martín, Emilio|||0000-0002-0985-872X
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lleó, Alberto|||0000-0002-2568-5478
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Pytel, Vanesa
  • Cano, Amanda|||0000-0001-9567-4283
  • Marquié, Marta|||0000-0002-0660-0950
  • Boada, Mercè|||0000-0003-2617-3009
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
Background: Clinical diagnosis of Alzheimer's disease (AD) increasingly incorporates CSF biomarkers. However, due to the intrinsic variability of the immunodetection techniques used to measure these biomarkers, establishing in-house cutoffs defining the positivity/negativity of CSF biomarkers is recommended. However, the cutoffs currently published are usually reported by using cross-sectional datasets, not providing evidence about its intrinsic prognostic value when applied to real-world memory clinic cases. Methods: We quantified CSF Aβ1-42, Aβ1-40, t-Tau, and p181Tau with standard INNOTEST® ELISA and Lumipulse G® chemiluminescence enzyme immunoassay (CLEIA) performed on the automated Lumipulse G600II. Determination of cutoffs included patients clinically diagnosed with probable Alzheimer's disease (AD, n = 37) and subjective cognitive decline subjects (SCD, n = 45), cognitively stable for 3 years and with no evidence of brain amyloidosis in 18F-Florbetaben-labeled positron emission tomography (FBB-PET). To compare both methods, a subset of samples for Aβ1-42 (n = 519), t-Tau (n = 399), p181Tau (n = 77), and Aβ1-40 (n = 44) was analyzed. Kappa agreement of single biomarkers and Aβ1-42/Aβ1-40 was evaluated in an independent group of mild cognitive impairment (MCI) and dementia patients (n = 68). Next, established cutoffs were applied to a large real-world cohort of MCI subjects with follow-up data available (n = 647). Results: Cutoff values of Aβ1-42 and t-Tau were higher for CLEIA than for ELISA and similar for p181Tau. Spearman coefficients ranged between 0.81 for Aβ1-40 and 0.96 for p181TAU. Passing-Bablok analysis showed a systematic and proportional difference for all biomarkers but only systematic for Aβ1-40. Bland-Altman analysis showed an average difference between methods in favor of CLEIA. Kappa agreement for single biomarkers was good but lower for the Aβ1-42/Aβ1-40 ratio. Using the calculated cutoffs, we were able to stratify MCI subjects into four AT(N) categories. Kaplan-Meier analyses of AT(N) categories demonstrated gradual and differential dementia conversion rates (p = 9.815). Multivariate Cox proportional hazard models corroborated these findings, demonstrating that the proposed AT(N) classifier has prognostic value. AT(N) categories are only modestly influenced by other known factors associated with disease progression. Conclusions: We established CLEIA and ELISA internal cutoffs to discriminate AD patients from amyloid-negative SCD individuals. The results obtained by both methods are not interchangeable but show good agreement. CLEIA is a good and faster alternative to manual ELISA for providing AT(N) classification of our patients. AT(N) categories have an impact on disease progression. AT(N) classifiers increase the certainty of the MCI prognosis, which can be instrumental in managing real-world MCI subjects.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Dimensionality and reliability of the online version of the Patient Health Questionnaire-4 (PHQ-4) in a large Colombian sample, Results from the PSY-COVID study

  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Gomez-Acosta, Andrés|||0000-0002-7932-0466
  • Castro Muñoz, John Alexander|||0000-0002-4881-6071
  • Rojas, Yonatan Ferney
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Luciano, Juan Vicente|||0000-0003-0750-1599
  • Sanz Ruiz, Antoni|||0000-0002-7952-4477
The Patient Health Questionnaire-4 (PHQ-4) is an ultra-brief screening instrument to measure depressive and anxiety symptoms. This study evaluated the dimensionality and reliability of the online version of the PHQ-4 in a large sample of the general population in Colombia. Data were collected during the first phase of lockdown measures occasioned by the COVID-19 pandemic. A total of 18,061 adult participants completed the online version of the PHQ-4. The characteristics of the items and subscales were explored. Dimensionality was examined using confirmatory factor analysis (CFA), including an examination of invariance (configural, metric, and scalar) across socio-demographic characteristics. Reliability indices were computed and known-groups validity was addressed by estimating associations between PHQ-4 scores and socio-demographic characteristics. The CFA showed significantly adequate fit indices for the expected two-factor structure, being invariant across gender, age, income level, education level, and region. Internal consistency was satisfactory for the PHQ-2 (α =.83), the GAD-2 (α =.79), and the PHQ-4 (α =.86). Higher scores on depressive (PHQ-2), anxiety (GAD-2), and psychological distress (PHQ-4) symptoms in females and young people, and those respondents with lower income, unemployed, and lower level of education were observed. The findings indicate that the PHQ-4 is a reliable scale for depressive and anxiety symptoms among adult Colombian people, being recommendable this tool for online surveys.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Economic evaluation of videoconference group acceptance and commitment therapy and behavioral activation therapy for depression versus usual care among adults with chronic low back pain plus comorbid depressive symptoms

  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • D'Amico, Francesco|||0000-0001-7995-826X
  • Cardeñosa, Eugenia|||0000-0002-9735-2269
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
  • Edo Izquierdo, Sílvia|||0000-0002-6564-3475
  • Borràs, Xavier|||0000-0003-3972-1385
  • McCracken, Lance M.|||0000-0002-9734-0153
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Sanz Ruiz, Antoni|||0000-0002-7952-4477
  • Luciano, Juan Vicente|||0000-0003-0750-1599
Chronic pain and depression are frequently comorbid conditions associated with significant healthcare and social costs.This study examined the cost-utility and cost-effectiveness of videoconference-based group forms of Acceptance and Commitment Therapy (ACT) and Behavioral Activation Therapy for Depression (BATD), as a complement to treatment-as-usual (TAU), for patients with chronic low back pain (CLBP) plus depressive symptoms, compared to TAU alone. A trial-based economic evaluation (n = 234) was conducted from a governmental and healthcare perspective with a time horizon of 12 months. Primary outcomes were the Brief Pain Inventory-Interference Scale (BPI-IS) and Quality Adjusted Life Year (QALY). Compared to TAU, ACT achieved a significant reduction in total costs (d = 0.47), and BATD achieved significant reductions in indirect (d = 0.61) and total costs (d = 0.63). Significant improvements in BPI-IS (d = 0.73 and d = 0.66, respectively) and QALY scores (d = 0.46 and d = 0.28, respectively) were found in ACT and BATD compared to TAU. No significant differences in costs and outcomes were found between ACT and BATD. In the intention-to-treat analyses, from the governmental and healthcare perspective, no significant differences in cost reduction and incremental effects were identified in the comparison between ACT, BATD, and TAU. However, in the complete case analysis, significant incremental effects of ACT (∆BPI-IS = -1.57 and -1.39, respectively) and BATD (∆BPI-IS = -1.08 and -1.04, respectively) compared with TAU were observed. In the per-protocol analysis, only the significant incremental effects of ACT (∆BPI-IS = -1.68 and -1.43, respectively) compared to TAU were detected. In conclusion, ACT and BATD might be efficient options in the management of CLBP plus comorbid depression symptoms as compared to usual care. However, no clear difference was found in the comparison between the two active therapies regarding cost-effectiveness or cost-utility. PERSPECTIVE: The economic evaluation of psychological therapies for the management of complex conditions is crucial as can be used in decision-making and resource allocation. This study provides evidence that videoconference group-based forms of ACT and BATD are more effective and involve a greater reduction in costs than usual care in the management of CLBP plus comorbid depressive symptoms. Both psychological therapies seem to offer good value for money to the Spanish national health service and the government.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Eosinophils in the Gastrointestinal Tract, Key Contributors to Neuro-Immune Crosstalk and Potential Implications in Disorders of Brain-Gut Interaction

  • Salvo-Romero, Eloísa
  • Rodiño-Janeiro, Bruno K.|||0000-0002-0633-6774
  • Albert-Bayo, Mercé|||0000-0002-9726-8083
  • Lobo Álvarez, Beatriz|||0000-0003-3391-7125
  • Santos, Javier|||0000-0002-4798-5033
  • Farré, Ricard|||0000-0001-7158-171X
  • Martínez, Cristina|||0000-0002-9368-1356
  • Vicario Perez, Maria|||0000-0001-9622-3185
Eosinophils are innate immune granulocytes actively involved in defensive responses and in local and systemic inflammatory processes. Beyond these effector roles, eosinophils are fundamental to maintaining homeostasis in the tissues they reside. Gastrointestinal eosinophils modulate barrier function and mucosal immunity and promote tissue development through their direct communication with almost every cellular component. This is possible thanks to the variety of receptors they express and the bioactive molecules they store and release, including cytotoxic proteins, cytokines, growth factors, and neuropeptides and neurotrophines. A growing body of evidence points to the eosinophil as a key neuro-immune player in the regulation of gastrointestinal function, with potential implications in pathophysiological processes. Eosinophil-neuron interactions are facilitated by chemotaxis and adhesion molecules, and the mediators released may have excitatory or inhibitory effects on each cell type, with physiological consequences dependent on the type of innervation involved. Of special interest are the disorders of the brain-gut interaction (DBGIs), mainly functional dyspepsia (FD) and irritable bowel syndrome (IBS), in which mucosal eosinophilia and eosinophil activation have been identified. In this review, we summarize the main roles of gastrointestinal eosinophils in supporting gut homeostasis and the evidence available on eosinophil-neuron interactions to bring new insights that support the fundamental role of this neuro-immune crosstalk in maintaining gut health and contributing to the pathophysiology of DBGIs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Effectiveness of a Multicomponent Treatment Based on Pain Neuroscience Education, Therapeutic Exercise, Cognitive Behavioral Therapy, and Mindfulness in Patients With Fibromyalgia (FIBROWALK Study), A Randomized Controlled Trial

  • Serrat López, Mayte|||0000-0002-5591-9407
  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Almirall, Míriam|||0000-0002-4874-8013
  • Musté, Marta|||0000-0002-0748-1121
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Méndez Ulrich, Jorge Luis|||0000-0001-9718-0607
  • Sanz Ruiz, Antoni|||0000-0002-7952-4477
  • Luciano, Juan Vicente|||0000-0003-0750-1599
Objective. The purpose of this study was to evaluate the effectiveness of a 12-week multicomponent treatment based on pain neuroscience education, therapeutic exercise, cognitive behavioral therapy, and mindfulness-in addition to treatment as usual-compared with treatment as usual only in patients with fibromyalgia. Methods. This randomized controlled trial involved a total of 272 patients who were randomly assigned to either multicomponent treatment (n = 135) or treatment as usual (n = 137). The multicomponent treatment (2-hour weekly sessions) was delivered in groups of 20 participants. Treatment as usual was mainly based on pharmacological treatment according to the predominant symptoms. Data on functional impairment using the Revised Fibromyalgia Impact Questionnaire as the primary outcome were collected as were data for pain, fatigue, kinesiophobia, physical function, anxiety, and depressive symptoms (secondary outcomes) at baseline, 12 weeks, and, for the multicomponent group only, 6 and 9 months. An intention-to-treat approach was used to analyze between-group differences. Baseline differences between responders (.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Psychometric examination of the Multidimensional Psychological Flexibility Inventory Short Form (MPFI-24) and the Psy-Flex Spanish versions in individuals with chronic pain

  • Navarrete Hidalgo, Jaime|||0000-0002-9482-4822
  • Rodríguez Freire, Carla|||0009-0006-6728-5778
  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Martínez-Rubio, David|||0000-0002-9346-3869
  • McCracken, Lance M.|||0000-0002-9734-0153
  • Gallego, Ana|||0000-0002-8060-2495
  • Sundström, Felicia T.A.|||0000-0002-7032-1614
  • Serrat López, Mayte|||0000-0002-5591-9407
  • Alonso, Jordi|||0000-0001-8627-9636
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Nieto Luna, Rubén|||0000-0002-8759-319X
  • Luciano, Juan Vicente|||0000-0003-0750-1599
BACKGROUND: Acceptance and Commitment Therapy (ACT) has been found to be beneficial for individuals dealing with chronic pain. The theoretical mechanisms of change proposed by ACT are based on the Hexaflex model. To comprehensively reflect this model, the Multidimensional Psychological Flexibility Inventory (MPFI) and Psy-Flex have been developed. The study aimed to adapt the MPFI-24 and the Psy-Flex for Spanish-speaking populations with chronic pain and to examine their dimensionality, internal consistency, convergent validity and incremental validity. METHODS: This cross-sectional study involved 309 Spanish-speaking adults with chronic pain who completed an online survey. The majority of the participants were women (88.3%). The ages ranged from 18 to 79 years. RESULTS: Factor analysis showed that the Spanish version of the MPFI-24 has 12 factors, consisting of six flexibility and six inflexibility factors, similar to the original version, but lacking second-order general factors. The Psy-Flex demonstrated a single-factor structure, maintaining the general factor of psychological flexibility seen in the original version. The MPFI-24 showed good internal consistency and adequate convergent validity, with the exception of the Acceptance and Experiential Avoidance subscales. The Psy-Flex showed good internal consistency and convergent validity. Notably, both the MPFI-24 and Psy-Flex scores significantly explained additional variance in psychological distress beyond other ACT-related measures of Hexaflex processes; however, only the Psy-Flex explained pain interference. CONCLUSIONS: The Spanish adaptations of the MPFI-24 and Psy-Flex are valid and reliable instruments for assessing the Hexaflex model processes in Spanish-speaking adults with chronic pain. SIGNIFICANCE STATEMENT: Practitioners and researchers in chronic pain will find the Spanish versions of the MPFI-24 and the Psy-Flex here, along with recommendations for their use and scoring based on a robust psychometric rationale. It should be noted that these measures surpass the Chronic Pain Acceptance Questionnaire (CPAQ) and the Psychological Inflexibility in Pain Scale (PIPS), which are considered gold standards in chronic pain assessment.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer

  • Giuntini, Fabio
  • Zacarias Fluck, Mariano F
  • Arnal, Magdalena
  • Pedretti, Flaminia
  • Grueso, Judit
  • Guzman Torres, Marta
  • González-Larreategui, Íñigo
  • Herencia Ropero, Andrea
  • Casacuberta-Serra, Sílvia
  • Serrano del Pozo, Erika
  • Rodríguez, Olga
  • Llop-Guevara, Alba
  • Balmaña, Judith
  • Nonell, Lara
  • Whitfield, Jonathan
  • Soucek, Laura
  • Serra, Violeta
Cancer; DNA damage; Omomyc, Càncer; Dany a l'ADN; Omomyc, Cáncer; Daño en el ADN; Omomyc, MYC is dysregulated in most human cancers and is a DNA damage response (DDR) modulator capable of both promoting genomic instability and enhancing DNA repair. Here, we show that Omomyc, the only direct MYC inhibitor that has completed a phase 1 trial, shuts down DDR genes in triple-negative breast cancer (TNBC), causing DDR defects and inducing DNA damage. Since DDR-deficient tumors are currently targeted by poly ADP-ribose polymerase inhibitors (PARPis), we tested combinations with Omomyc. We show that Omomyc-induced DNA damage is enhanced by PARPis and that the inhibitors cooperate even in models with intrinsic or acquired PARPi resistance, both in vitro and in vivo. Moreover, using patient-derived models and clinical samples, we reveal a role for MYC as a predictor of PARPi resistance. Overall, our research highlights the opportunity of combining MYC inhibition by Omomyc with PARPis in PARPi-resistant TNBC, where MYC transcriptional activity represents a predictive biomarker of resistance to therapy., We acknowledge the kind support from the Vall d’Hebron Institute of Oncology and the Cellex Foundation for providing research facilities and equipment. We thank the Spanish Association of Metastatic Breast Cancer for the Chiara Giorgetti Award 2022, Instituto de Salud Carlos III (FI20/00274 – F.G., PFIS doctoral bursary); Ministerio de Ciencia e Innovación (Retos de Colaboración RTC2019-007067-1 and Líneas Estratégicas PLEC2021-007959); Generalitat de Catalunya (AGAUR 2017/SGR 537 and 2021/SGR 01509); EDIReX (H2020 INFRAIA 731105-2); the European Research Council (ERC-2023-ADG 101142260); the Spanish Ministry of Science and Innovation and the European Union through the NextGenerationEU program, in the context of the Plan de Recuperacion, Transformacion y Resiliencia (RETOS; CPP2022-009808); and the Fero Foundation for funding support.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

  • ADAM-ARTIGUES, ANNA
  • Brasó-Maristany, Fara
  • Cervera Vidal, Raimundo
  • Tormo, Eduardo
  • Arribas López, Joaquin Vicente
  • Arenas Lahuerta, Enrique Javier
  • Martínez-Sabadell, Alex
Breast cancer; Heterodimerization, Cáncer de mama; Heterodimerización, Càncer de mama; Heterodimerització, Anti-HER2 therapies have markedly improved prognosis of HER2-positive breast cancer. However, different mechanisms play a role in treatment resistance. Here, we identified AXL overexpression as an essential mechanism of trastuzumab resistance. AXL orchestrates epithelial-to-mesenchymal transition and heterodimerizes with HER2, leading to activation of PI3K/AKT and MAPK pathways in a ligand-independent manner. Genetic depletion and pharmacological inhibition of AXL restored trastuzumab response in vitro and in vivo. AXL inhibitor plus trastuzumab achieved complete regression in trastuzumab-resistant patient-derived xenograft models. Moreover, AXL expression in HER2-positive primary tumors was able to predict prognosis. Data from the PAMELA trial showed a change in AXL expression during neoadjuvant dual HER2 blockade, supporting its role in resistance. Therefore, our study highlights the importance of targeting AXL in combination with anti-HER2 drugs across HER2-amplified breast cancer patients with high AXL expression. Furthermore, it unveils the potential value of AXL as a druggable prognostic biomarker in HER2-positive breast cancer., A.A.-A., E.J.A., and F.B.-M. were supported by Asociación Española contra el Cáncer AECC (PRDVA18013LLUC to A.A.-A., POSTD211413AREN to E.J.A., and AECC_Postdoctoral17-1062 to F.B.-M.). A.M.-S. was funded by the Spanish Government (PFIS FI20/00188). J.Ar. is supported by Breast Cancer Research Foundation (BCRF-20-08), Instituto de Salud Carlos III Project reference number AC15/00062, and the EC under the framework of the ERA-NET TRANSCAN-2 initiative cofinanced by FEDER, Instituto de Salud Carlos III (CB16/12/00449 and PI19/01181), and Asociación Española Contra el Cáncer (AECC). A.P. was supported by Instituto de Salud Carlos III—PI19/01846, Breast Cancer Now—2018NOVPCC1294. P.E. and A.L. were funded by Instituto de Salud Carlos III and cofinanced by FEDER (PI18/01219 to P.E. and CB16/12/00481 to A.L.). J.M.C. was funded by Sociedad Española de Oncología Médica (Rio Hortega-SEOM) and Compromiso ADAMED.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

The leading role of MYC in DNA damage response: exploring opportunities for therapeutic inhibition

  • Giuntini, Fabio
  • Massó-Vallés, Daniel
  • Whitfield, Jonathan
  • Soucek, Laura
DNA damage response; DNA damage response inhibitors; MYC inhibition, Respuesta al daño del ADN; Inhibidores de la respuesta al daño del ADN; Inhibición de MYC, Resposta al dany de l'ADN; Inhibidors de la resposta al dany de l'ADN; Inhibició de MYC, MYC performs a dual role in DNA Damage Response (DDR), promoting genomic instability through replication stress, R-loop formation, and topoisomerase-mediated damage, while simultaneously activating DNA repair pathways to maintain cell survival. This review provides a comprehensive analysis of how MYC inhibition affects DDR pathway dependencies. In fact, when MYC is inhibited, cancer cells lose both their proficient DNA repair capacity and their protective mechanisms against replication stress. This creates a therapeutic window in which combining MYC inhibitors with DDR-targeting agents may achieve synergistic anti-cancer effects. Central to this approach is the exploration of rational combination strategies that pair MYC inhibitors with various DDR modulators including Poly (ADP-ribose) polymerase (PARP) inhibitors, ATR/CHK1 inhibitors, and other DNA repair pathway disruptors. This review summarizes preclinical evidence demonstrating enhanced therapeutic efficacy when MYC inhibition is combined with DDR-targeting agents and discusses early clinical findings that support this promising therapeutic strategy., The author(s) declared that financial support was received for this work and/or its publication. We thank the Spanish Association of Metastatic Breast Cancer for the Chiara Giorgetti Award 2022, Instituto de Salud Carlos III (FI20/00274 – FG PFIS doctoral bursary), Ministerio de Ciencia e Innovación (Retos de Colaboración RTC2019-007067-1, Líneas Estratégicas PLEC2021-007959), Generalitat de Catalunya (AGAUR 2017/SGR 537 and 2021/SGR 01509), EDIReX (H2020 INFRAIA 731105-2), the European Research Council (ERC-2023-ADG 101142260), the Spanish Ministry of Science and Innovation and European Union through the NextGenerationEU program, in the context of the Plan de Recuperacion, Transformacion y Resiliencia (RETOS; CPP2022-009808) and the FERO foundation for funding support.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

The target antigen determines the mechanism of acquired resistance to T cell-based therapies

  • Morancho Armisen, Beatriz
  • Román Alonso, Macarena
  • Ovejero Romero, Pablo
  • Arribas López, Joaquin Vicente
  • Arenas Lahuerta, Enrique Javier
  • Martínez-Sabadell, Alex
  • Rius Ruiz, Irene
  • Escorihuela Baez, Marta
Cancer; Antigen; Resistance, Cáncer; Antígeno; Resistencia, Càncer; Antigen; Resistència, Despite the revolution of immunotherapy in cancer treatment, patients eventually progress due to the emergence of resistance. In this scenario, the selection of the tumor antigen can be decisive in the success of the clinical response. T cell bispecific antibodies (TCBs) are engineered molecules that include binding sites to the T cell receptor and to a tumor antigen. Using gastric CEA+/HER2+ MKN45 cells and TCBs directed against CEA or HER2, we show that the mechanism of resistance to a TCB is dependent on the tumor antigen. Acquired resistant models to a high-affinity-CEA-targeted TCB exhibit a reduction of CEA levels due to transcriptional silencing, which is reversible upon 5-AZA treatment. In contrast, a HER2-TCB resistant model maintains HER2 levels and exhibit a disruption of the interferon-gamma signaling. These results will help in the design of combinatorial strategies to increase the efficacy of cancer immunotherapies and to anticipate and overcome resistances., This work was supported by Asociación Española Contra el Cancer (AECC), Breast Cancer Research Foundation (BCRF-21-008), and Instituto de Salud Carlos III (PI19/01181). A.M.S. was funded by the Spanish Government (PFIS FI20/00188). B.M. was funded by a fellowship from PERIS (Departament de Salut, Generalitat de Catalunya). M.R.A. was funded by Agency for Management of University and Research Grants (AGAUR, 2022 FI_B2 00080). P.O.R. was funded by the BBVA. E.J.A. was funded by the AECC (POSTD211413AREN). VHIO acknowledges the Cellex Foundation for providing research facilities and equipment, the Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) from the Institute of Health Carlos III (ISCIII), and the Department of Health (Generalitat de Catalunya, SLT008/18/00198 SLT008/18/00205) for their support on this research. The authors acknowledge financial support from the State Agency for Research (Agencia Estatal de Investigación) (CEX2020-001024-S/AEI/10.13039/501100011033) and for the Cancer Immunology and Immunotherapy (CAIMI-2) program funded by BBVA Foundation. We would like to remark the funding from B.M PERIS (Spain). The authors thank Dr. Anne Freimoser-Grundschober and Roche for helping provide the TCBs. The graphical abstract was created with BioRender.com.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Present and Future Therapeutic Approaches to Barrier Dysfunction

  • Albert Bayo, Merce
  • Abril-Gil, Mar
  • Serra Ruiz, Xavier
  • Henao Paez, Alejandro
  • Exposito Fernandez, Elba
  • Gonzalez Castro, Ana Maria
  • Lobo Alvarez, Beatriz
  • Santos Vicente, Fco Javier
  • Guagnozzi, Danila
  • Fortea, Marina
  • Alonso Cotoner, Carmen
  • Ganda Mall, John-Peter
Permeabilidad intestinal; Nutrientes; Prebióticos, Intestinal permeability; Nutrients; Prebiotics, Permeabilitat intestinal; Nutrients; Prebiòtics, There is converging and increasing evidence, but also uncertainty, for the role of abnormal intestinal epithelial barrier function in the origin and development of a growing number of human gastrointestinal and extraintestinal inflammatory disorders, and their related complaints. Despite a vast literature addressing factors and mechanisms underlying changes in intestinal permeability in humans, and its connection to the appearance and severity of clinical symptoms, the ultimate link remains to be established in many cases. Accordingly, there are no directives or clinical guidelines related to the therapeutic management of intestinal permeability disorders that allow health professionals involved in the management of these patients to carry out a consensus treatment based on clinical evidence. Instead, there are multiple pseudoscientific approaches and commercial propaganda scattered on the internet that confuse those affected and health professionals and that often lack scientific rigor. Therefore, in this review we aim to shed light on the different therapeutic options, which include, among others, dietary management, nutraceuticals and medical devices, microbiota and drugs, and epigenetic and exosomes-manipulation, through an objective evaluation of the scientific publications in this field. Advances in the knowledge and management of intestinal permeability will sure enable better options of dealing with this group of common disorders to enhance quality of life of those affected., This work was supported in part by Fondo Europeo de Desarrollo Regional (FEDER), Fondo de Investigación Sanitaria and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Subdirección General de Investigación Sanitaria, Ministerio de Economía y Competitividad, Ajuts per a la contractació de personal investigador FI–Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya; The Swedish Research Council, and the European Commision. PI19/0164 (BL), FI20/00256 and 2020FI_B1 00127, 2019FI_B 00817 (MA-B); PI17/0190 (JS); CIBERehd CB06/04/0021 (JS and CA-C); dnr 2019-00653 (JP-GM); GA no:848228 (JS, CA-C, EE, AG-C, and BL). MF received support from FWO (Fonds Wetenschappelijk Onderzoek) grant G.093818 to P. Vanden Berghe, KU Leuven.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Acute stress triggers sex-dependent rapid alterations in the human small intestine microbiota composition

  • Rodiño Janeiro, Bruno Kotska
  • Khannous, Olfat
  • Pigrau Pastor, Marc
  • Willis, Jesse R.
  • Pardo Camacho, Cristina
  • Albert Bayo, Mercé
  • Martínez Martínez, Cristina
  • lobo, beatriz
  • Santos, Javier
  • Salvo Romero, Eloisa
  • Nieto Ruiz, Adoración
  • Expósito , Elba
  • Fortea, Marina
  • González Castro, Ana Maria
  • Guagnozzi, Danila
  • Vicario Perez, Maria
  • Alonso Cotoner, Carmen
Irritable bowel syndrome; Small intestine microbiota; Stress, Síndrome del intestino irritable; Microbiota del intestino delgado; Estrés, Síndrome de l'intestí irritable; Microbiota de l'intestí prim; Estrès, Background/aims: Digestive disorders of gut-brain interaction (DGBI) are very common, predominant in females, and usually associated with intestinal barrier dysfunction, dysbiosis, and stress. We previously found that females have increased susceptibility to intestinal barrier dysfunction in response to acute stress. However, whether this is associated with changes in the small bowel microbiota remains unknown. We have evaluated changes in the small intestinal microbiota in response to acute stress to better understand stress-induced intestinal barrier dysfunction. Methods: Jejunal biopsies were obtained at baseline and 90 min after cold pain or sham stress. Autonomic (blood pressure and heart rate), hormonal (plasma cortisol and adrenocorticotropic hormone) and psychological (Subjective Stress Rating Scale) responses to cold pain and sham stress were monitored. Microbial DNA from the biopsies was analyzed using a 16S metabarcoding approach before and after cold pain stress and sham stress. Differences in diversity and relative abundance of microbial taxa were examined. Results: Cold pain stress was associated with a significant decrease in alpha diversity (P = 0.015), which was more pronounced in females, along with significant sex differences in the abundance of specific taxa and the overall microbiota composition. Microbiota alterations significantly correlated with changes in psychological responses, hormones, and gene expression in the intestinal mucosal. Cold pain stress was also associated with activation of autonomic, hormonal and psychological response, with no differences between sexes. Conclusions: Acute stress elicits rapid alterations in bacterial composition in the jejunum of healthy subjects and these changes are more pronounced in females. Our results may contribute to the understanding of female predominance in DGBI., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by Fondo Europeo de Desarrollo Regional (FEDER), Fondo de Investigación Sanitaria and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), y de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Subdirección General de Investigación Sanitaria, Ministerio de Economía y Competitividad y Ministerio de Ciencia e Innovación: EII2011-0035, CD15/00010 and MV17-00043 (BR-J); CM10/00155 (MP); FI12/00254 (ES-R); FI20/00256 (MA-B); CP18/00116 (CM); PI19/01643 (BL); PI16/00583, PI19/01643 and CPII16/00031 (MV); PI17/0190 (JS); INB Grant PT17/0009/0023 (TG); PI15/00301 (CA-C); CIBEREHD CB06/04/0021 (AG-C, DG, BL, MV, JS, CA-C); CIBERINFEC CB21/13/00061 (TG). Vall d'Hebron Institut de Recerca, Programa de becas predoctorales Amics de Vall d'Hebron: PRED-VHIR-2014-018 (MF), PRED-VHIR-2016-53 (CP-C). Ajuts per a la contractació de personal investigador FI, Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya: 2020FI_B1 00127 & 2019FI_B 00817 (MA-B), SGR423 (TG). Formación de profesorado universitario (FPU) program from the Spanish Ministerio de Universidades: FPU2020-02907 (OK-L). European Union's Horizon 2020 research and innovation program: ERC-2016-724173 (TG). Gordon and Betty Moore Foundation: GBMF9742 (TG).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma

  • Zacarias Fluck, Mariano F
  • Massó-Vallés, Daniel
  • Giuntini, Fabio
  • González-Larreategui, Íñigo
  • Kaur, Jastrinjan
  • Casacuberta-Serra, Sílvia
  • Jauset González, Antoni
  • Martínez Martín, Sandra
  • Martín Fernández, Génesis
  • Serrano del Pozo, Erika
  • Foradada Felip, Laia
  • Grueso Gragera, Judit
  • Nonell Malezon, Lara
  • Whitfield, Jonathan
  • Beaulieu, Marie-Eve
  • Soucek, Laura
MYC; Omomyc; Melanoma, MYC; Omomyc; Melanoma, MYC; Omomyc; Melanoma, MYC's key role in oncogenesis and tumor progression has long been established for most human cancers. In melanoma, its deregulated activity by amplification of 8q24 chromosome or by upstream signaling coming from activating mutations in the RAS/RAF/MAPK pathway—the most predominantly mutated pathway in this disease—turns MYC into not only a driver but also a facilitator of melanoma progression, with documented effects leading to an aggressive clinical course and resistance to targeted therapy. Here, by making use of Omomyc, the most characterized MYC inhibitor to date that has just successfully completed a phase I clinical trial, we show for the first time that MYC inhibition in melanoma induces remarkable transcriptional modulation, resulting in severely compromised tumor growth and a clear abrogation of metastatic capacity independently of the driver mutation. By reducing MYC's transcriptional footprint in melanoma, Omomyc elicits gene expression profiles remarkably similar to those of patients with good prognosis, underlining the therapeutic potential that such an approach could eventually have in the clinic in this dismal disease., M.F.Z.-F. was supported by the Juan de la Cierva Programme of the Spanish Ministry of Economy and Competitiveness (IJCI-2014-22403) and Fundació La Marató de TV3 (grant 474/C/2019); F.G. was supported by Spanish Ministry of Science and Innovation Contratos Predoctorales de Formación en Investigación en Salud (PFIS; FI20/00274); I.G.-L. was supported by a grant from the University Teacher Training Program (FPU), Ministry of Universities (FPU20/04812); and S.M.-M. was supported by the Generalitat de Catalunya “Contractació de Personal Investigador Novell (FI-DGR)” 2016 fellowship (2016FI_B 00592). This project was funded by grants from the Spanish Ministry of Science and Innovation (Fondo de Inversión en Salud [FIS] PI19/01277, which also supported I.G.-L. and S.M.-M, and Retos-Colaboración 2019 RTC2019-007067-1), La Marató TV3, the Generalitat de Catalunya AGAUR 2017 grant SGR-3193, and the European Research Council (ERC-PoC II/3079/SYST-iMYC [813132]). We thank the rest of the Soucek laboratory for critical reading of the manuscript, and the personnel at Vall d'Hebron Research Institute (VHIR) High Technology Unit. We acknowledge Vall d'Hebron Institute of Oncology and the Cellex Foundation for providing research facilities and equipment.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Brain structural and functional substrates of ADGRL3 (latrophilin 3) haplotype in attention-deficit/hyperactivity disorder

  • Moreno‑Alcázar, Ana
  • Ribases Haro, Marta
  • Sanchez Mora, Cristina P
  • Palomar Martínez, Gloria
  • Bosch Munso, Rosa M
  • Casas Brugué, Miquel
  • Ramos-Quiroga, Josep Antoni
TDAH; Genotipatge; Imatges per ressonància magnètica, TDAH; Genotipado; Imagen de resonancia magnética, ADHD; Genotyping; Magnetic resonance imaging, Previous studies have shown that the gene encoding the adhesion G protein-coupled receptor L3 (ADGRL3; formerly latrophilin 3, LPHN3) is associated with Attention-Deficit/Hyperactivity Disorder (ADHD). Conversely, no studies have investigated the anatomical or functional brain substrates of ADGRL3 risk variants. We examined here whether individuals with different ADGRL3 haplotypes, including both patients with ADHD and healthy controls, showed differences in brain anatomy and function. We recruited and genotyped adult patients with combined type ADHD and healthy controls to achieve a sample balanced for age, sex, premorbid IQ, and three ADGRL3 haplotype groups (risk, protective, and others). The final sample (n = 128) underwent structural and functional brain imaging (voxel-based morphometry and n-back working memory fMRI). We analyzed the brain structural and functional effects of ADHD, haplotypes, and their interaction, covarying for age, sex, and medication. Individuals (patients or controls) with the protective haplotype showed strong, widespread hypo-activation in the frontal cortex extending to inferior temporal and fusiform gyri. Individuals (patients or controls) with the risk haplotype also showed hypo-activation, more focused in the right temporal cortex. Patients showed parietal hyper-activation. Disorder-haplotype interactions, as well as structural findings, were not statistically significant. To sum up, both protective and risk ADGRL3 haplotypes are associated with substantial brain hypo-activation during working memory tasks, stressing this gene’s relevance in cognitive brain function. Conversely, we did not find brain effects of the interactions between adult ADHD and ADGRL3 haplotypes., This work was supported by several grants from the Plan Nacional de I+D+i and co-funded by the Instituto de Salud Carlos III-Subdirección General de Evaluación y Fomento de la Investigación and the European Regional Development Fund (FEDER): Research Project Grant (PI11/01629, PI11/01766, PI16/01505, PI17/00289, PI18/01788, PI19/00394, PI19/00721, and PI19/01224), Miguel Servet Research Contracts (CP09/00119 and CPII15/00023 to MR, CP10/00596 to EP-C and CP14/00041 and CPII19/00009 to JR), Sara Borrell contract (CD15/00199 to CSM), PFIS contract (FI20/00047 to LF), mobility grant (MV16/00039 to CSM), Pla Estratègic de Recerca i Innovació en Salut (PERIS); Generalitat de Catalunya (MENTAL-Cat; SLT006/17/287) and the Agència de Gestió d’Ajuts Universitaris i de Recerca-AGAUR, Catalonian Government (2009SGR211 and 2017SGR1461). The funding organizations played no role in the study design, data collection and analysis, or manuscript approval.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Eosinophils in the Gastrointestinal Tract: Key Contributors to Neuro-Immune Crosstalk and Potential Implications in Disorders of Brain-Gut Interaction

  • Rodiño Janeiro, Bruno Kotska
  • Albert Bayo, Merce
  • Lobo Alvarez, Beatriz
  • Santos Vicente, Fco Javier
  • Farre, Ricard
  • Martínez, Cristina
  • Vicario Perez, Maria
  • Salvo Romero, Eloisa
Disorders of brain-gut interaction; Intestinal eosinophils; Neuro-immune interaction, Trastorns de la interacció cervell-intestí; Eosinòfils intestinals; Interacció neuroimmune, Trastornos de la interacción cerebro-intestino; Eosinófilos intestinales; Interacción neuroinmune, Eosinophils are innate immune granulocytes actively involved in defensive responses and in local and systemic inflammatory processes. Beyond these effector roles, eosinophils are fundamental to maintaining homeostasis in the tissues they reside. Gastrointestinal eosinophils modulate barrier function and mucosal immunity and promote tissue development through their direct communication with almost every cellular component. This is possible thanks to the variety of receptors they express and the bioactive molecules they store and release, including cytotoxic proteins, cytokines, growth factors, and neuropeptides and neurotrophines. A growing body of evidence points to the eosinophil as a key neuro-immune player in the regulation of gastrointestinal function, with potential implications in pathophysiological processes. Eosinophil–neuron interactions are facilitated by chemotaxis and adhesion molecules, and the mediators released may have excitatory or inhibitory effects on each cell type, with physiological consequences dependent on the type of innervation involved. Of special interest are the disorders of the brain–gut interaction (DBGIs), mainly functional dyspepsia (FD) and irritable bowel syndrome (IBS), in which mucosal eosinophilia and eosinophil activation have been identified. In this review, we summarize the main roles of gastrointestinal eosinophils in supporting gut homeostasis and the evidence available on eosinophil–neuron interactions to bring new insights that support the fundamental role of this neuro-immune crosstalk in maintaining gut health and contributing to the pathophysiology of DBGIs., This study was funded in part by the Fondo Europeo de Desarrollo Regional (FEDER), the Fondo de Investigación Sanitaria, the Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), the Instituto de Salud Carlos III, Subdirección General de Investigación Sanitaria, and the Ministerio de Economía y Competitividad: FI12/00254 (E.S-R.), CD15/00010 (B.K.R.-J.), FI20/00256 (M.A-B.), PI19/01643 (B.L.), PI17/0190 (J.S.), CP18/00116 (C.M), CPII16/00031 and PI19/01643 (M.V.), CIBEREHD CB06/04/0021 (J.S., R.F., M.V.).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

The Role of Purported Mucoprotectants in Dealing with Irritable Bowel Syndrome, Functional Diarrhea, and Other Chronic Diarrheal Disorders in Adults

  • Abril Gil, Maria del Mar
  • Albert Bayo, Merce
  • Exposito Fernandez, Elba
  • Gonzalez Castro, Ana Maria
  • Lobo Alvarez, Beatriz
  • Santos Vicente, Fco Javier
  • Alonso Cotoner, Carmen
  • Ganda Mall, John-Peter
Chronic diarrhea; Mucoprotectans; Mucus, Diarrea crónica; Mucoprotectores; Moco, Diarrea crònica, Mucoprotectors; Moc, Chronic diarrhea is a frequent presenting symptom, both in primary care medicine and in specialized gastroenterology units. It is estimated that more than 5% of the global population suffers from chronic diarrhea. and that about 40% of these subjects are older than 60 years. The clinician is frequently faced with the need to decide which is the best therapeutic approach for these patients. While the origin of chronic diarrhea is diverse, impairment of intestinal barrier function, dysbiosis. and mucosal micro-inflammation are being increasingly recognized as underlying phenomena characterizing a variety of chronic diarrheal diseases. In addition to current pharmacological therapies, there is growing interest in alternative products such as mucoprotectants, which form a mucoadhesive film over the epithelium to reduce and protect against the development of altered intestinal permeability, dysbiosis, and mucosal micro-inflammation. This manuscript focuses on chronic diarrhea in adults, and we will review recent evidence on the ability of these natural compounds to improve symptoms associated with chronic diarrhea and to exert protective effects for the intestinal barrier., Supported in part by Fondo Europeo de Desarrollo Regional (FEDER), Fondo de Investigación Sanitaria and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Subdirección General de Investigación Sanitaria, Ministerio de Economía y Competitividad, Ajuts per a la contractació de personal investigador FI—Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya, The Swedish Research Council and The European Commision: FIS LOBO 2019? (BL); FI20/00256 (MA-B). PI17/0190 (JS); PI15/00301 (CA-C); CIBERehd CB06/04/0021 (JS & CA-C); dnr 2019–00653 (J-PGM); 2020FI_B1 00127, 2019FI_B 00817 (MA-B); GA No:848228 (JS, CA-C, EE, AMG-C, BL).
e_Buah Biblioteca Digital Universidad de Alcalá
Publication Artículo científico (JournalArticle)

Machine-learning analysis identifies "elite" viral controllers with increased survival and homeostatic responses in critical COVID-19

  • García Mateo, Nadia
  • Álvaro Meca, Alejandro
  • Postigo, Tamara
  • Ortega, Alicia
  • Fuente, Amanda de La
  • Almansa, Raquel
  • Jorge, Noelia
  • González González, Laura
  • Sánchez Recio, Lara
  • Martínez, Isidoro
  • Martín Vicente, María Dolores
  • Muñoz Gómez, María José
  • Más, Vicente
  • Vázquez, Mónica
  • Cano, Olga
  • Vélez Serrano, Daniel
  • Tamayo, Luis
  • Berezo, José Ángel
  • Herrán Monge, Rubén
  • Blanco, Jesús
  • Enríquez, Pedro
  • Ryan Murúa, Pablo
  • Martínez de la Gándara, Amalia de la
  • Rodríguez, Covadonga
  • Andrade, Gloria
  • Bustamante Munguira, Elena
  • Renedo Sánchez Girón, Gloria
  • Cicuéndez Ávila, Ramón
  • Bustamante Munguira, Juan
  • Trapiello, Wysali
  • Gallego Curto, Elena
  • Úbeda Iglesias, Alejandro
  • Salgado Villén, María
  • Berruguilla Pérez, Enrique
  • Torre, María del Carmen de la
  • Güel, Estel
  • Casadiego, Fernando
  • Estella, Ángel
  • Recuerda Núñez, María
  • Sánchez Calvo, Juan Manuel
  • Campos Fernández, Sandra
  • Peñasco Martín, Yhivian
  • García Unzueta, María Teresa
  • Martínez Varela, Ignacio
  • Bouza Vieiro, María Teresa
  • Pérez García, Felipe|||0000-0002-4885-4334
  • Moreno Romero, Ana
  • Socias Crespí, Lorenzo
  • López Messa, Juan
  • Pérez Bastida, Leire
  • Vidal Cortés, Pablo
  • Río Carbajo, Lorena del
  • Nieto del Olmo, Jorge del
  • Prol Silva, Estefanía
  • Sagredo Meneses, Víctor
  • Albalá Martínez, Noelia
  • González Rivera, Milagros
  • Gómez, José Manuel
  • Carbonell, Nieves
  • Blasco, María Luisa
  • Gonzalo Calvo, David de
  • González, Jessica
  • Caballero, Jesús
  • Barberà, Carme
  • Martín Delgado, María Cruz
  • Valdivia, Luis Jorge
  • Martín López, Caridad
  • Nieto, María Teresa
  • Jorge García, Ruth Noemí
  • Maseda, Emilio
  • Loza Vázquez, Ana
  • Eiros, José María
  • Motos, Anna
  • Fernández Barat, Laia
  • Casenco Ribas, Joan
  • Ceccato, Adrián
  • Barbé, Ferran
  • Kelvin, David J.
  • Bermejo Martín, Jesús Francisco
  • Tedim, Ana P.
  • Resino, Salvador
  • Torres, Antoni
9 p., Instituto de Salud Carlos III, Canadian Institutes of Health Research, Fondo Europeo de Desarrollo Regional, European Social Fund, European Society of Clinical Microbiology and Infectious Diseases
e_Buah Biblioteca Digital Universidad de Alcalá
Publication Artículo científico (JournalArticle)

Effect of Kidney Transplantation on Accelerated Immunosenescence and Vascular Changes Induced by Chronic Kidney Disease.

  • Ceprían, Noemí
  • González de Pablos, Ignacio
  • Oliva, Carlos
  • Figuer Rubio, Andrea|||0000-0001-9788-0136
  • Praga, Manuel
  • Alique Aguilar, Matilde|||0000-0002-7912-1133
  • Ramírez Chamond, Manuel Rafael|||0000-0003-4598-339X
  • Morales, Enrique
  • Carracedo Añón, Julia María
  • Valera, Gemma
  • Caro, Jara
  • Yuste, Claudia
  • Serroukh, Nadia
Kidney transplantation is the best option for patients with end-stage renal disease. Despite the improvement in cardiovascular burden (leading cause of mortality among patients with chronic kidney disease), cardiovascular adverse outcomes related to the inflammatory process remain a problem. Thus, the aim of the present study was to characterize the immune profile and microvesicles of patients who underwent transplantation. We investigated the lymphocyte phenotype (CD3, CD4, CD8, CD19, and CD56) and monocyte phenotype (CD14, CD16, CD86, and CD54) in peripheral blood, and endothelium-derived microvesicles (annexin V+CD31+CD41&-) in plasma of patients with advanced chronic kidney disease (n = 40), patients with transplantation (n = 40), and healthy subjects (n = 18) recruited from the University Hospital "12 de Octubre" (Madrid, Spain). Patients with kidney transplantation had B-cell lymphopenia, an impairment in co-stimulatory (CD86) and adhesion (CD54) molecules in monocytes, and a reduction in endothelium-derived microvesicles in plasma. The correlations between those parameters explained the modifications in the expression of co-stimulatory and adhesion molecules in monocytes caused by changes in lymphocyte populations, as well as the increase in the levels of endothelial-derived microvesicles in plasma caused by changes in lymphocyte and monocytes populations. Immunosuppressive treatment could directly or indirectly induce those changes. Nevertheless, the particular characteristics of these cells may partly explain the persistence of cardiovascular and renal alterations in patients who underwent transplantation, along with the decrease in arteriosclerotic events compared with advanced chronic kidney disease. In conclusion, the expression of adhesion molecules by monocytes and endothelial-derived microvesicles is related to lymphocyte alterations in patients with kidney transplantation., Instituto de Salud Carlos III, Sociedad Española de Nefrología, Comunidad de Madrid, Fondo Social Europeo
e_Buah Biblioteca Digital Universidad de Alcalá
Publication Artículo científico (JournalArticle)

Premature Aging in Chronic Kidney Disease: The Outcome of Persistent Inflammation beyond the Bounds

  • Figuer Rubio, Andrea|||0000-0001-9788-0136
  • Bodega Magro, Guillermo|||0000-0003-1469-3242
  • Tato Moreno, Patricia
  • Valera, Gemma
  • Serroukh, Nadia
  • Ceprían, Noemí
  • Sequera Ortiz, Patricia de
  • Morales, Enrique
  • Carracedo Añón, Julia María
  • Ramírez Chamond, Manuel Rafael|||0000-0003-4598-339X
  • Alique Aguilar, Matilde|||0000-0002-7912-1133
Over the last hundred years, life expectancy in developed countries has increased because of healthier living habits and the treatment of chronic pathologies causing premature aging. Aging is an inexorable, time-dependent, multifactorial process characterized by a series of progressive and irreversible physiological changes associated with loss of functional, psychological, and social capabilities. Numerous factors, such as oxidative stress, inflammation, and cellular senescence, and an irreversible geriatric syndrome known as frailty, contribute to human body deterioration in aging. The speed of aging may differ between individuals depending on the presence or absence of multiple factors (genetic and/or environment) and the subsequent misbalance of homeostasis, together with the increase of frailty, which also plays a key role in developing chronic diseases. In addition, pathological circumstances have been reported to precipitate or accelerate the aging process. This review investigated the mechanisms involved in the developing pathologies, particularly chronic kidney disease, associated with aging., Instituto de Salud Carlos III, Sociedad Española de Nefrología, Comunidad de Madrid, Fondo Social Europeo